Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression

Codon-modified Factor VIII variants address the challenges of factor VIII gene therapy by enhancing expression and packaging, offering a more efficient and less frequent treatment option for hemophilia A.

JP2024167251AInactive Publication Date: 2024-12-03BAXALTA INC +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024135845
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-06-26
Filing Date
2024-08-16
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for hemophilia A, such as factor VIII replacement therapy, are costly, require frequent administration, and can lead to the development of inhibitor antibodies, while factor VIII gene therapy faces challenges due to the large size of the factor VIII coding sequence and poor expression of B domain deleted constructs.

Method used

Development of codon-modified Factor VIII variants, including a polynucleotide encoding a Factor VIII polypeptide with a furin cleavage site and a shortened B domain, optimized for expression using AAV gene therapy vectors, enhancing packaging and expression efficiency.

Benefits of technology

The codon-modified Factor VIII variants demonstrate significantly improved expression and virion packaging, potentially providing long-term therapeutic levels of Factor VIII activity with reduced treatment frequency and lower immunogenicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167251000001_ABST
    Figure 2024167251000001_ABST
Patent Text Reader

Abstract

To provide codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells.SOLUTION: A method for treating hemophilia A comprises intravenously infusing, to a human subject diagnosed with hemophilia A, a dose of 2×1012 adeno-associated virus (AAV) particles per kilogram body weight of the human subject, wherein the AAV particles comprise a polynucleotide comprising a specific nucleic acid sequence (CS04-FL-NA).SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 698,680, filed July 16, 2018, and to U.S. Provisional Patent Application No. 62 / 867,171, filed June 26, 2019, both of which are incorporated by reference in their entireties.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated by reference in its entirety. The ASCII copy was created on July 15, 2019, but is named 008073_5202_WO_Sequence_Listing.txt and is 85,000 bytes in size. [Background technology]

[0003] Background of the disclosure Blood coagulation proceeds through a complex and dynamic biological pathway of interdependent biochemical reactions called the coagulation cascade. Coagulation factor VIII (FVIII) is a critical component of the cascade. Factor VIII is recruited to the site of bleeding and forms an Xase complex with activated factor IX (FIXa) and factor X (FX). The Xase complex activates FX, which in turn activates prothrombin to thrombin, which then activates other components of the coagulation cascade to generate a stable clot (reviewed in Saenko et al., Trends Cardiovasc. Med., 9:185-192 (1999) (Non-Patent Document 1); Lenting et al., Blood, 92:3983-3996 (1998) (Non-Patent Document 2)).

[0004] Hemophilia A is a congenital X-linked bleeding disorder characterized by a deficiency in factor VIII activity. The weakened factor VIII activity inhibits a positive feedback loop in the coagulation cascade. This leads to defective clotting, which manifests as bleeding episodes of increased duration, large bruises, spontaneous oral and nosebleeds, joint stiffness and chronic pain, and possible internal bleeding and anemia in severe cases (Zhang et al, Clinic. Rev. Allerg. Immunol., 37:114-124 (2009)).

[0005] Hemophilia A is traditionally treated with factor VIII replacement therapy, which consists of administering factor VIII protein (e.g., plasma-derived or recombinantly produced factor VIII) to individuals with hemophilia A. Factor VIII is administered prophylactically in response to acute bleeding episodes to prevent or reduce the frequency of bleeding episodes and / or perioperatively to manage bleeding during surgery. However, factor VIII replacement therapy has several undesirable characteristics.

[0006] First, factor VIII replacement therapy is used to treat or manage hemophilia A, but does not cure the underlying factor VIII deficiency. Because of this, individuals with hemophilia A require factor VIII replacement therapy for the rest of their lives. Continuous treatment is expensive and requires individuals to maintain strict compliance, as missing just a few prophylactic doses can lead to serious outcomes in individuals with severe hemophilia A.

[0007] Second, because factor VIII has a relatively short half-life in vivo, traditional prophylactic factor VIII replacement therapy requires dosing every 2 or 3 days. This places a burden on individuals to maintain lifelong compliance. Although third-generation "long-acting" factor VIII drugs can reduce the frequency of dosing, prophylactic FVIII replacement therapy with these drugs still requires monthly, weekly, or more frequent dosing in perpetuity. For example, prophylactic treatment with ELOCTATE™ [Antihemophilic Factor (Recombinant), Fc Fusion Protein] requires dosing every 3 to 5 days (Prescribing Information for ELOCTATE™, Biogen Idec Inc., (2015)). Moreover, the long-term effects of chemically modified biology (e.g., pegylated polypeptides) are not yet fully understood.

[0008] Third, 15-30% of all individuals receiving factor VIII replacement therapy develop anti-factor VIII inhibitor antibodies, rendering the therapy inefficient. Factor VIII bypass therapy (e.g., administration of plasma-derived or recombinantly produced prothrombin complex concentrates) can be used to treat hemophilia in individuals who form inhibitor antibodies. However, factor VIII bypass therapy is less effective than factor VIII replacement therapy (Mannucci PM, J Thromb Haemost., 1(7):1349-55 (2003) (Non-Patent Document 5)) and may be associated with an increased risk of cardiovascular complications (Luu and Ewenstein, Haemophilia, 10 Suppl. 2:10-16 (2004) (Non-Patent Document 6)).

[0009] Somatic cell gene therapy holds great promise for the treatment of hemophilia A because it does not provide an individual with a one-time dose of factor VIII activity, but rather corrects the underlying low expression of functional factor VIII activity (e.g., due to missense or nonsense mutations). Because of this difference in mechanism of action, a one-time administration of a factor VIII gene therapy vector compared to factor VIII replacement therapy may provide an individual with factor VIII for several years, reducing the cost of treatment and eliminating the need for continued patient compliance.

[0010] Coagulation factor IX (FIX) gene therapy has been used effectively to treat individuals with hemophilia B, a related blood clotting condition characterized by weakened factor IX activity (Manno CS, et al., Nat Med., 12(3):342-47 (2006)). However, factor VIII gene therapy presents some unique challenges. For example, the full-length wild-type factor VIII polypeptide (2351 amino acids, UniProt accession number P00451) is five times longer than the full-length wild-type factor IX polypeptide (461 amino acids, UniProt accession number P00740). Thus, the coding sequence for wild-type factor VIII is 7053 base pairs, which is too large to be packaged into conventional AAV gene therapy vectors. Furthermore, reported recombinant expression of the B-domain deleted mutant of factor VIII (BDD-FVIII) has been poor. For this reason, several groups have attempted to modify the codon usage of the BDD-FVIII construct, but without much success. [Prior art documents] [Non-patent literature]

[0011] [Non-Patent Document 1] Saenko et al.,Trends Cardiovasc.Med.,9:185-192(1999) [Non-Patent Document 2] Lenting et al.,Blood,92:3983-3996(1998) [Non-Patent Document 3] Zhang et al,Clinic.Rev.Allerg.Immunol.,37:114-124(2009) [Non-Patent Document 4] ELOCTATE(TM) Prescribing Information, Biogen Idec Inc., (2015) [Non-Patent Document 5] Mannucci PM, J Thromb Haemost.,1(7):1349-55(2003) [Non-Patent Document 6] Luu and Ewenstein, Haemophilia, 10 Suppl.2:10-16(2004) [Non-Patent Document 7] Manno CS, et al., Nat Med., 12(3):342-47(2006) Summary of the Invention

[0012] Disclosure Summary Thus, there is a need for factor VIII variants whose coding sequences can be more efficiently packaged and delivered by gene therapy vectors. There is also a need for synthetic codon-modified nucleic acids that allow for more efficient expression of factor VIII. Such factor VIII variants and codon-modified nucleic acids allow for improved treatment of factor VIII deficiency (e.g., hemophilia A). The above deficiencies, and other problems associated with the treatment of factor VIII deficiency (e.g., hemophilia A), are reduced or eliminated by the codon-modified factor VIII variants of the present disclosure.

[0013] According to some embodiments, the present disclosure provides nucleic acids encoding Factor VIII variants having high sequence identity to the codon-modified sequences of the present disclosure of the Factor VIII heavy (e.g., CS04-HC-NA) and light (e.g., CS04-LC-NA) chains. In some embodiments, these nucleic acids further comprise a sequence encoding a linker sequence (e.g., a linker sequence comprising a furin cleavage site) that replaces the native Factor VIII B domain between the sequences encoding the Factor VIII heavy and light chains.

[0014] In one aspect, the disclosure provides a polynucleotide comprising a nucleotide sequence encoding a factor VIII polypeptide. The factor VIII polypeptide comprises a light chain, a heavy chain, and a polypeptide linker linking the C-terminus of the heavy chain to the N-terminus of the light chain. The heavy chain of the factor VIII polypeptide is encoded by a first nucleotide sequence having at least 95% identity to CS04-HC-NA (SEQ ID NO:3). The light chain of the factor VIII polypeptide is encoded by a second nucleotide sequence having at least 95% identity to CS04-LC-NA (SEQ ID NO:4). The polypeptide linker comprises a furin cleavage site.

[0015] In one embodiment of the above polynucleotide, the polypeptide linker is encoded by a third nucleotide sequence having at least 95% identity to BDLO04 (SEQ ID NO:5).

[0016] In one embodiment of the above polynucleotide, the first nucleotide sequence encoding the heavy chain of the FVIII polypeptide has at least 96% identity with the respective heavy chain sequence (e.g., CS04-HC-NA (SEQ ID NO: 3)), and the second nucleotide sequence encoding the light chain of the FVIII polypeptide has at least 96% identity with the respective light chain sequence (e.g., CS04-LC-NA (SEQ ID NO: 4)).

[0017] In one embodiment of the above polynucleotide, the first nucleotide sequence encoding the heavy chain of the FVIII polypeptide has at least 97% identity with the respective heavy chain sequence (e.g., CS04-HC-NA (SEQ ID NO: 3)), and the second nucleotide sequence encoding the light chain of the FVIII polypeptide has at least 97% identity with the respective light chain sequence (e.g., CS04-LC-NA (SEQ ID NO: 4)).

[0018] In one embodiment of the above polynucleotide, the first nucleotide sequence encoding the heavy chain of the FVIII polypeptide has at least 98% identity with the respective heavy chain sequence (e.g., CS04-HC-NA (SEQ ID NO: 3)), and the second nucleotide sequence encoding the light chain of the FVIII polypeptide has at least 98% identity with the respective light chain sequence (e.g., CS04-LC-NA (SEQ ID NO: 4)).

[0019] In one embodiment of the above polynucleotide, the first nucleotide sequence encoding the heavy chain of the FVIII polypeptide has at least 99% identity with the respective heavy chain sequence (e.g., CS04-HC-NA (SEQ ID NO: 3)), and the second nucleotide sequence encoding the light chain of the FVIII polypeptide has at least 99% identity with the respective light chain sequence (e.g., CS04-LC-NA (SEQ ID NO: 4)).

[0020] In one embodiment of the above polynucleotide, the first nucleotide sequence encoding the heavy chain of the FVIII polypeptide has at least 99.5% identity with the respective heavy chain sequence (e.g., CS04-HC-NA (sequence number 3)), and the second nucleotide sequence encoding the light chain of the FVIII polypeptide has at least 99.5% identity with the respective light chain sequence (e.g., CS04-LC-NA (sequence number 4)).

[0021] In one embodiment of the above polynucleotide, the first nucleotide sequence encoding the heavy chain of the FVIII polypeptide has at least 99.9% identity with the respective heavy chain sequence (e.g., CS04-HC-NA (sequence number 3)), and the second nucleotide sequence encoding the light chain of the FVIII polypeptide has at least 99.9% identity with the respective light chain sequence (e.g., CS04-LC-NA (sequence number 4)).

[0022] In one embodiment of the above polynucleotide, the first nucleotide sequence encoding the heavy chain of the factor VIII polypeptide is CS04-HC-NA (sequence number 3) and the second nucleotide sequence encoding the light chain of the factor FVIII polypeptide is CS04-LC-NA (sequence number 4).

[0023] In one aspect, the disclosure provides a polynucleotide comprising a nucleotide sequence having at least 95% identity to CS04-FL-NA, wherein the polynucleotide encodes a Factor VIII polypeptide.

[0024] In one embodiment of the above polynucleotides, the nucleotide sequence has at least 96% identity to the respective full-length polynucleotide sequence (eg, CS04-FL-NA (SEQ ID NO:1)).

[0025] In one embodiment of the above polynucleotides, the nucleotide sequence has at least 97% identity to the respective full-length polynucleotide sequence (eg, CS04-FL-NA (SEQ ID NO:1)).

[0026] In one embodiment of the above polynucleotides, the nucleotide sequence has at least 98% identity to the respective full-length polynucleotide sequence (eg, CS04-FL-NA (SEQ ID NO:1)).

[0027] In one embodiment of the above polynucleotides, the nucleotide sequence has at least 99% identity to the respective full-length polynucleotide sequence (eg, CS04-FL-NA (SEQ ID NO:1)).

[0028] In one embodiment of the above polynucleotides, the nucleotide sequence has at least 99.5% identity to the respective full-length polynucleotide sequence (eg, CS04-FL-NA (SEQ ID NO:1)).

[0029] In one embodiment of the above polynucleotides, the nucleotide sequence has at least 99.9% identity to the respective full-length polynucleotide sequence (eg, CS04-FL-NA (SEQ ID NO:1)).

[0030] In one embodiment of the above polynucleotide, the nucleotide sequence is CS04-FL-NA (SEQ ID NO:1).

[0031] In one embodiment of the above polynucleotide, the polynucleotide encodes a Factor VIII polypeptide comprising an amino acid sequence having at least 95% identity to CS04-FL-AA (SEQ ID NO:2).

[0032] In one embodiment of the above polynucleotide, the polynucleotide encodes a Factor VIII polypeptide comprising an amino acid sequence having at least 96% identity to CS04-FL-AA (SEQ ID NO:2).

[0033] In one embodiment of the above polynucleotide, the polynucleotide encodes a Factor VIII polypeptide comprising an amino acid sequence having at least 97% identity to CS04-FL-AA (SEQ ID NO:2).

[0034] In one embodiment of the above polynucleotide, the polynucleotide encodes a Factor VIII polypeptide comprising an amino acid sequence having at least 98% identity to CS04-FL-AA (SEQ ID NO:2).

[0035] In one embodiment of the above polynucleotide, the polynucleotide encodes a Factor VIII polypeptide comprising an amino acid sequence having at least 99% identity to CS04-FL-AA (SEQ ID NO:2).

[0036] In one embodiment of the above polynucleotide, the polynucleotide encodes a Factor VIII polypeptide comprising an amino acid sequence having at least 99.5% identity to CS04-FL-AA (SEQ ID NO:2).

[0037] In one embodiment of the above polynucleotide, the polynucleotide encodes a Factor VIII polypeptide comprising an amino acid sequence having at least 99.9% identity to CS04-FL-AA (SEQ ID NO:2).

[0038] In one embodiment of the above polynucleotide, the polynucleotide encodes a Factor VIII polypeptide comprising the amino acid sequence of CS04-FL-AA (SEQ ID NO:2).

[0039] In one embodiment of the above polynucleotide, the nucleotide sequence has at least 95% identity to a sequence selected from the group consisting of CS04-FL-NA, CS04-HC-NA, and CS04-LC-NA.

[0040] In one embodiment of the above polynucleotide, the nucleotide sequence has at least 96% identity to a sequence selected from the group consisting of CS04-FL-NA, CS04-HC-NA, and CS04-LC-NA.

[0041] In one embodiment of the above polynucleotide, the nucleotide sequence has at least 97% identity to a sequence selected from the group consisting of CS04-FL-NA, CS04-HC-NA, and CS04-LC-NA.

[0042] In one embodiment of the above polynucleotide, the nucleotide sequence has at least 98% identity to a sequence selected from the group consisting of CS04-FL-NA, CS04-HC-NA, and CS04-LC-NA.

[0043] In one embodiment of the above polynucleotide, the nucleotide sequence has at least 99% identity to a sequence selected from the group consisting of CS04-FL-NA, CS04-HC-NA, and CS04-LC-NA.

[0044] In one embodiment of the above polynucleotide, the nucleotide sequence has at least 99.5% identity to a sequence selected from the group consisting of CS04-FL-NA, CS04-HC-NA, and CS04-LC-NA.

[0045] In one embodiment of the above polynucleotide, the nucleotide sequence has at least 99.5% identity to a sequence selected from the group consisting of CS04-FL-NA, CS04-HC-NA, and CS04-LC-NA.

[0046] In one embodiment of the above polynucleotide, the nucleotide sequence is selected from the group consisting of CS04-FL-NA, CS04-HC-NA, and CS04-LC-NA.

[0047] In one embodiment of the above polynucleotide, the polynucleotide also comprises a promoter element operably linked to the polynucleotide encoding the Factor VIII polypeptide.

[0048] In one embodiment of the above polynucleotide, the polynucleotide also comprises an enhancer element operably linked to the polynucleotide encoding the Factor VIII polypeptide.

[0049] In one embodiment of the above polynucleotide, the polynucleotide also comprises polyadenylation elements operably linked to the polynucleotide encoding the Factor VIII polypeptide.

[0050] In one embodiment of the above polynucleotide, the polynucleotide also comprises an intron operably linked to the nucleotide sequence encoding the Factor VIII polypeptide.

[0051] In one embodiment of the above polynucleotide, an intron is located between the promoter element and the translation start site (eg, the first coding ATG) of the nucleotide sequence encoding the Factor VIII polypeptide.

[0052] In another aspect, the disclosure provides a mammalian gene therapy vector comprising the above-described polynucleotide.

[0053] In one embodiment of the above mammalian gene therapy vectors, the mammalian gene therapy vector is an adeno-associated virus (AAV) vector.

[0054] In one embodiment of the above mammalian gene therapy vectors, the AAV vector is an AAV-8 vector.

[0055] In another aspect, the disclosure provides a method of treating hemophilia A comprising administering to a patient in need thereof the mammalian gene therapy vector described above.

[0056] In another embodiment, the disclosure provides a mammalian gene therapy vector as described above for treating hemophilia A.

[0057] In another aspect, the disclosure provides the use of a mammalian gene therapy vector as described above for the manufacture of a medicament for treating hemophilia A. [The present invention 1001] A human subject diagnosed with hemophilia A is administered 2×10 12 1. A method of treating hemophilia A comprising intravenously infusing a dose of adeno-associated virus (AAV) particles, wherein the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA). [The present invention 1002] A human subject diagnosed with hemophilia A is administered 6×10 12 1. A method of treating hemophilia A comprising intravenously infusing a dose of adeno-associated virus (AAV) particles, wherein the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA). [The present invention 1003] The method of claim 1001 or 1002, further comprising administering to said human subject diagnosed with hemophilia A a course of prednisolone or prednisone. [The present invention 1004] The method of claim 1003, wherein the course of prednisolone or prednisone is administered after infusion of the AAV particles. [The present invention 1005] administering said course of prednisolone or prednisone; administering to the human subject 60 mg of prednisolone or prednisone per day for the first week immediately following infusion of the AAV particles; administering to the human subject 40 mg of prednisolone or prednisone per day for a second week immediately following infusion of the AAV particles; and administering to the human subject 30 mg of prednisolone or prednisone per day for the third week immediately following infusion of the AAV particles. The method of the present invention 1003 or 1004, comprising: [The present invention 1006] The method of claim 1005, further comprising administering tapering doses of prednisolone or prednisone immediately following the third week following infusion of the AAV particles. [The present invention 1007] administering said tapered dose of prednisolone or prednisone, administering to said human subject 20 mg of prednisolone or prednisone per day for five consecutive days immediately following completion of an initial course of prednisolone or prednisone; administering to said human subject 15 mg of prednisolone or prednisone per day for three consecutive days immediately following said five day period during which said human subject was administered 20 mg of prednisolone or prednisone; administering to said human subject 10 mg of prednisolone or prednisone per day for three consecutive days immediately following the three day period during which said human subject was administered 15 mg of prednisolone or prednisone; and administering to said human subject 5 mg of prednisolone or prednisone per day for three consecutive days immediately following said three days during which said human subject was administered 10 mg of prednisolone or prednisone. The method of the present invention 1006, comprising: [The present invention 1008] administering said tapered dose of prednisolone or prednisone, administering to said human subject 30 mg of prednisolone or prednisone per day for seven consecutive days immediately following completion of said initial course of prednisolone or prednisone; administering to said human subject 20 mg of prednisolone or prednisone per day for seven consecutive days immediately following said seven day period during which said human subject was administered 30 mg of prednisolone or prednisone; administering to said human subject 15 mg of prednisolone or prednisone per day for 5 consecutive days immediately following said 7 day period during which said human subject was administered 20 mg of prednisolone or prednisone; administering to said human subject 10 mg of prednisolone or prednisone per day for 5 consecutive days immediately following the 5 day period during which said human subject was administered 15 mg of prednisolone or prednisone; and administering to said human subject 5 mg of prednisolone or prednisone per day for 5 consecutive days immediately following said 5 day period during which said human subject was administered 10 mg of prednisolone or prednisone. The method of the present invention 1006, comprising: [The present invention 1009] determining a first level of factor VIII activity in a blood sample collected from a human subject diagnosed with hemophilia A after administering to the human subject an adeno-associated virus (AAV) particle comprising a polynucleotide encoding a factor VIII protein and while the human subject is receiving an initial course of glucocorticoid steroid treatment; determining a second level of factor VIII activity in a blood sample collected from the human subject after completion of the first course of glucocorticoid steroid treatment; comparing said second level of factor VIII activity with said first level of factor VIII activity; and administering tapering doses of said glucocorticoid steroid, if said second level of factor VIII activity is equal to or greater than said first level of factor VIII activity, then a first tapered dose of said glucocorticoid steroid is administered over a period of not more than three weeks; if the second level of factor VIII activity is less than the first level of factor VIII activity, a second tapered dose of the glucocorticoid steroid is administered over a period of more than three weeks. The administering The method includes: [The present invention 1010] determining a first level of liver enzyme activity in a blood sample collected from a human subject diagnosed with hemophilia A prior to administering to the human subject an adeno-associated virus (AAV) particle comprising a polynucleotide encoding a Factor VIII protein; determining a second level of liver enzyme activity in a blood sample collected from the human subject after administering to the human an AAV particle comprising a polynucleotide encoding a Factor VIII protein and after completing an initial course of glucocorticoid steroid treatment; comparing said second level of liver enzyme activity to said first level of liver enzyme activity; and administering tapering doses of said glucocorticoid steroid, if said second level of liver enzyme activity is equal to or less than said first level of liver enzyme activity, a first tapered dose of said glucocorticoid steroid is administered over a period of not more than three weeks; if the second level of liver enzyme activity is greater than the first level of factor VIII activity, a second tapered dose of the glucocorticoid steroid is administered for a period of greater than three weeks. The administering The method includes: [The present invention 1011] administering said first tapered dose of said glucocorticoid steroid; administering to said human subject 20 mg of prednisolone or prednisone per day for 5 consecutive days immediately following completion of said initial course of glucocorticoid steroid treatment; administering to said human subject 15 mg of prednisolone or prednisone per day for three consecutive days immediately following said five day period during which said human subject was administered 20 mg of prednisolone or prednisone; administering to said human subject 10 mg of prednisolone or prednisone per day for three consecutive days immediately following the three day period during which said human subject was administered 15 mg of prednisolone or prednisone; and administering to said human subject 5 mg of prednisolone or prednisone per day for three consecutive days immediately following said three days during which said human subject was administered 10 mg of prednisolone or prednisone. The method of the present invention 1009 or 1010, comprising: [The present invention 1012] administering said second tapered dose of said glucocorticoid steroid; administering to said human subject 30 mg of prednisolone or prednisone per day for seven consecutive days immediately following completion of said initial course of glucocorticoid steroid treatment; administering to said human subject 20 mg of prednisolone or prednisone per day for seven consecutive days immediately following said seven day period during which said human subject was administered 30 mg of prednisolone or prednisone; administering to said human subject 15 mg of prednisolone or prednisone per day for 5 consecutive days immediately following said 7 day period during which said human subject was administered 20 mg of prednisolone or prednisone; administering to said human subject 10 mg of prednisolone or prednisone per day for 5 consecutive days immediately following the 5 day period during which said human subject was administered 15 mg of prednisolone or prednisone; and administering to said human subject 5 mg of prednisolone or prednisone per day for 5 consecutive days immediately following said 5 day period during which said human subject was administered 10 mg of prednisolone or prednisone. Any of the methods of 1009 to 1011 of the present invention. [The present invention 1013] 1. A method for monitoring the effectiveness of factor VIII gene therapy for hemophilia A using an adeno-associated virus (AAV) particle comprising a polynucleotide encoding a factor VIII polypeptide, comprising: determining whether factor VIII inhibitor antibodies are present in a blood sample collected from the human subject after administration of the AAV particles to the human subject; and Upon detecting the presence of a factor VIII inhibitor in the blood of said human subject, administering to said human subject an alternative drug for the treatment of hemophilia A. The method comprising: [The present invention 1014] The method of any one of claims 1 to 3, wherein said replacement agent comprises a chemically modified human Factor VIII protein. [The present invention 1015] The method of claim 1013, wherein said alternative agent comprises porcine factor VIII protein. [The present invention 1016] The method of claim 1013, wherein said alternative agent is a factor VIII bypass therapy agent, including factors II, IX and X. [The present invention 1017] a) To a patient with hemophilia A, 2 x 10 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of SEQ ID NO:1 or a fragment thereof in the bloodstream of said patient at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1018] a) To a patient with hemophilia A, 6 x 10 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of SEQ ID NO:1 or a fragment thereof in the bloodstream of said patient at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1019] a) administering to a patient with hemophilia A a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide encoding a factor VIII protein; and b) measuring the level of the polynucleotide encoding the Factor VIII protein or a fragment thereof in the bloodstream of the patient at a later time point, wherein the later time point is 7 days or later. The method includes: [The present invention 1020] Any of the methods of claims 1017 to 1019, wherein said later time point is 7 days. [The present invention 1021] Any of the methods of claims 1017 to 1019, wherein the later time point is 14 days. [The present invention 1022] Any of the methods of claims 1017 to 1019, wherein said later time point is 21 days. [The present invention 1023] a) To a patient with hemophilia A, 2 x 10 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of said capsid protein in the bloodstream of said patient at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1024] a) To a patient with hemophilia A, 6 x 10 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of said capsid protein in the bloodstream of said patient at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1025] a) administering to a patient with hemophilia A a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide encoding a factor VIII protein; and b) measuring the level of said capsid protein in the bloodstream of said patient at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1026] 1026. The method of any one of claims 1023 to 1025, wherein said later time point is 7 days. [The present invention 1027] 1026. The method of any one of claims 1023 to 1025, wherein said later time point is 14 days. [The present invention 1028] 1026. The method of any one of claims 1023 to 1025, wherein said later time point is 21 days. [The present invention 1029] a) To a patient with hemophilia A, 2 x 10 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of anti-Factor VIII antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1030] a) To a patient with hemophilia A, 6 x 10 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of anti-Factor VIII antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1031] a) administering to a patient with hemophilia A a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide encoding a factor VIII protein; and b) measuring the level of anti-Factor VIII antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1032] 1032. The method of any one of claims 1029 to 1031, wherein said later time point is 7 days. [The present invention 1033] 1032. The method of any one of claims 1029 to 1031, wherein the later time point is 14 days. [The present invention 1034] 1032. The method of any one of claims 1029 to 1031, wherein said later time point is 21 days. [The present invention 1035] a) To a patient with hemophilia A, 2 x 10 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of anti-capsid protein antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1036] a) To a patient with hemophilia A, 6 x 10 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of anti-capsid protein antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1037] a) administering to a patient with hemophilia A a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide encoding a factor VIII protein; and b) measuring the level of anti-capsid protein antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes: [The present invention 1038] c) measuring a baseline level of anti-capsid protein antibodies in the bloodstream of the patient prior to administering to the patient the dose of the adeno-associated virus (AAV) particles; and d) optionally comparing said measured level of anti-capsid protein antibodies in said patient's bloodstream at said later time point with said baseline level of anti-capsid protein antibodies in said patient's bloodstream. Any of the methods of claims 1035 to 1037, further comprising: [The present invention 1039] The method of any one of claims 1035 to 1038, wherein said later time point is 7 days. [The present invention 1040] The method of any one of claims 1035 to 1038, wherein said later time point is 14 days. [The present invention 1041] The method of any one of claims 1035 to 1038, wherein said later time point is 21 days. [Brief description of the drawings]

[0058] [Figure 1] FIG. 1 shows a schematic diagram of wild-type and ReFacto-type human Factor VIII protein constructs. [Figure 2A] FIG. 1 shows the CS04 codon-modified nucleotide sequence (SEQ ID NO:1) encoding a Factor VIII variant according to some embodiments (full length coding sequence "CS04-FL-NA"). [Figure 2B] FIG. 1 shows the CS04 codon-modified nucleotide sequence (SEQ ID NO:1) encoding a Factor VIII variant according to some embodiments (full length coding sequence "CS04-FL-NA"). [Diagram 3]1 shows the Factor VIII variant amino acid sequence (SEQ ID NO:2) encoded by the CS04 codon-modified nucleotide sequence according to some embodiments (full-length amino acid sequence "CS04-FL-AA"). [Figure 4] 1 shows a portion ("CS04-HC-NA") of the CS04 codon-modified nucleotide sequence (SEQ ID NO:3) encoding the heavy chain of a Factor VIII mutant according to some embodiments. [Diagram 5] 1 shows a portion ("CS04-LC-NA") of the CS04 codon-modified nucleotide sequence (SEQ ID NO:4), encoding the light chain of a Factor VIII mutant according to some embodiments. [Figure 6] An exemplary coding sequence (SEQ ID NO:5) of a B domain replacement linker according to some embodiments is shown. BDLO04 (SEQ ID NO:5) is a unique portion of the CS04 codon-modified nucleotide sequence that encodes the B domain replacement linker. [Figure 7A] FIG. 1 shows an AAV vector sequence (SEQ ID NO:8) containing the CS04 codon-altered nucleotide sequence according to some embodiments ("CS04-AV-NA"). [Figure 7B] FIG. 1 shows an AAV vector sequence (SEQ ID NO:8) containing the CS04 codon-altered nucleotide sequence according to some embodiments ("CS04-AV-NA"). [Figure 7C] FIG. 1 shows an AAV vector sequence (SEQ ID NO:8) containing the CS04 codon-altered nucleotide sequence according to some embodiments ("CS04-AV-NA"). [Figure 8A] 1 shows the CS08 codon-modified nucleotide sequence (SEQ ID NO:7) encoding a Factor VIII mutant according to some embodiments ("CS08-FL-NA"). [Figure 8B] 1 shows the CS08 codon-modified nucleotide sequence (SEQ ID NO:7) encoding a Factor VIII mutant according to some embodiments ("CS08-FL-NA"). [Figure 9A]1 shows the CS10 codon-modified nucleotide sequence (SEQ ID NO:8) encoding a Factor VIII mutant according to some embodiments ("CS10-FL-NA"). [Figure 9B] 1 shows the CS10 codon-modified nucleotide sequence (SEQ ID NO:8) encoding a Factor VIII mutant according to some embodiments ("CS10-FL-NA"). [Figure 10A] 1 shows the CS11 codon-modified nucleotide sequence (SEQ ID NO:9) encoding a Factor VIII mutant according to some embodiments ("CS11-FL-NA"). [Figure 10B] 1 shows the CS11 codon-modified nucleotide sequence (SEQ ID NO:9) encoding a Factor VIII mutant according to some embodiments ("CS11-FL-NA"). [Figure 11A] 1 shows the CS40 wild-type ReFacto coding sequence (SEQ ID NO: 10) ("CS40-FL-NA") according to some embodiments. [Figure 11B] 1 shows the CS40 wild-type ReFacto coding sequence (SEQ ID NO: 10) ("CS40-FL-NA") according to some embodiments. [Figure 12A] 1 shows a CH25 codon-modified nucleotide sequence (SEQ ID NO:11) encoding a Factor VIII mutant according to some embodiments ("CH25-FL-NA"). [Figure 12B] 1 shows a CH25 codon-modified nucleotide sequence (SEQ ID NO:11) encoding a Factor VIII mutant according to some embodiments ("CH25-FL-NA"). [Figure 13] 1 shows the wild-type human Factor VIII amino acid sequence (SEQ ID NO: 12) ("FVIII-FL-AA") according to some embodiments. [Figure 14] FIG. 1 shows a scheme for cloning the pCS40, pCS04, pCS08, pCS10, pCS11 and pCh25 constructs by inserting the synthetic Refacto type BDD-FVIII DNA sequence into the vector backbone pCh-BB01 via the AscI and NotI restriction sites. [Figure 15]Figure 1 shows the integrity of the AAV vector genome constructs analyzed by agarose gel electrophoresis. Lane 1, DNA marker; lane 2, vCS40; lane 4, vCS04. The AAV vectors all have the same size genome, migrating at approximately 5 kb (arrow, right). The scale on the left indicates the size of the DNA fragment in kilobases (kb). [Figure 16] PAGE and silver stain protein analysis of AAV vector constructs are shown. Lane 1, protein marker (M); lane 2, vCS40; and lane 4, vCS04. All constructs have the same AAV8 capsid consisting of VP1, VP2, and VP3 (arrows on the right). The scale on the left indicates the size of the protein markers in kilodaltons (kDa). [Figure 17] Figure 1 shows FVIII activity following systemic administration of an (r)AAV8-based gene therapy vector containing the CS04 Factor VIII codon-optimized construct described in Example 3. cp, vector capsid particle; FVIII, Factor VIII; LLOQ, lower limit of quantification. Graph shows time points of 14, 28, 42 and 56 days from left to right. [Figure 18] Figure 2 shows reduced blood loss in a tail tip bleeding assay following systemic administration of (r)AAV8-based gene therapy vectors containing the CS04 Factor VIII codon-optimized construct described in Example 3. cp, vector capsid particle. [Figure 19A] 1 shows the biodistribution of (r)AAV8-based gene therapy vectors containing CS04 Factor VIII codon-optimized construct DNA following systemic administration: 1902=liver, 1904=lymph nodes, 1906=skeletal muscle, 1908=heart, 1910=kidney, 1912=spleen, 1914=lung, 1916=testis, 1918=brain. [Figure 19B] 1 shows the biodistribution of (r)AAV8-based gene therapy vectors containing CS04 Factor VIII codon-optimized construct DNA following systemic administration: 1902=liver, 1904=lymph nodes, 1906=skeletal muscle, 1908=heart, 1910=kidney, 1912=spleen, 1914=lung, 1916=testis, 1918=brain. [Figure 19C]1 shows the biodistribution of (r)AAV8-based gene therapy vectors containing CS04 Factor VIII codon-optimized construct DNA following systemic administration: 1902=liver, 1904=lymph nodes, 1906=skeletal muscle, 1908=heart, 1910=kidney, 1912=spleen, 1914=lung, 1916=testis, 1918=brain. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0059] Detailed Description of the Disclosure I. Introduction AAV-based gene therapy holds great promise in the treatment of hemophilia. In hemophilia B, initial clinical data are encouraging in that FIX levels of approximately 10% can be maintained for more than one year in at least some patients. However, in hemophilia A, achieving therapeutic expression levels of 5-10% with AAV vectors remains a challenge for a variety of reasons. First, the factor VIII coding sequence is too large for conventional AAV-based vectors. Second, engineered factor VIII constructs with deleted or truncated B domains suffer from poor in vivo expression, even when codon-optimized. Third, these factor VIII mutant constructs with deleted or truncated B domains have short half-lives in vivo, exacerbating the effects of poor expression. Fourth, even when expressed, FVIII is not efficiently secreted from cells in the same way as other clotting factors, such as factor IX. Thus, strategies to improve FVIII expression are needed to make FVIII gene therapy a viable treatment option for hemophilia A patients.

[0060] The present disclosure relates to the discovery of codon-modified factor VIII variants encoding sequences that overcome these and other challenges associated with factor VIII gene therapy. For example, the polynucleotides disclosed herein provide significantly improved expression in mammalian cells and exhibit improved virion packaging due to stabilization of packing interactions. In some embodiments, these advantages are realized by using coding sequences for the heavy and light chains of factor VIII that have high sequence identity with the codon-modified CS04 construct (e.g., high sequence identity with the CS04-HC heavy chain coding sequence and high sequence identity with the CS04-LC light chain coding sequence).

[0061] In some embodiments, the Factor VIII molecules encoded by the polynucleotides described herein are shortened by truncating, deleting or replacing the wild-type B domain, making them more suitable for expressing Factor VIII by traditional gene therapy vectors that inefficiently express larger polypeptides such as wild-type Factor VIII.

[0062] Advantageously, it is shown herein that the CS04 codon-modified factor VIII variant coding sequence results in superior expression of B-domain deleted factor VIII constructs in vivo. For example, Example 2 and Table 4 demonstrate that intravenous administration of an AAV-based gene therapy vector carrying the CS04 (SEQ ID NO: 1) coding sequence in factor VIII knockout mice results in a 74-fold increase in factor VIII expression compared to the corresponding CS40 construct encoded by the wild-type polynucleotide sequence (SEQ ID NO: 10) (Table 4).

[0063] It is further shown herein that the CS04 codon-modified factor VIII variant coding sequence results in superior virion packaging and virus production. For example, Example 1 demonstrates that AAV vector constructs containing the CS04 construct result in 5-7 fold higher virus yields compared to the corresponding CS40 construct encoded by the wild-type polynucleotide sequence when isolated from the same amount of cell pellet.

[0064] II. Definition As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

[0065] As used herein, the terms "Factor VIII" and "FVIII" are used interchangeably and refer to any protein having Factor VIII activity (e.g., activated FVIII, often referred to as FVIIIa), or a protein precursor (e.g., a proprotein or preproprotein) of a protein having Factor VIII activity, particularly Factor IXa cofactor activity. In exemplary embodiments, a Factor VIII polypeptide refers to a polypeptide having a sequence that has high (e.g., at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or more) sequence identity to the heavy and light chains of a wild-type Factor VIII polypeptide. In some embodiments, the B domain of the Factor VIII polypeptide is deleted, truncated, or replaced with a linker polypeptide to reduce the size of the polynucleotide encoding the Factor VIII polypeptide. In exemplary embodiments, amino acids 20 to 1457 of CS04-FL-AA constitute the Factor VIII polypeptide.

[0066] Non-limiting examples of wild-type factor VIII polypeptides include human preprofactor VIII (e.g., GenBank Accession Nos. AAA52485, CAA25619, AAA58466, AAA52484, AAA52420, AAV85964, BAF82636, BAG36452, CAI41660, CAI41666, CAI41672, CAI43241, CAO03404, EAW72645, AAH22513, AAH64380, AAH98389, AAI11968, AAI11970, or AAB61261), the corresponding profactor VIII, and naturally occurring variants thereof; porcine preprofactor VIII (e.g., , UniProt Accession Nos. F1RZ36 or K7GSZ5), the corresponding pro-factor VIII, and naturally occurring variants thereof; mouse prepro-factor VIII (e.g., GenBank Accession Nos. AAA37385, CAM15581, CAM26492, or EDL29229), the corresponding pro-factor VIII, and naturally occurring variants thereof; rat prepro-factor VIII (e.g., GenBank Accession No. AAQ21580), the corresponding pro-factor VIII, and naturally occurring variants thereof; rat prepro-factor VIII; and other mammalian factor VIII homologs (e.g., monkey, ape, hamster, guinea pig, etc.).

[0067] As used herein, Factor VIII polypeptides include naturally occurring variants and artificial constructs that have Factor IX cofactor activity. As used within this disclosure, Factor VIII encompasses any naturally occurring variant, alternate sequence, isoform, or mutein that retains some basal Factor IX cofactor activity (e.g., at least 5%, 10%, 25%, 50%, 75% or more of the corresponding wild-type activity). Examples of Factor VIII amino acid variants (relative to FVIII-FL-AA (SEQ ID NO: 12)) found in the human population include, but are not limited to: TIFF2024167251000002.tif63165TIFF2024167251000003.tif208165. Factor VIII proteins also include polypeptides that contain post-translational modifications.

[0068] Typically, a polynucleotide encoding factor VIII encodes an inactive single-chain polypeptide (eg, a preproprotein) that is post-translationally processed to form an activated factor VIII protein (eg, FVIIIa). For example, with reference to FIG. 1 , wild-type human factor VIII preproprotein is first cleaved to release the encoded signal peptide (not shown) to form a first single-chain proprotein (denoted as “human wild-type FVIII”). The proprotein is then cleaved between the B and A3 domains to form a first polypeptide comprising a factor VIII heavy chain (e.g., A1 and A2 domains) and a B domain, and a second polypeptide comprising a factor VIII light chain (e.g., A3, C1 and C3 domains). The first polypeptide is further cleaved to remove the B domain and to separate the A1 and A2 domains, which remain associated with the factor VIII light chain in the mature factor VIIIa protein. For a review of the factor VIII maturation process, see Graw et al., Nat Rev Genet., 6(6):488-501 (2005), the contents of which are incorporated herein by reference in their entirety for all purposes.

[0069] However, in some embodiments, the Factor VIII polypeptide is a single-chain Factor VIII polypeptide. Single-chain Factor VIII polypeptides are engineered to remove the natural cleavage site and, optionally, to remove, truncate, or replace the B domain of Factor VIII. Thus, they do not undergo maturation by cleavage (other than cleavage of the optional signal and / or leader peptide) and are active as single chains. Non-limiting examples of single-chain Factor VIII polypeptides are described in Zollner et al. (Thromb Res, 134(1):125-31(2014)) and Donath et al. (Biochem J., 312(1):49-55(1995)), the disclosures of which are incorporated by reference in their entirety for all purposes.

[0070] As used herein, the term "Factor VIII heavy chain" or simply "heavy chain" refers to an aggregate of the A1 and A2 domains of a Factor VIII polypeptide. In an exemplary embodiment, amino acids 20 to 759 of CS04-FL-AA (SEQ ID NO: 2) constitute the Factor VIII heavy chain.

[0071] As used herein, the term "Factor VIII light chain" or simply "light chain" refers to an aggregate of the A3, C1 and C2 domains of a Factor VIII polypeptide. In an exemplary embodiment, amino acids 774-1457 CS04-FL-AA (SEQ ID NO:2) constitute the Factor VIII light chain. In some embodiments, the acidic a3 peptide, which is liberated during in vivo maturation, is excluded from the Factor VIII light chain.

[0072] Typically, the Factor VIII heavy and light chains are expressed as a single polypeptide chain, e.g., together with an optional B domain or B domain-substituted linker. However, in some embodiments, the Factor VIII heavy chain and the Factor VIII light chain are expressed (e.g., co-expressed) as separate polypeptide chains and reconstituted to form the Factor VIII protein (e.g., in vivo or in vitro).

[0073] As used herein, the terms "B domain replacement linker" and "Factor VIII linker" are used interchangeably and refer to a truncated form of the wild-type Factor VIII B domain (e.g., amino acids 760-1667 of FVIII-FL-AA (SEQ ID NO: 12)) or a peptide engineered to replace the B domain of a Factor VIII polypeptide. As used herein, a Factor VIII linker is located between the C-terminus of the Factor VIII heavy chain and the N-terminus of the Factor VIII light chain in the Factor VIII mutant polypeptides of some embodiments. Non-limiting examples of B domain replacement linkers are described in U.S. Pat. Nos. 4,868,112, 5,112,950, 5,171,844, 5,543,502, 5,595,886, 5,610,278, 5,789,203, 5,972,885, 6,048,720, 6,060,447, 6,114,148, 6 ,228,620, 6,316,226, 6,346,513, 6,458,563, 6,924,365, 7,041,635 and 7,943,374; U.S. Patent Application Publication Nos. 2013 / 024960, 2015 / 0071883 and 2015 / 0158930; and PCT Publication Nos. WO2014 / 064277 and WO2014 / 127215.

[0074] Unless otherwise indicated herein, the numbering of factor VIII amino acids refers to the corresponding amino acids in the full-length wild-type human factor VIII sequence (FVIII-FL-AA) shown in Figure 13 as SEQ ID NO: 12. Thus, when referring to amino acid substitutions in the factor VIII variant proteins disclosed herein, the recited amino acid numbers refer to similar (e.g., structurally or functionally equivalent) and / or homologous (e.g., evolutionarily conserved in the primary amino acid sequence) amino acids in the full-length wild-type factor VIII sequence. For example, the T2105N amino acid substitution refers to a T to N substitution at position 2105 of the full-length wild-type human factor VIII sequence (FVIII-FL-AA, SEQ ID NO: 12) and a T to N substitution at position 1211 of the factor VIII variant protein encoded by CS04 (CS04-FL-AA, SEQ ID NO: 2).

[0075] As described herein, the Factor VIII amino acid numbering system depends on whether the Factor VIII signal peptide (e.g., amino acids 1-19 of the full-length wild-type human Factor VIII sequence) is included. If the signal peptide is included, the numbering is referred to as "signal peptide included" or "SPI." If the signal peptide is not included, the numbering is referred to as "signal peptide excluded" or "SPE." For example, F328S is the SPI numbering for the same amino acid as F309S in the SPE numbering. Unless otherwise indicated, all amino acid numbering refers to the corresponding amino acid in the full-length wild-type human Factor VIII sequence (FVIII-FL-AA) shown in FIG. 13 as SEQ ID NO: 12.

[0076] As described herein, the codon-modified polynucleotide (e.g., when administered as part of a gene therapy vector) results in enhanced expression of transgenic factor VIII in vivo compared to the level of factor VIII expression provided by a naturally encoded factor VIII construct (e.g., a polynucleotide encoding the same factor VIII construct using wild-type human codons). As used herein, the term "enhanced expression" means that the level of transgenic factor VIII activity in the blood of an animal administered the codon-modified polynucleotide encoding factor VIII is increased compared to the level of transgenic factor VIII activity in the blood of an animal administered the naturally encoded factor VIII construct. The activity level can be measured using any factor VIII activity assay known in the art. An exemplary assay for determining factor VIII activity is the Technochrome FVIII assay (Technoclone, Vienna, Austria).

[0077] In some embodiments, enhanced expression means that the level of transgenic Factor VIII activity in the blood of an animal administered the codon-modified Factor VIII polynucleotide is at least 25% greater than the level of transgenic Factor VIII activity in the blood of an animal administered a naturally encoded Factor VIII polynucleotide. In some embodiments, enhanced expression means that the level of transgenic Factor VIII activity in the blood of an animal administered the codon-modified Factor VIII polynucleotide is at least 50% greater, at least 75% greater, at least 100% greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater, at least 15-fold greater, at least 20-fold greater, at least 25-fold greater, at least 30-fold greater, at least 40-fold greater, at least 50-fold greater, at least 60-fold greater, at least 70-fold greater, at least 80-fold greater, at least 90-fold greater, at least 100-fold greater, at least 125-fold greater, at least 150-fold greater, at least 175-fold greater, at least 200-fold greater, at least 225-fold greater, or at least 250-fold greater than the level of transgenic Factor VIII activity in the blood of an animal administered a naturally encoded Factor VIII polynucleotide.

[0078] As described herein, the codon-modified polynucleotide provides enhanced vector production compared to the level of vector production provided by naturally encoded factor VIII constructs (e.g., polynucleotides encoding the same factor VIII constructs using wild-type human codons). As used herein, the term "enhanced virus production" refers to an increase in vector yield (e.g., titer per liter of culture) in cell cultures seeded with codon-modified polynucleotides encoding factor VIII compared to vector yield in cell cultures seeded with naturally encoded factor VIII constructs. Vector yield can be measured using any vector titer assay known in the art. An exemplary assay for determining vector yield (e.g., of AAV vectors) is qPCR targeting AAV2 terminal inverted repeat sequences (Aumhammer, Human Gene Therapy Methods:Part B 23:18-28(2012)).

[0079] In some embodiments, enhanced virus production means that the codon-modified vector yield is at least 25% higher than the naturally encoded Factor VIII construct yield in the same type of culture. In some embodiments, enhanced vector production means that the codon-modified vector yield is at least 50% greater, at least 75% greater, at least 100% greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater, at least 15-fold greater, or at least 20-fold greater than the naturally encoded Factor VIII construct yield in the same type of culture.

[0080] As used herein, the term "hemophilia" refers to a group of disease states broadly characterized by impaired blood clotting or coagulation. Hemophilia can refer to hemophilia A, B or C, or a combined form of all three disease types. Hemophilia A (hemophilia A) is caused by impaired or lost factor VIII (FVIII) activity and is the most well-known of the hemophilia subtypes. Hemophilia B (hemophilia B) results from impaired or lost factor IX (FIX) clotting function. Hemophilia C (hemophilia C) is the result of impaired or lost factor XI (FXI) clotting activity. Hemophilia A and B are X-linked disorders, while hemophilia C is autosomal. Conventional treatments for hemophilia include both prophylactic and on-demand administration of clotting factors such as FVIII, FIX, e.g. Bebulin®-VH, and FXI, as well as FEIBA-VH, desmopressin, and plasma infusions.

[0081] As used herein, the term "FVIII gene therapy" includes any therapeutic approach that provides a patient with a nucleic acid encoding factor VIII to alleviate, reduce, or prevent the recurrence of one or more symptoms (e.g., clinical factors) associated with hemophilia. The term encompasses the administration of any compound, drug, procedure, or regimen that includes a nucleic acid encoding a factor VIII molecule, including any modified form of factor VIII (e.g., factor VIII mutant), to maintain or improve the health of an individual with hemophilia. One of skill in the art will appreciate that the course of FVIII therapy or the dosage of the FVIII therapeutic agent may be modified, for example, based on the results obtained in accordance with the present disclosure.

[0082] As used herein, the term "bypass therapy" includes any therapeutic approach that provides a patient with a non-factor VIII hemostatic agent, compound, or clotting factor to alleviate, reduce, or prevent the recurrence of one or more symptoms (e.g., clinical factors) associated with hemophilia. Non-factor VIII compounds and clotting factors include, but are not limited to, factor VIII antibody bypassing complex (FEIBA), recombinant activated factor VII (FVIIa), prothrombin complex concentrate, and activated prothrombin complex concentrate. These non-factor VIII compounds and clotting factors can be recombinant or plasma-derived. One of skill in the art will appreciate that the course of bypass therapy or the dose of bypass therapy can be modified based on, for example, the results obtained in accordance with the present disclosure.

[0083] As used herein, "combination therapy" comprising administration of a nucleic acid encoding a Factor VIII molecule and a conventional hemophilia A therapeutic agent includes any therapeutic approach that provides a patient with both a nucleic acid encoding a Factor VIII molecule and a Factor VIII molecule and / or a non-Factor VIII hemostatic agent (e.g., a bypass therapy agent) to alleviate, reduce, or prevent the recurrence of one or more symptoms (e.g., clinical factors) associated with hemophilia. The term encompasses the administration of any compound, drug, procedure, or regimen comprising a nucleic acid encoding a Factor VIII molecule, including any modified form of Factor VIII, that is useful for maintaining or improving the health of an individual with hemophilia and that includes any of the therapeutic agents described herein.

[0084] The term "therapeutically effective amount or dose" or "therapeutically sufficient amount or dose" or "effective or sufficient amount or dose" refers to a dose that produces the therapeutic effect for which it is administered. For example, a therapeutically effective amount of a drug useful for treating hemophilia may be an amount that can prevent or alleviate one or more symptoms associated with hemophilia. The exact dose will depend on the purpose of the treatment and will be ascertained by one of ordinary skill in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

[0085] As used herein, the term "gene" refers to a portion of a DNA molecule that encodes a polypeptide chain (e.g., a coding region). In some embodiments, a gene includes regions immediately preceding, following, and / or intervening the coding region (e.g., regulatory elements, such as promoters, enhancers, polyadenylation sequences, 5' untranslated regions, 3' untranslated regions, or introns) that are involved in producing the polypeptide chain.

[0086] As used herein, the term "regulatory elements" refers to nucleotide sequences, such as promoters, enhancers, terminators, polyadenylation sequences, introns, and the like, that provide for the expression of a coding sequence in a cell.

[0087] As used herein, the term "promoter element" refers to a nucleotide sequence that assists in controlling the expression of a coding sequence. Typically, promoter elements are located 5' to the translation start site of a gene. However, in certain embodiments, promoter elements may be located within an intron sequence or 3' to the coding sequence. In some embodiments, promoters useful in gene therapy vectors are derived from the native gene of the protein of interest (e.g., the factor VIII promoter). In some embodiments, promoters useful in gene therapy vectors are specific for expression in a particular cell or tissue of the organism of interest (e.g., a liver-specific promoter). In still other embodiments, one of a number of well-characterized promoter elements is used in the gene therapy vectors described herein. Non-limiting examples of well-characterized promoter elements include the CMV early promoter, the β-actin promoter, and the methyl-CpG binding protein 2 (MeCP2) promoter. In some embodiments, the promoter is a constitutive promoter, which drives substantially constant expression of the protein of interest. In other embodiments, the promoter is an inducible promoter, which drives expression of the protein of interest in response to a particular stimulus (e.g., exposure to a particular treatment or drug). For a review of designing promoters for AAV-mediated gene therapy, see Gray et al. (Human Gene Therapy 22:1143-53 (2011)), the contents of which are expressly incorporated by reference in their entirety for all purposes.

[0088] As used herein, the term "vector" refers to any vehicle used to transfer a nucleic acid (e.g., encoding a Factor VIII gene therapy construct) to a host cell. In some embodiments, a vector comprises a replicon that functions to replicate the vehicle together with the nucleic acid of interest. Non-limiting examples of vectors useful for gene therapy include plasmids, phages, cosmids, artificial chromosomes, and viruses that function as autonomous replication units in vivo. In some embodiments, the vector is a viral vehicle for introducing the nucleic acid of interest (e.g., a codon-modified polynucleotide encoding a Factor VIII variant). Many modified eukaryotic viruses useful for gene therapy are known in the art. For example, adeno-associated virus (AAV) is particularly well suited for use in human gene therapy because humans are the natural host of the virus, the natural virus is not known to cause any disease, and the virus induces a weak immune response.

[0089] As used herein, the term "CpG island" refers to a region within a polynucleotide that is statistically dense for CpG dinucleotides. As used herein, a region of a polynucleotide (e.g., a polynucleotide encoding a codon-modified Factor VIII protein) is one in which, over a frame of more than 200 base pairs, (i) the GC content of the region is greater than 50% and (ii) the relationship is met: A CpG island is one where the ratio of observed to predicted CpG dinucleotides as defined in TIFF2024167251000004.tif8128 is at least 0.6. For more information on how to identify CpG islands, see Gardiner-Garden M. et al., J Mol Biol., 196(2):261-82 (1987), the entire contents of which are incorporated by reference for all purposes.

[0090] As used herein, the term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides or polymers thereof, in either single-stranded or double-stranded form, and their complements. The term encompasses synthetic, naturally occurring, and non-naturally occurring nucleic acids that contain known nucleotide analogs or modified backbone residues or linkages that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to the reference nucleotide. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methyl phosphonates, asymmetric methyl phosphonates, 2-O-methyl ribonucleotides, and peptide nucleic acids (PNAs).

[0091] The term "amino acid" refers to naturally occurring amino acids, as well as non-naturally occurring amino acids, including amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids include those encoded by the genetic code, as well as those that are later modified, such as hydroxyproline, y-carboxyglutamate, and O-phosphoserine. Naturally occurring amino acids can include, for example, D- and L-amino acids. As used herein, amino acids can also include unnatural amino acids. An amino acid analog refers to a compound that has the same basic chemical structure as a naturally occurring amino acid, i.e., any carbon bonded to a hydrogen, a carboxyl group, an amino group, and an R group, such as homoserine, norleucine, methionine sulfoxide, or methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. An amino acid mimetic refers to a chemical compound that has a structure that is different from the general chemical structure of an amino acid, but functions in a manner similar to a naturally occurring amino acid. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may likewise be referred to by their commonly accepted one-letter codes.

[0092] With respect to amino acid sequences, those skilled in the art will recognize that individual substitutions, deletions, or additions to a nucleic acid or peptide sequence that alter, add, or delete a single amino acid or a small percentage of amino acids in the encoded sequence are "conservatively modified variants" in which the modification replaces an amino acid with a chemically similar amino acid. Conservative substitution tables resulting in functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to, and do not exclude, polymorphic variants, interspecies homologs, and alleles of the present disclosure.

[0093] Conservative amino acid substitutions that result in functionally similar amino acids are well known in the art. Depending on the functionality of a particular amino acid, for example, catalytic, structural or sterically important amino acids, various classes of amino acids can be considered as conservative substitutions for each other. Table 1 shows the classes of amino acids that are considered as conservative substitutions based on the charge and polarity of the amino acid, the hydrophobicity of the amino acid, the surface exposure / structural properties of the amino acid, and the secondary structure tendency of the amino acid.

[0094] Table 1. Classification of conservative amino acid substitutions based on the functionality of the residues in a protein. TIFF2024167251000005.tif202164

[0095] The term "identical" or percent "identity" with respect to two or more nucleic acid or peptide sequences means two or more sequences or subsequences that are the same or have a specified percentage of the same amino acid residues or nucleotides (i.e., about 60% identity over a specified region when compared and aligned to maximize correspondence over a comparison window or specified region, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identity) as measured, for example, using the BLAST or BLAST 2.0 sequence comparison algorithm with the default parameters set forth below, or by manual alignment and visual inspection.

[0096] As is known in the art, a number of different programs can be used to identify whether a protein (or nucleic acid, as described below) has sequence identity or similarity to a known sequence. Sequence identity and / or similarity may be determined by standard techniques known in the art, including, but not limited to, using the local sequence identity algorithm of Smith & Waterman, Adv. Appl. Math., 2:482 (1981), by the sequence identity alignment algorithm of Needleman & Wunsch, J. Mol. Biol., 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Natl. Acad. Sci. USA, 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics software package of the Genetics Computer Group, 575 Science Drive, Madison, Wis.), preferably using the default settings of the Best Fit sequence program described in Devereux et al., Nucl. Acid Res., 12:387-395 (1984), or by inspection. Preferably, the percent identity is calculated by FastDB based on parameters of mismatch penalty of 1, gap penalty of 1, gap size penalty of 0.33, and joining penalty of 30, “Current Methods in Sequence Comparison and Analysis,” Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp127-149 (1988), Alan R. Liss, Inc., the entire contents of which are incorporated by reference.

[0097] One example of a useful algorithm is PILEUP. PILEUP creates multiple sequence alignments from a group of related sequences using progressive pairwise alignment. It can also plot a tree diagram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, J. Mol. Evol. 35:351-360 (1987), which is similar to the method described in Higgins & Sharp CABIOS 5:151-153 (1989), both of which are incorporated by reference. Useful PILEUP parameters include a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.

[0098] Another example of a useful algorithm is the BLAST algorithm described in Altschul et al., J. Mol. Biol. 215, 403-410, (1990), Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997), and Karlin et al., Proc. Natl. Acad. Sci. USA 90:5873-5787 (1993), both of which are incorporated by reference. A particularly useful BLAST program is the WU-BLAST-2 program, obtained from Altschul et al., Methods in Enzymology, 266:460-480 (1996), http: / / blast.wustl / edu / blast / README.html. WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap distance = 1, overlap rate = 0.125, word threshold (T) = 11. The HSP S and HSP S2 parameters are dynamic values ​​and are established by the program itself depending on the composition of the particular sequence and the particular database in which the sequence of interest is searched, but the values ​​may be adjusted to improve sensitivity.

[0099] A further useful algorithm is Gapped BLAST reported by Altschul et al., Nucl. Acids Res., 25:3389-3402, which is incorporated by reference. Gapped BLAST uses a BLOSUM-62 substitution score; a threshold T parameter set to 9; a two-hit method for triggering ungapped extensions; a charge gap length of k; a cost of 10+k; Xu set to 16, and Xg set to 40 in the database search stage and 67 in the output stage of the algorithm. The gapped algorithm is triggered by a score corresponding to approximately 22 bits.

[0100] Percent amino acid sequence identity is determined by dividing the number of matching identical residues in the aligned region by the total number of residues in the "longer" sequence. The "longer" sequence is the sequence with the most actual residues in the aligned region (ignoring gaps introduced by WU-Blast-2 to maximize the alignment score). Similarly, "percent (%) nucleic acid sequence identity" with respect to the coding sequence of an identified polypeptide is defined as the percentage of nucleotide residues in a candidate sequence that are identical to nucleotide residues in the coding sequence of a cell cycle protein. A preferred method utilizes the BLASTN module of WU-BLAST-2 set to default parameters, with overlap distance and overlap rate set to 1 and 0.125, respectively.

[0101] Alignment may include introducing gaps in the sequences to be aligned. In addition, it is understood that for sequences that contain more or fewer amino acids than the protein encoded by the sequence of Figure 2 (SEQ ID NO: 1), the percentage of sequence identity will in one embodiment be determined based on the number of identical amino acids or nucleotides with respect to the total number of amino acids or nucleotides. Thus, for example, the sequence identity of a sequence shorter than that shown in Figure 2 (SEQ ID NO: 1) will in one embodiment be determined using the number of nucleotides in the shorter sequence, as described below. The percent identity calculation does not assign relative weight to various manifestations of sequence changes such as insertions, deletions, substitutions, etc.

[0102] In one embodiment, only identity is scored positively (+1) and any form of sequence variation, including gaps, is assigned a value of "0", thereby eliminating the need for weighting factors or parameters in sequence similarity calculations described below. Percent sequence identity can be calculated, for example, by dividing the number of matching identical residues in the aligned region by the total number of residues in the "shorter" sequence and multiplying by 100. The "longer" sequence is the sequence with the most actual residues in the aligned region.

[0103] The term "allelic variant" refers to polymorphic forms of a gene at a particular locus, as well as to the cDNA derived from the mRNA transcript of that gene and the polypeptides encoded thereby. The term "preferred mammalian codons" refers to a subset of codons from the set of codons that encode the amino acids most frequently used in proteins expressed in mammalian cells, selected from the following: TIFF2024167251000006.tif26166

[0104] As used herein, the term codon modified refers to a polynucleotide sequence encoding a polypeptide (e.g., a Factor VIII variant protein) in which at least one codon of a native polynucleotide encoding the polypeptide has been altered to improve a property of the polynucleotide sequence. In some embodiments, the improved property promotes enhanced transcription of the mRNA encoding the polypeptide, increased stability of the mRNA (e.g., improved mRNA half-life), enhanced translation of the polypeptide, and / or enhanced packaging of the polynucleotide into a vector. Non-limiting examples of modifications that can be used to obtain improved properties include altering the codon usage and / or distribution for particular amino acids, adjusting the global and / or local GC content, removing AT-rich sequences, removing repetitive sequence elements, adjusting the global and / or local CpG dinucleotide content, removing cryptic regulatory elements (e.g., TATA box and CCAAT box elements), removing intron / exon splice sites, improving regulatory sequences (e.g., introduction of Kozak consensus sequences), and removing sequence elements capable of forming secondary structures in the transcribed mRNA (e.g., stem-loops).

[0105] As described herein, there are various nomenclatures that refer to the components disclosed herein. A "CS number" (e.g., "CS04") refers to a codon-modified polynucleotide encoding a FVIII polypeptide, including variants, and / or the encoded polypeptide. For example, CS04-FL refers to a full-length codon-modified CS04 polynucleotide sequence or the amino acid sequence encoded by the CS04 polynucleotide sequence (sometimes referred to herein as "CS04-FL-AA" for the amino acid sequence and "CS04-FL-NA" for the nucleic acid sequence). Similarly, "CS04-LC" refers to either a codon-modified nucleic acid sequence encoding the light chain of a FVIII polypeptide ("CS04-LC-NA") or the amino acid sequence of the FVIII light chain encoded by the CS04 polynucleotide sequence (sometimes referred to herein as "CS04-LC-AA"). Similarly, CS04-HC, CS04-HC-AA, and CS04-HC-NA are the same for the FVIII heavy chain. As will be appreciated by one of skill in the art, in the case of constructs such as CS04 that are only codon modified (e.g., they contain no additional amino acid substitutions compared to Refacto), the amino acid sequence will be identical to the amino acid sequence without the codon optimization modifications. Thus, sequence constructs of the present disclosure include, but are not limited to, CS04-FL-NA, CS04-FL-AA, CS04-LC-NA, CS04-LC-AA, CS04-HC-AA, and CS04-HC-NA.

[0106] III. Codon-modified Factor VIII Mutants In some embodiments, the present disclosure provides codon-modified polynucleotides encoding factor VIII variants. These codon-modified polynucleotides result in significantly enhanced expression of factor VIII when administered in an AAV-based gene therapy construct. The codon-modified polynucleotides also exhibit improved AAV virion packaging compared to conventional codon-optimized constructs. As demonstrated in Example 2 and Table 4, Applicants have achieved these advantages through the discovery of a codon-modified polynucleotide (CS04-FL-NA) encoding a factor VIII polypeptide having a human wild-type factor VIII heavy / light chain and a short 14 amino acid B domain replacement linker ("SQ" linker) containing a furin cleavage site to facilitate maturation of active FVIIIa protein in vivo.

[0107] In one embodiment, the codon modified polynucleotides provided herein have a nucleotide sequence that has at least high sequence identity to sequences in CS04 (SEQ ID NO: 1) encoding the factor VIII heavy chain and the factor VIII light chain. As is known in the art, the B domain of factor VIII is not important for activity in vivo. Thus, in some embodiments, the codon modified polynucleotides provided herein are completely devoid of the factor VIII B domain. In some embodiments, the native factor VIII B domain is replaced with a short amino acid linker containing a furin cleavage site, such as the "SQ" linker consisting of amino acids 760-773 of the CS04 (SEQ ID NO: 2) construct. The "SQ" linker is also referred to as BDLO04 (-AA is the amino acid sequence, -NA is the nucleotide sequence).

[0108] In one embodiment, each of the factor VIII heavy and light chains encoded by the codon-modified polynucleotides is a human factor VIII heavy and light chain. In other embodiments, the factor VIII heavy and light chains encoded by the codon-modified polynucleotides are heavy and light chain sequences from another mammal (e.g., porcine factor VIII). In yet other embodiments, the factor VIII heavy and light chains are chimeric heavy and light chains (e.g., a combination of human and second mammalian sequences). In yet other embodiments, the factor VIII heavy and light chains are humanized forms of heavy and light chains from another mammal, e.g., heavy and light chain sequences from another mammal with substitutions of human residues at selected positions to reduce immunogenicity of the resulting peptide upon administration to humans.

[0109] The GC content of human genes varies widely, ranging from less than 25% to more than 90%. However, human genes with higher GC content are usually expressed at higher levels. For example, Kudla et al. (PLoS Biol., 4(6):80(2006)) have shown that increasing the GC content of a gene enhances the expression of the encoded polypeptide, primarily by increasing transcription and increasing steady-state mRNA transcript levels. In most cases, the GC content of a codon-optimized gene construct is desired to be 60% or higher. However, the native AAV genome has a GC content of around 56%.

[0110] Thus, in some embodiments, the codon-modified polynucleotides provided herein have a CG content that is closer to the GC content of native AAV virions (e.g., around 56% GC), which is lower than the desirable CG content of conventionally codon-optimized polynucleotides for expression in mammalian cells (e.g., 60% GC or higher). As outlined in Example 1, CS04-FL-NA (SEQ ID NO: 1), which has a GC content of about 56%, has improved virion packaging compared to a similarly codon-modified coding sequence with a higher GC content.

[0111] Thus, in some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is less than 60%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is less than 59%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is less than 58%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is less than 57%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is 56% or less.

[0112] In some embodiments, the overall GC content of the codon modified polynucleotide encoding the Factor VIII polypeptide is 54-59%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding the Factor VIII polypeptide is 55-59%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding the Factor VIII polypeptide is 56-59%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding the Factor VIII polypeptide is 54-58%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding the Factor VIII polypeptide is 55-58%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding the Factor VIII polypeptide is 56-58%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding the Factor VIII polypeptide is 54-57%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding the Factor VIII polypeptide is 55-57%. In some embodiments, the overall GC content of the codon-modified polynucleotide encoding a Factor VIII polypeptide is between 56-57%. In some embodiments, the overall GC content of the codon-modified polynucleotide encoding a Factor VIII polypeptide is between 54-56%. In some embodiments, the overall GC content of the codon-modified polynucleotide encoding a Factor VIII polypeptide is between 55-56%.

[0113] In some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is 56±0.5%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is 56±0.4%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is 56±0.3%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is 56±0.2%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is 56±0.1%. In some embodiments, the overall GC content of the codon modified polynucleotide encoding a Factor VIII polypeptide is 56%.

[0114] A. Factor VIII B Domain Replacement Linkers In some embodiments, the linkage between the heavy and light chains of FVIII (e.g., the B domain in wild-type factor VIII) is further modified. Due to size constraints of AAV packaging capacity, mutants with deleted, truncated, and / or linker-substituted B domains must improve the efficacy of FVIII gene therapy constructs. The most commonly used B domain-substituted linker is that of SQ FVIII, which retains only 14 amino acids of the B domain as a linker sequence. Another variant of porcine VIII ("OBI-1" as described in U.S. Pat. No. 6,458,563) expresses well in CHO cells and has a slightly longer linker of 24 amino acids. In some embodiments, the factor VIII constructs encoded by the codon-modified polynucleotides described herein comprise an SQ-type B domain linker sequence. In other embodiments, the factor VIII constructs encoded by the codon-modified polynucleotides described herein comprise an OBI-1-type B domain linker sequence.

[0115] In some embodiments, the encoded factor VIII polypeptide described herein is a SQ-type B domain linker comprising amino acids 760-762 / 1657-1667 of the wild-type human factor VIII B domain (FVIII-FL-AA, SEQ ID NO: 12). TIFF2024167251000007.tif4128 (Sandberg et al. Thromb. Haemost. 85:93 (2001)). In some embodiments, the SQ-type B domain linker has one amino acid substitution compared to the corresponding wild-type sequence. In some embodiments, the SQ-type B domain linker has two amino acid substitutions compared to the corresponding wild-type sequence.

[0116] In some embodiments, the encoded factor VIII polypeptide described herein comprises a Greengene-type B domain linker comprising amino acids 760 / 1582-1667 of the wild-type human factor VIII B domain (FVIII-FL-AA, SEQ ID NO: 12) (Oh et al., Biotechnol. Prog., 17:1999 (2001)). In some embodiments, the Greengene-type B domain linker has one amino acid substitution compared to the corresponding wild-type sequence. In some embodiments, the Greengene-type B domain linker has two amino acid substitutions compared to the corresponding wild-type sequence.

[0117] In some embodiments, the encoded factor VIII polypeptide described herein comprises an extended SQ-type B-domain linker that includes amino acids 760-769 / 1657-1667 of the wild-type human factor VIII B-domain (FVIII-FL-AA, SEQ ID NO: 12) (Thim et al., Haemophilia, 16:349 (2010)). In some embodiments, the extended SQ-type B-domain linker has one amino acid substitution compared to the corresponding wild-type sequence. In some embodiments, the extended SQ-type B-domain linker has two amino acid substitutions compared to the corresponding wild-type sequence.

[0118] In some embodiments, the encoded factor VIII polypeptide described herein comprises the amino acid sequence from the wild-type porcine factor VIII B domain. The porcine OBI-1 type B domain linker comprises TIFF2024167251000008.tif4128 (Toschi et al., Curr. Opin. Mol. Ther. 12:517 (2010)). In some embodiments, the porcine OBI-1 type B domain linker has one amino acid substitution compared to the corresponding wild-type sequence. In some embodiments, the porcine OBI-1 type B domain linker has two amino acid substitutions compared to the corresponding wild-type sequence.

[0119] In some embodiments, the encoded factor VIII polypeptide described herein comprises a human OBI-1 type B domain linker comprising amino acids 760-772 / 1655-1667 of the wild-type human factor VIII B domain (FVIII-FL-AA, SEQ ID NO: 12). In some embodiments, the human OBI-1 type B domain linker has one amino acid substitution compared to the corresponding wild-type sequence. In some embodiments, the human OBI-1 type B domain linker has two amino acid substitutions compared to the corresponding wild-type sequence.

[0120] In some embodiments, the encoded factor VIII polypeptide described herein comprises the amino acid sequence from the wild-type porcine factor VIII B domain. TIFF2024167251000009.tif5128 (Toschi et al., Curr. Opin. Mol. Ther. 12:517 (2010)). In some embodiments, the porcine OBI-1 type B domain linker has one amino acid substitution compared to the corresponding wild-type sequence. In some embodiments, the porcine OBI-1 type B domain linker has two amino acid substitutions compared to the corresponding wild-type sequence.

[0121] B. Codon-modified polynucleotides encoding factor VIII variants with cleavable linkers CS04 Codon-modified polynucleotide In one embodiment, the codon-modified polynucleotide provided herein comprises a nucleotide sequence encoding a variant Factor VIII polypeptide having a linker that can be cleaved in vivo. The Factor VIII polypeptide comprises a Factor VIII light chain, a Factor VIII heavy chain, and a polypeptide linker linking the C-terminus of the heavy chain to the N-terminus of the light chain. The heavy chain of the Factor VIII polypeptide is encoded by a first nucleotide sequence having high sequence identity with CS04-HC-NA (SEQ ID NO:3), which is part of CS04-FL-NA (SEQ ID NO:1), which encodes the Factor VIII heavy chain. The light chain of the Factor VIII polypeptide is encoded by a second nucleotide sequence having high sequence identity with CS04-LC-NA (SEQ ID NO:4), which is part of CS04-FL-NA (SEQ ID NO:1), which encodes the Factor VIII light chain. The polypeptide linker comprises a furin cleavage site that allows for in vivo maturation (e.g., following in vivo expression or administration of the precursor polypeptide).

[0122] In some embodiments, the first and second nucleotide sequences have at least 95% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 96% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 97% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 98% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 99% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 99.5% sequence identity to CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 99.9% sequence identity to CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences are identical to CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively.

[0123] In some embodiments, the polypeptide linker of the Factor VIII construct is encoded by a third nucleotide sequence having high sequence identity to BDLO04 (SEQ ID NO:5), which encodes a 14 amino acid linker corresponding to amino acids 760-773 of CS04-FL-AA (SEQ ID NO:2). In some embodiments, the third nucleotide sequence has at least 95% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence has at least 96% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence has at least 97% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence has at least 98% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence is identical to BDLO04 (SEQ ID NO:5).

[0124] In some embodiments, the codon modified polynucleotide has a nucleotide sequence that has high sequence identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 95% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 96% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 97% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 98% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 99% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 99.5% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 99.9% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence is identical to CS04-FL-NA (SEQ ID NO:1).

[0125] In some embodiments, the factor VIII variant encoded by the codon-modified polynucleotide has an amino acid sequence with high sequence identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 97% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 98% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 99% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 99.5% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 99.9% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence is identical to CS04-FL-AA (SEQ ID NO:2).

[0126] C. Factor VIII Expression Vector In some embodiments, the codon modified polynucleotides described herein are incorporated into expression vectors, non-limiting examples of which include viral vectors (e.g., vectors suitable for gene therapy), plasmid vectors, bacteriophage vectors, cosmids, phagemids, artificial chromosomes, and the like.

[0127] Non-limiting examples of viral vectors include retroviruses, such as Moloney murine leukemia virus (MMLV), Harvey murine sarcoma virus, mouse mammary tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40 virus; polyoma virus; Epstein-Barr virus; papilloma virus; herpes virus; vaccinia virus; and polio virus.

[0128] In some embodiments, the codon-modified polynucleotides described herein are incorporated into gene therapy vectors. In some embodiments, the gene therapy vector is a retrovirus, particularly a replication-deficient retrovirus. Protocols for producing replication-deficient retroviruses are known in the art. For reviews, see Kriegler, M., Gene Transfer and Expression, A Laboratory Manual, WH Freeman Co., New York (1990), and Murry, EJ, Methods in Molecular Biology, Vol. 7, Humana Press, Inc., Cliffton, NJ (1991).

[0129] In one embodiment, the gene therapy vector is an adeno-associated virus (AAV)-based gene therapy vector. AAV systems have been previously described and are generally well known in the art (Kelleher and Vos, Biotechniques, 17(6):1110-17(1994); Cotten et al., Proc Natl Acad Sci USA, 89(13):6094-98(1992); Curiel, Nat Immun, 13(2-3):141-64(1994); Muzyczka, Curr Top Microbiol Immunol, 158:97-129(1992); and Asokan A, et al., Mol. Ther., 20(4):699-708(2012), each of which is incorporated herein by reference in its entirety for all purposes). Details regarding the generation and use of rAAV vectors are described, for example, in U.S. Patent Nos. 5,139,941 and 4,797,368, each of which is incorporated by reference in its entirety for all purposes. In particular embodiments, the AAV vector is an AAV-8 vector.

[0130] In some embodiments, the codon-modified polynucleotides described herein are incorporated into retroviral expression vectors. These systems have been previously described and are generally well known in the art (Mann et al., Cell, 33:153-159, 1983; Nicolas and Rubinstein, In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez and Denhardt, eds., Stoneham: Butterworth, pp. 494-513, 1988; Temin, In: Gene Transfer, Kucherlapati (ed.), New York: Plenum Press, pp. 149-188, 1986). In specific embodiments, the retroviral vector is a lentiviral vector (see, e.g., Naldini et al., Science, 272(5259):263-267, 1996; Zufferey et al., Nat Biotechnol, 15(9):871-875, 1997; Blomer et al., J Virol, 71(9):6641-6649, 1997; U.S. Patent Nos. 6,013,516 and 5,994,136).

[0131] A wide variety of vectors can be used for the expression of Factor VIII polypeptide from codon-modified polypeptide in cell culture, including eukaryotic and prokaryotic expression vectors. In certain embodiments, plasmid vectors are contemplated for use in the expression of Factor VIII polypeptide in cell culture. Usually, plasmid vectors containing replicon and control sequences derived from species compatible with the host cell are used in connection with these hosts. The vector may carry a replication site and a marking sequence that can provide phenotypic selection in transformed cells. The plasmid will contain a codon-modified polynucleotide encoding a Factor VIII polypeptide operably linked to one or more control sequences, such as a promoter.

[0132] Non-limiting examples of vectors for prokaryotic expression include plasmids such as pRSET, pET, pBAD, and promoters used for prokaryotic expression vectors include lac, trc, trp, recA, araBAD, and the like. Examples of vectors for eukaryotic expression include (i) vectors such as pAO, pPIC, pYES, pMET for expression in yeast using promoters such as AOX1, GAP, GAL1, AUG1, etc., (ii) vectors such as pMT, pAc5, pIB, pMIB, pBAC for expression in insect cells using promoters such as PH, p10, MT, Ac5, OpIE2, gp64, polh, etc., and (iii) vectors such as pSVL, pCMV, pRc / RSV, pcDNA3, pBPV for expression in mammalian cells using promoters such as CMV, SV40, EF-1, UbC, RSV, ADV, BPV and β-actin, etc., and vectors derived from viral systems such as vaccinia virus, adeno-associated virus, herpes virus, retrovirus, etc.

[0133] D. Medication The present invention provides for the administration of a codon-optimized construct of the invention to a human patient diagnosed with hemophilia A (a "hemophilia A patient" or "patient"). Generally, administration is performed using AAV particles containing a codon-optimized construct of the invention, as outlined herein. Additionally, administration of the construct of the invention may be augmented by also administering prednisolone or prednisone, as described in more detail below.

[0134] 2 x 10 per kilogram of body weight 12 adeno-associated virus (AAV) particles In one embodiment, the present disclosure provides a method for administering hemophilia A to a patient at a dose of 2×10 per kilogram of body weight of the human patient. 12Provided is a method of treating hemophilia A comprising intravenously infusing (e.g., by peripheral intravenous infusion) a dose of adeno-associated virus (AAV) particles, wherein the AAV particles comprise a codon-modified polynucleotide having high sequence identity to SEQ ID NO:1 (CS04-FL-NA) and encoding a Factor VIII polypeptide.

[0135] In one embodiment, 2×10 per kilogram of body weight of a human patient 12 A codon-modified polynucleotide with high sequence identity to SEQ ID NO:1 (CS04-FL-NA), administered to a human patient in a dose of adeno-associated virus (AAV) particles, encodes a mutant factor VIII polypeptide with a linker that can be cleaved in vivo. The factor VIII polypeptide comprises a factor VIII light chain, a factor VIII heavy chain, and a polypeptide linker connecting the C-terminus of the heavy chain to the N-terminus of the light chain. The heavy chain of the factor VIII polypeptide is encoded by a first nucleotide sequence with high sequence identity to CS04-HC-NA (SEQ ID NO:3), which is part of CS04-FL-NA (SEQ ID NO:1) that encodes the factor VIII heavy chain. The light chain of the factor VIII polypeptide is encoded by a second nucleotide sequence with high sequence identity to CS04-LC-NA (SEQ ID NO:4), which is part of CS04-FL-NA (SEQ ID NO:1) that encodes the factor VIII light chain. The polypeptide linker comprises a furin cleavage site that allows for in vivo maturation (eg, following in vivo expression or administration of a precursor polypeptide).

[0136] In some embodiments, the first and second nucleotide sequences have at least 95% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 96% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 97% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 98% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 99% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 99.5% sequence identity to CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 99.9% sequence identity to CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences are identical to CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In these embodiments, the amino acid sequences encoded by these nucleotide sequences are identical to CS04-HC-AA and CS04-LC-AA.

[0137] In some embodiments, the polypeptide linker of the Factor VIII construct is encoded by a third nucleotide sequence having high sequence identity to BDLO04 (SEQ ID NO:5), which encodes a 14 amino acid linker corresponding to amino acids 760-773 of CS04-FL-AA (SEQ ID NO:2). In some embodiments, the third nucleotide sequence has at least 95% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence has at least 96% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence has at least 97% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence has at least 98% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence is identical to BDLO04 (SEQ ID NO:5). In these embodiments, the amino acid sequences encoded by these nucleotide sequences are identical to amino acids 760-773 of CS04-FL-AA (SEQ ID NO:2). In some embodiments, the Factor VIII construct is encoded by a third nucleotide sequence having high sequence identity to BDLO04 (SEQ ID NO:5), which encodes a 14 amino acid linker corresponding ... 12The codon-modified polynucleotide administered to a human patient in a dose of adeno-associated virus (AAV) particles has a nucleotide sequence that has high sequence identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 95% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 96% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 97% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 98% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 99% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 99.5% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequences have at least 99.9% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequences are identical to CS04-FL-NA (SEQ ID NO:1). In these embodiments, the amino acid sequences encoded by these nucleotide sequences are identical to CS04-FL-AA.

[0138] In some embodiments, the factor VIII variant encoded by the codon-modified polynucleotide has an amino acid sequence with high sequence identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 97% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 98% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 99% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 99.5% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 99.9% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence is identical to CS04-FL-AA (SEQ ID NO:2).

[0139] Thus, in one embodiment, the present disclosure provides a method for administering hemophilia A patients with hemophilia A a dose of 2×10 per kilogram of human patient body weight. 12 A method of treating hemophilia A comprising intravenously infusing a dose of adeno-associated virus (AAV) particles, wherein the AAV particles comprise a polynucleotide having the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA) is provided.

[0140] In some embodiments, the AAV particles are administered in a single dose by intravenous infusion (e.g., into a vein in the patient's arm). In some embodiments, a portion of the single dose is administered and the patient is monitored for signs of adverse reactions to the administration for a short period of time (e.g., 30 minutes), after which the remaining portion of the single dose is administered to the patient (e.g., if no signs of adverse reactions appear).

[0141] In some embodiments, the human patient to whom the AAV particles are administered has severe hemophilia A. For example, in some embodiments, the patient, when not receiving factor VIII replacement therapy, has a level of factor VIII activity in their bloodstream that is less than 2% of the amount of factor VIII activity found in a reference blood sample, e.g., a blood sample having normal factor VIII activity (e.g., a blood sample from a subject determined to not have hemophilia A), or the average factor VIII activity found in blood samples from multiple subjects determined to not have hemophilia A. In some embodiments, the subject, when not receiving factor VIII replacement therapy, has a level of factor VIII activity in their bloodstream that is less than 2% of the amount of factor VIII activity found in a reference blood sample.

[0142] In some embodiments, the human patient receiving the AAV particles does not have inhibitors to FVIII (e.g., factor VIII inhibitor antibodies), a severe hemostatic disorder other than hemophilia A, chronic liver insufficiency and / or severe renal impairment.

[0143] Thus, in some embodiments, the methods described herein provide a method for delivering 2×10 12The method includes qualifying a patient for administration of a dose of adeno-associated virus (AAV) particles, the AAV particles comprising a codon-modified polynucleotide encoding a factor VIII polypeptide having high sequence identity to SEQ ID NO:1 (CS04-FL-NA). The method includes determining a level of factor VIII activity in the patient's bloodstream when the patient is not receiving factor VIII replacement therapy, and qualifying the patient for administration of the AAV particles if the level of factor VIII activity in the patient's bloodstream is less than about 2% or less than about 1% of the level of factor VIII in a reference sample. In some embodiments, the method includes determining whether the patient has one or more of an inhibitor to FVIII (e.g., factor VIII inhibitor antibodies), a severe hemostatic disorder other than hemophilia A, chronic liver dysfunction, and severe renal dysfunction, and disqualifying the patient if they have any of the listed symptoms.

[0144] 6 x 10 per kilogram of body weight 12 adeno-associated virus (AAV) particles In one embodiment, the present disclosure provides a method for administering hemophilia A to a patient at a dose of 6×10 per kilogram of body weight of the human patient. 12 Provided is a method of treating hemophilia A comprising intravenously infusing (e.g., by peripheral intravenous infusion) a dose of adeno-associated virus (AAV) particles, wherein the AAV particles comprise a codon-modified polynucleotide having high sequence identity to SEQ ID NO:1 (CS04-FL-NA) and encoding a Factor VIII polypeptide.

[0145] In one embodiment, 6×10 per kilogram of body weight of a human patient 12A codon-modified polynucleotide with high sequence identity to SEQ ID NO:1 (CS04-FL-NA), administered to a human patient in a dose of adeno-associated virus (AAV) particles, encodes a mutant factor VIII polypeptide with a linker that can be cleaved in vivo. The factor VIII polypeptide comprises a factor VIII light chain, a factor VIII heavy chain, and a polypeptide linker connecting the C-terminus of the heavy chain to the N-terminus of the light chain. The heavy chain of the factor VIII polypeptide is encoded by a first nucleotide sequence with high sequence identity to CS04-HC-NA (SEQ ID NO:3), which is part of CS04-FL-NA (SEQ ID NO:1) that encodes the factor VIII heavy chain. The light chain of the factor VIII polypeptide is encoded by a second nucleotide sequence with high sequence identity to CS04-LC-NA (SEQ ID NO:4), which is part of CS04-FL-NA (SEQ ID NO:1) that encodes the factor VIII light chain. The polypeptide linker comprises a furin cleavage site that allows for in vivo maturation (eg, following in vivo expression or administration of a precursor polypeptide).

[0146] In some embodiments, the first and second nucleotide sequences have at least 95% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 96% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 97% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 98% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 99% sequence identity with CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 99.5% sequence identity to CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences have at least 99.9% sequence identity to CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In some embodiments, the first and second nucleotide sequences are identical to CS04-HC-NA and CS04-LC-NA (SEQ ID NO:3 and SEQ ID NO:4), respectively. In these embodiments, the amino acid sequences encoded by these nucleotide sequences are identical to CS04-HC-AA and CS04-LC-AA.

[0147] In some embodiments, the polypeptide linker of the Factor VIII construct is encoded by a third nucleotide sequence having high sequence identity to BDLO04 (SEQ ID NO:5), which encodes a 14 amino acid linker corresponding to amino acids 760-773 of CS04-FL-AA (SEQ ID NO:2). In some embodiments, the third nucleotide sequence has at least 95% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence has at least 96% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence has at least 97% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence has at least 98% identity to BDLO04 (SEQ ID NO:5). In some embodiments, the third nucleotide sequence is identical to BDLO04 (SEQ ID NO:5). In these embodiments, the amino acid sequence encoded by these nucleotide sequences is identical to amino acids 760-773 of CS04-FL-AA (SEQ ID NO:2).

[0148] In some embodiments, 6×10 per kilogram of body weight of a human patient 12The codon-modified polynucleotide administered to a human patient in a dose of adeno-associated virus (AAV) particles has a nucleotide sequence that has high sequence identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 95% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 96% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 97% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 98% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 99% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequence has at least 99.5% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequences have at least 99.9% identity to CS04-FL-NA (SEQ ID NO:1). In some embodiments, the nucleotide sequences are identical to CS04-FL-NA (SEQ ID NO:1). In these embodiments, the amino acid sequences encoded by these nucleotide sequences are identical to CS04-FL-AA.

[0149] In some embodiments, the factor VIII variant encoded by the codon-modified polynucleotide has an amino acid sequence with high sequence identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 97% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 98% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 99% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 99.5% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence has at least 99.9% identity to CS04-FL-AA (SEQ ID NO:2). In some embodiments, the amino acid sequence is identical to CS04-FL-AA (SEQ ID NO:2).

[0150] Thus, in one embodiment, the present disclosure provides a hemophilia A patient with 6×10 12 A method of treating hemophilia A comprising intravenously infusing a dose of adeno-associated virus (AAV) particles, wherein the AAV particles comprise a polynucleotide having the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA) is provided.

[0151] In some embodiments, the AAV particles are administered in a single dose by intravenous infusion (e.g., into a vein in the patient's arm). In some embodiments, a portion of the single dose is administered and the patient is monitored for signs of adverse reactions to the administration for a short period of time (e.g., 30 minutes), after which the remaining portion of the single dose is administered to the patient (e.g., if no signs of adverse reactions appear).

[0152] In some embodiments, the human patient to whom the AAV particles are administered has severe hemophilia A. For example, in some embodiments, the patient, when not receiving factor VIII replacement therapy, has a level of factor VIII activity in their bloodstream that is less than 2% of the amount of factor VIII activity found in a reference blood sample, e.g., a blood sample having normal factor VIII activity (e.g., a blood sample from a subject determined to not have hemophilia A), or the average factor VIII activity found in blood samples from multiple subjects determined to not have hemophilia A. In some embodiments, the subject, when not receiving factor VIII replacement therapy, has a level of factor VIII activity in their bloodstream that is less than 2% of the amount of factor VIII activity found in a reference blood sample.

[0153] In some embodiments, the human patient receiving the AAV particles does not have inhibitors to FVIII (e.g., factor VIII inhibitor antibodies), a severe hemostatic disorder other than hemophilia A, chronic liver insufficiency and / or severe renal impairment.

[0154] Thus, in some embodiments, the methods described herein can deliver 6×10 mAbs per kilogram of body weight to a human patient. 12The method includes qualifying a patient for administration of a dose of adeno-associated virus (AAV) particles, the AAV particles comprising a codon-modified polynucleotide encoding a factor VIII polypeptide having high sequence identity to SEQ ID NO:1 (CS04-FL-NA). The method includes determining a level of factor VIII activity in the patient's bloodstream when the patient is not receiving factor VIII replacement therapy, and qualifying the patient for administration of the AAV particles if the level of factor VIII activity in the patient's bloodstream is less than about 2% or less than about 1% of the level of factor VIII in a reference sample. In some embodiments, the method includes determining whether the patient has one or more of an inhibitor to FVIII (e.g., factor VIII inhibitor antibodies), a severe hemostatic disorder other than hemophilia A, chronic liver dysfunction, and severe renal dysfunction, and disqualifying the patient if they have any of the listed symptoms.

[0155] Coadministration with prednisolone or prednisone In some embodiments, the methods of treating hemophilia A by administering AAV particles at any dose also include administering to the human patient a course of prednisolone or prednisone to, e.g., reduce the level of the inflammatory response, e.g., by reducing the production of cytokines and / or chemokines in the subject. Examples of methods of co-administering prednisolone or prednisone with gene therapy are described, e.g., in International Patent Application Publication No. WO2008 / 069942, the entire contents of which are incorporated herein by reference for all purposes.

[0156] In some embodiments, prednisolone or prednisone is administered to a human patient prior to administration of an adeno-associated virus (AAV) particle having a polynucleotide encoding a factor VIII polypeptide that has high sequence identity to SEQ ID NO:1 (CS04-FL-NA). For example, in some embodiments, prednisolone or prednisone is administered about 1 week or about 1 or 2 days before administration of the AAV particle to the patient. In some embodiments, a course of prednisolone or prednisone is administered beginning about 1 week or about 1 or 2 days before administration of the AAV particle and continuing after administration of the AAV particle.

[0157] In some embodiments, prednisolone or prednisone is co-administered to a human subject when administering an adeno-associated virus (AAV) particle having a polynucleotide with high sequence identity to SEQ ID NO:1 (CS04-FL-NA) and encoding a factor VIII polypeptide. For example, in some embodiments, prednisolone or prednisone is administered on the same day, for example, immediately before or after administration of the AAV particle. In some embodiments, a course of prednisolone or prednisone is administered on the same day that the AAV particle is administered and continues after administration of the AAV particle.

[0158] In some embodiments, prednisolone or prednisone is administered to the patient after administration of an adeno-associated virus (AAV) particle having a polynucleotide that has high sequence identity to SEQ ID NO:1 (CS04-FL-NA) and encodes a Factor VIII polypeptide. For example, in some embodiments, prednisolone or prednisone is first administered about 1 or 2 days after administration of the AAV particle to the patient.

[0159] It should be noted that prednisolone or prednisone are small molecule drugs that are administered orally (although they can also be administered intravenously), and thus "co-administration" in this context does not require that a single liquid contain both drugs.

[0160] In some embodiments, the patient is administered a course of prednisolone or prednisone, for example, every day or every two days, for a period of at least two weeks. In some embodiments, the patient is administered a course of prednisolone or prednisone for a period of at least three weeks. In some embodiments, the dose of prednisolone or prednisone is decreased during the course. For example, in one embodiment, the course begins with administration of about 60 mg of prednisolone or prednisone per day, and is decreased as the course progresses.

[0161] In one embodiment, the course comprises administering to the human patient about 60 mg of prednisolone or prednisone per day during the first week of the course, administering to the patient about 40 mg of prednisolone or prednisone per day during the second week of the course, and administering to the patient about 30 mg of prednisolone or prednisone per day during the third week immediately following infusion of the AAV particles.

[0162] In some embodiments, the course includes further tapering of prednisolone or prednisone after the third week, e.g., administering tapering doses of prednisolone or prednisone. In some embodiments, the tapering doses of prednisolone or prednisone include sequential administration of doses (e.g., one or more doses of each level) of about 20 mg prednisolone or prednisone per day, about 15 mg prednisolone or prednisone per day, about 10 mg prednisolone or prednisone per day, and about 5 mg prednisolone or prednisone per day.

[0163] In one embodiment, the tapering dose of prednisolone or prednisone includes administering to the patient about 20 mg of prednisolone or prednisone per day for five consecutive days following (e.g., immediately after) completion of the initial course of prednisolone or prednisone, administering to the patient about 15 mg of prednisolone or prednisone per day for three consecutive days following (e.g., immediately after) the five days after the patient was administered 20 mg of prednisolone or prednisone, administering to the patient about 10 mg of prednisolone or prednisone per day for three consecutive days after (e.g., immediately) the three days after the patient was administered 15 mg of prednisolone or prednisone, and administering to the patient about 5 mg of prednisolone or prednisone per day for three consecutive days after (e.g., immediately) the three days after the patient was administered 10 mg of prednisolone or prednisone.

[0164] In one embodiment, the tapering dose of prednisolone or prednisone comprises administering to the patient about 30 mg of prednisolone or prednisone per day for seven consecutive days immediately following completion of the initial course of prednisolone or prednisone; administering to the patient about 20 mg of prednisolone or prednisone per day for seven consecutive days immediately following the seven days during which the patient was administered 30 mg of prednisolone or prednisone; administering to the patient about 20 mg of prednisolone or prednisone per day for seven consecutive days immediately following the seven days during which the patient was administered 20 mg of prednisolone or prednisone to the human subject. administering to the patient about 15 mg of prednisolone or prednisone per day for five consecutive days immediately following the five days after which the patient was administered 15 mg of prednisolone or prednisone, administering to the patient about 10 mg of prednisolone or prednisone per day for five consecutive days immediately following the five days after which the patient was administered 15 mg of prednisolone or prednisone, and administering to the patient about 5 mg of prednisolone or prednisone per day for five consecutive days immediately following the five days after which the patient was administered 10 mg of prednisolone or prednisone.

[0165] In some embodiments, the length of the tapered dose of prednisolone or prednisone administered to a patient is determined based on whether the patient still exhibits signs of liver inflammation (e.g., as indicated by a decrease in factor VIII levels, e.g., factor VIII titer or factor VIII activity, or an increase in liver enzymes) at the end of the initial course of prednisolone or prednisone.

[0166] For example, in one embodiment, a first level (e.g., titer or activity) of factor VIII is determined in the patient's bloodstream (e.g., a blood sample collected from the patient) while the patient is undergoing a first course of glucocorticoid steroid treatment after administration of an adeno-associated virus (AAV) particle comprising a polynucleotide encoding a factor VIII protein. A second level (e.g., titer or activity) of factor VIII is determined in the patient's bloodstream after the first course of glucocorticoid steroid treatment is completed. The second level of factor VIII is then compared to the first level of factor VIII. If the second level of factor VIII is not reduced (e.g., the second level of factor VIII is equal to or greater than the first level of factor VIII or equal to or greater than a threshold amount less than the first level of factor VIII), a first tapering dose of glucocorticoid steroid is administered to the patient over a period of no more than three weeks. If the second level of factor VIII is decreased (e.g., if the second level of factor VIII is less than the first level of factor VIII or is less than a threshold amount less than the first level of factor VIII), the patient is administered a second tapering dose of a glucocorticoid steroid for a period of more than three weeks.

[0167] Similarly, in some embodiments, a first level of liver enzymes (e.g., liver enzyme titer or activity) is determined in the patient's bloodstream prior to (e.g., or shortly after) administration of an adeno-associated virus (AAV) particle comprising a polynucleotide encoding a factor VIII protein to the patient. A second level of liver enzymes (e.g., liver enzyme titer or activity) is determined in the patient's bloodstream after the first course of glucocorticoid steroid treatment is completed. The second level of liver enzymes is then compared to the first level of liver enzymes. If the second level of liver enzymes is not elevated (e.g., the second level of liver enzymes is below the first level of liver enzymes or below a threshold amount above the first level of liver enzymes), the patient is administered a first tapered dose of glucocorticoid steroid for a period of no more than three weeks. If the second level of liver enzymes is elevated (e.g., the second level of liver enzymes is higher than the first level of liver enzymes or higher than a threshold amount above the first level of liver enzymes), the patient is administered a second tapered dose of glucocorticoid steroid for a period of more than three weeks.

[0168] In some embodiments, the first tapering dose of prednisolone or prednisone comprises administering to the patient about 20 mg of prednisolone or prednisone per day for five consecutive days following (e.g., immediately after) completion of the initial course of prednisolone or prednisone, administering to the patient about 15 mg of prednisolone or prednisone per day for three consecutive days following (e.g., immediately after) the five days after 20 mg of prednisolone or prednisone was administered to the patient, administering to the patient about 10 mg of prednisolone or prednisone per day for three consecutive days after (e.g., immediately) the three days after 15 mg of prednisolone or prednisone was administered to the human subject, and administering to the patient about 5 mg of prednisolone or prednisone per day for three consecutive days after (e.g., immediately) the three days after 10 mg of prednisolone or prednisone was administered to the patient.

[0169] In some embodiments, the second tapering dose of prednisolone or prednisone comprises administering to the patient about 30 mg of prednisolone or prednisone per day for seven consecutive days immediately following completion of the first course of prednisolone or prednisone, administering to the patient about 20 mg of prednisolone or prednisone per day for seven consecutive days immediately following the seven days during which the patient was administered 30 mg of prednisolone or prednisone, administering to the patient about 20 mg of prednisolone or prednisone per day for seven consecutive days immediately following the seven days during which the patient was administered 20 mg of prednisolone or prednisone, administering to the patient about 15 mg of prednisolone or prednisone per day for five consecutive days immediately following the five days after which the patient was administered 15 mg of prednisolone or prednisone, administering to the patient about 10 mg of prednisolone or prednisone per day for five consecutive days immediately following the five days after which the patient was administered 15 mg of prednisolone or prednisone, and administering to the patient about 5 mg of prednisolone or prednisone per day for five consecutive days immediately following the five days after which the patient was administered 10 mg of prednisolone or prednisone.

[0170] In some embodiments, administer a course of prednisolone or prednisone after detecting signs of immune response in patient following administration of AAV particles.In some embodiments, administer a course of prednisolone or prednisone after detecting signs of liver inflammation in patient.For example, in some embodiments, monitor patient for liver inflammation after administration of AAV particles, and administer a course of prednisolone or prednisone to patient upon detection of liver inflammation.

[0171] In some embodiments, a sudden or large drop in factor VIII expression or factor VIII activity in the patient's bloodstream indicates liver inflammation in the subject. In some embodiments, it is possible that an early peak in factor VIII activity is followed by a small and / or slow drop, after which factor VIII protein can be produced at a somewhat lower level without the need for a course of prednisolone or prednisone. For example, in some embodiments, the amount of factor VIII (e.g., factor VIII titer or factor VIII activity level) in the patient's bloodstream following administration of AAV particles is monitored, and if a sudden or large drop in the amount of factor VIII (e.g., a drop above a threshold in factor VIII titer or factor VIII activity level compared to the level in the patient's bloodstream after administration of AAV particles) is detected, the subject is administered a course of prednisolone or prednisone.

[0172] In some embodiments, an increase in the level of liver enzymes in a patient indicates liver inflammation in the subject. For example, in some embodiments, the level of liver enzymes in a patient is monitored following administration of the AAV particles, and if an increase in the level of liver enzymes (e.g., an increase above a threshold amount of liver enzymes when compared to the baseline level of liver enzymes in the patient before administration of the AAV particles or shortly after administration of the AAV particles) is detected, the subject patient is administered a course of prednisolone or prednisone.

[0173] Post-Infusion Monitoring In some embodiments, methods are provided for monitoring a patient for side effects and / or therapeutic efficacy following administration of an adeno-associated virus (AAV) particle having a polynucleotide encoding a Factor VIII polypeptide, e.g., a polynucleotide having high sequence identity to SEQ ID NO:1 (CS04-FL-NA). In some embodiments, the patient is monitored for one or more of: (a) signs of liver inflammation (e.g., by a sudden or large drop in Factor VIII levels (e.g., titer or activity) and / or an increase in liver enzymes (e.g., titer or activity)); (b) an increase in Factor VIII inhibitor antibodies in the patient's bloodstream; (c) an increase in capsid protein in the patient's bloodstream; (d) an increase in anti-capsid protein antibodies in the patient's bloodstream; and (e) an increase in polynucleotides encoding Factor VIII polypeptides or fragments thereof in the patient's bloodstream. In some embodiments, the subject is further treated upon detection of one or more side effects and / or ineffectiveness of the treatment.

[0174] For example, in one embodiment, a method is provided for monitoring the effectiveness of factor VIII gene therapy for hemophilia A using adeno-associated virus (AAV) particles comprising a polynucleotide encoding a factor VIII polypeptide. The method includes determining whether factor VIII inhibitor antibodies are present in the patient's bloodstream (e.g., in a blood sample collected from the patient) after administering the AAV particles to the patient. In some embodiments, if factor VIII inhibitor antibodies are detected in the patient's bloodstream (e.g., if an elevated level of factor VIII inhibitor antibodies is detected compared to the level in the patient prior to administration of the AAV particles), the method includes administering to the patient an alternative agent for the treatment of hemophilia A.

[0175] In some embodiments, the alternative agent for treating hemophilia A is an alternative form of factor VIII (e.g., one that does not contain or masks one of the many epitopes targeted by detected factor VIII inhibitor antibodies). In some embodiments, the alternative form of factor VIII is a chemically modified factor VIII protein (e.g., a chemically modified human or porcine factor VIII protein). In some embodiments, the alternative form of factor VIII is a factor VIII protein derived from a non-human factor VIII protein, e.g., a porcine factor VIII protein. In some embodiments, the alternative agent for treating hemophilia A is a factor VIII bypass therapy, e.g., a therapy comprising factor II, factor IX, and factor X. For example, in some embodiments, the factor VIII bypass therapy is a factor VIII inhibitor bypassing activity (FEIBA) complex, recombinant activated factor VII (FVIIa), prothrombin complex concentrate, or activated prothrombin complex concentrate.

[0176] In one embodiment, a method is provided for monitoring the level of a polynucleotide or fragment thereof encoding a factor VIII polypeptide in the bloodstream of a patient following administration of AAV particles. In one embodiment, the method comprises administering to a hemophilia A patient a dose of adeno-associated virus (AAV) particles per kilogram of the patient's body weight, where at a first time point, the AAV particles comprise a polynucleotide encoding a factor VIII protein. The method also comprises measuring the level of a polynucleotide or fragment thereof encoding a factor VIII protein in the bloodstream of the patient at a later time point, where the later time point is 7 days or later. In one embodiment, the method comprises administering to a hemophilia A patient a dose of 2×10 6 polynucleotides or fragments thereof per kilogram of the patient's body weight. 12The method includes administering a dose of adeno-associated virus (AAV) particles, where at a first time point, the AAV particles comprise a polynucleotide having the nucleic acid sequence of SEQ ID NO: 1 (CS04-FL-NA). The method also includes measuring a level of the nucleic acid of SEQ ID NO: 1 or a fragment thereof in the patient's bloodstream at a later time point, where the later time point is 7 days or later. In one embodiment, the method includes administering to a hemophilia A patient 6×10 per kilogram of the patient's body weight. 12 The method includes administering a dose of adeno-associated virus (AAV) particles, where at a first time point, the AAV particles include a polynucleotide having the nucleic acid sequence of SEQ ID NO: 1 (CS04-FL-NA). The method also includes measuring a level of the nucleic acid of SEQ ID NO: 1 or a fragment thereof in the patient's bloodstream at a later time point, where the later time point is 7 days or later. In some embodiments of the method, the later time point is at least 14 days or later or at least 21 days or later. In some embodiments, the later time point is 7 days, 14 days, or 21 days after administration of the AAV particles.

[0177] In one embodiment, a method is provided for monitoring the level of capsid protein in the bloodstream of a patient following administration of AAV particles. In one embodiment, the method comprises administering to a hemophilia A patient 2×10 per kilogram of the patient's body weight. 12 The method includes administering a dose of adeno-associated virus (AAV) particles, where at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 1 (CS04-FL-NA). The method also includes measuring a level of capsid protein in the patient's bloodstream at a later time point, where the later time point is 7 days or later. In one embodiment, the method includes administering to a hemophilia A patient 6×10 per kilogram of the patient's body weight. 12The method includes administering a dose of adeno-associated virus (AAV) particles to a hemophilia A patient, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA). The method also includes measuring the level of the capsid protein in the bloodstream of the patient at a later time point, the later time point being 7 days or later. In one embodiment, the method includes administering a dose of adeno-associated virus (AAV) particles per kilogram of the patient's body weight to a hemophilia A patient, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide encoding a factor VIII protein. The method also includes measuring the level of the capsid protein in the bloodstream of the patient at a later time point, the later time point being 7 days or later. In some embodiments of the method, the later time point is at least 14 days or later or at least 21 days or later. In some embodiments, the later time point is 7 days, 14 days or 21 days after administration of the AAV particles.

[0178] In one embodiment, a method is provided for monitoring the level of factor VIII inhibitor antibodies in the bloodstream of a patient following administration of AAV particles. In one embodiment, the method comprises administering 2×10 per kilogram of patient body weight to a hemophilia A patient. 12 The method includes administering a dose of adeno-associated virus (AAV) particles, where at a first time point, the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 1 (CS04-FL-NA). The method also includes measuring a level of anti-Factor VIII antibodies in the patient's bloodstream at a later time point, where the later time point is 7 days or later. In one embodiment, the method includes administering to a hemophilia A patient 6×10 per kilogram of the patient's body weight. 12The method includes administering a dose of adeno-associated virus (AAV) particles to a hemophilia A patient, where at a first time point, the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA). The method also includes measuring a level of anti-Factor VIII antibodies in teh patient's bloodstream at a later time point, said later time point being 7 days or later. In one embodiment, the method includes administering a dose of adeno-associated virus (AAV) particles to a hemophilia A patient, where at a first time point, the AAV particles comprise a polynucleotide encoding a Factor VIII protein. The method also includes measuring a level of anti-Factor VIII antibodies in teh patient's bloodstream at a later time point, said later time point being 7 days or later. In some embodiments of the method, the later time point is at least 14 days or later or at least 21 days or later. In some embodiments, the later time point is 7 days, 14 days or 21 days after administration of the AAV particles.

[0179] In one embodiment, a method is provided for monitoring the level of anti-capsid protein antibodies in the bloodstream of a subject following administration of AAV particles. In one embodiment, the method comprises administering to a hemophilia A patient 2×10 per kilogram of the patient's body weight. 12 The method includes administering a dose of adeno-associated virus (AAV) particles, where at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 1 (CS04-FL-NA). The method also includes measuring a level of anti-capsid protein antibodies in the patient's bloodstream at a later time point, where the later time point is 7 days or later. In one embodiment, the method includes administering to a hemophilia A patient 6×10 per kilogram of the patient's body weight. 12The method includes administering a dose of adeno-associated virus (AAV) particles to a hemophilia A patient, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA). The method also includes measuring the level of anti-capsid protein antibodies in the patient's bloodstream at a later time point, the later time point being 7 days or later. In one embodiment, the method includes administering a dose of adeno-associated virus (AAV) particles per kilogram of the patient's body weight to a hemophilia A patient, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide encoding a factor VIII protein. The method also includes measuring the level of anti-capsid protein antibodies in the patient's bloodstream at a later time point, the later time point being 7 days or later. In some embodiments of the method, the later time point is at least 14 days or later or at least 21 days or later. In some embodiments, the later time point is 7 days, 14 days or 21 days after administration of the AAV particles. EXAMPLES

[0180] IV. Working Examples Example 1 - Construction of codon-modified factor VIII variant expression sequences Two obstacles had to be overcome to create an effective factor VIII coding sequence for gene therapy of hemophilia A. First, the encoded factor VIII polypeptide had to be significantly shortened due to the limited genome size of conventional gene therapy delivery vectors (e.g., AAV virions). Second, the coding sequence had to be modified to (i) stabilize packaging interactions within the delivery vector, (ii) stabilize the mRNA intermediate, and (iii) improve the robustness of mRNA transcription / translation.

[0181] To achieve the first objective, the applicants started with a B-domain deleted factor VIII mutant construct, referred to herein as "FVIII-BDD-SQ", in which the B-domain is replaced with a 14 amino acid sequence, referred to as the "SQ" sequence. Recombinant FVIII-BDD-SQ is sold under the trade name REFACTO® and has been shown to be effective in the management of hemophilia A. However, the native coding sequence of FVIII-BDD-SQ, which contains the human wild-type nucleic acid sequences of the factor VIII heavy and light chains, is not effectively expressed in gene therapy vectors.

[0182] To address the poor expression of native FVIII-BDD-SQ, the codon optimization algorithm described by Fath et al. (PLoS ONE, 6:e17596 (2011)) with modifications as described by Ward et al. (Blood, 117:798 (2011)) and McIntosh et al. (Blood, 121, 3335-3344 (2013)) was applied to the FVIII-BDD-SQ sequence to generate the first intermediate coding sequence, CS04a. However, the applicants recognized that the CS04a sequence generated using the modification algorithm could be improved by further modifications of the sequence. Consequently, we have reintroduced CpG dinucleotides, reintroduced CGC codons for arginine, altered the leucine and serine codon distribution, reintroduced highly conserved codon pairs, and removed cryptic TATA box, CCAAT box and splice site elements while avoiding CpG islands and local over-representation of AT-rich and GC-rich stretches.

[0183] First, the modified algorithm systematically replaces codons containing CpG dinucleotides (e.g., arginine codons) with non-CpG dinucleotide codons, eliminating / avoiding CpG dinucleotides created by adjacent codons. This strict avoidance of CpG dinucleotides is usually performed to prevent TLR-induced immunity after intramuscular injection of DNA vaccines. However, doing so limits the possibilities for codon optimization. For example, the modified algorithm excludes the use of the entire set of CGX arginine codons. This is particularly hindrance when coding genes for expression in human cells, because CGC is the most frequently used arginine codon in highly expressed human genes. In addition, avoiding CpG created by adjacent codons further limits the possibilities for optimization (e.g., restricts the number of codon pairs that can be used together).

[0184] Since TLR-induced immunity is not expected to be an issue associated with liver-specific AAV-based gene therapy, CpG-containing codons and adjacent codons that produce CpGs were reintroduced into the intermediate coding sequence CS04a, preferably in the sequence encoding the factor VIII light chain (e.g., at the 3' end of the FVIII-BDD-SQ coding sequence). This allowed for more frequent use of desirable human codons, particularly those for arginine. However, care was taken to avoid creating CpG islands, which are regions of the coding sequence with a high frequency of CpG sites. This is contrary to the teachings of Krinner et al. (Nucleic Acids Res., 42(6):3551-64(2014)), who suggest that CpG domains downstream of the transcription start site promote high levels of gene expression.

[0185] Second, the modification algorithm exclusively applies certain codons, e.g., CTG for leucine, GTG for valine, and CAG for glutamine. However, this contradicts the principle of balanced codon usage, e.g., as proposed by Haas et al. (Current Biology, 6(3):315-24 (1996)). To accommodate overuse of preferred codons by the modification algorithm, alternative leucine codons were reintroduced when permitted by other rules applied to codon modification (e.g., CpG frequency and GC content).

[0186] Third, the modification algorithm replaces codon pairs if certain criteria (e.g., the presence of CG dinucleotides) are met, without considering how conserved they are in nature. The most conserved codon pairs replaced by the algorithm, and the most conserved preferred codon pairs, for example as described in Tats et al. (BMC Genomics 9:463 (2008)), were analyzed and adjusted, if permitted by other rules applied to codon modification (e.g., CpG frequency and GC content), to accommodate beneficial properties that may have been conserved by evolution.

[0187] Fourth, the serine codons used in the intermediate coding sequence were also re-engineered: specifically, AGC, TCC and TCT serine codons were introduced more frequently into the modified coding sequence to better match overall human codon usage (Haas et al., supra).

[0188] Fifth, TATA boxes, CCAAT box elements, and intron / exon splice sites were selected and removed from the modified coding sequences. In modifying the coding sequences, care was taken to avoid local over-representation of AT-rich or GC-rich stretches.

[0189] Finally, in addition to optimizing codon usage within the coding sequence, the structural requirements of the underlying AAV virion were taken into consideration when further improving the intermediate coding sequence CS04a. AAV vectors (e.g., the nucleic acid portion of the AAV virion) are packaged within their capsids as single-stranded DNA molecules (for review, see Daya and Berns, Clin. Microbiol Rev., 21(4):583-93 (2008)). Thus, the GC content of the vector can affect the packaging of the genome and therefore the vector yield during production. Like many algorithms, the modified algorithm used here produces optimized gene sequences with a GC content of at least 60% (Fath et al., PLoS One, 6(3):el7596 (2011) (see errata in PLoS One, (6)3 (2011)). However, the AAV8 capsid protein is encoded by a nucleotide sequence with a lower GC content of about 56%. For this reason, the GC content of the middle coding sequence CS04a was reduced to 56% to better mimic the native AAV8 capsid protein coding sequence.

[0190] The resulting CS04 coding sequence, shown in Figure 2, has an overall GC content of 56%. The sequence has a moderate CpG dinucleotide content. However, the CpG dinucleotides are mainly located in the downstream part of the coding sequence, e.g., in the part encoding the factor VIII light chain. The CS04 sequence shares 79.77% nucleotide sequence identity with the corresponding coding sequence in wild-type factor VIII (Genbank accession number M14113).

[0191] For comparison purposes, several other codon-optimized ReFacto constructs were generated. The CS08ReFacto construct was codon-optimized as described in Radcliff PM et al., Gene Therapy, 15:289-97 (2008), the entire contents of which are expressly incorporated herein by reference for all purposes. The CS10 codon-optimized ReFacto construct was obtained from Eurofins Genomics (Ebersberg, Germany). The CS11 codon-optimized ReFacto construct was obtained from Integrated DNA Technologies, Inc. (Coralville, USA). The CH25 codon-optimized ReFacto construct was obtained from ThermoFischer Scientific's GeneArt services (Regensburg, Germany). The CS40ReFacto construct consists of the wild-type factor VIII coding sequence. The sequence identity shared between each ReFacto coding sequence is shown in Table 2 below.

[0192] Table 2. Percent identity of codon-modified Factor VIII constructs. TIFF2024167251000010.tif50128

[0193] The plasmids of each construct were constructed by cloning the various synthetic DNA fragments into the same vector backbone plasmid (pCh-BB01). DNA synthesis of the refacto BDD-FVIII fragments with flanking AscI and NotI enzyme restriction sites was performed by ThermoFischer Scientific (Regensburg, Germany). The vector backbone contains two flanking AAV2-derived inverted terminal repeats (ITRs) encompassing the promoter / enhancer sequence derived from the liver-specific mouse transthyretin gene, AscI and NotI enzyme restriction sites for the insertion of each refacto BDD-FVIII, and a synthetic polyA site. After ligation of the generated vector backbone and insert via the AscI and NotI sites, the resulting plasmids were amplified to milligram scale. Verification of the refacto BDD-FVIII sequence of the constructs was performed by direct sequencing (Microsynth, Balgach, Switzerland). Cloning yielded seven different plasmid constructs, designated pCS40, pCS04, pCS08, pCS10, pCS11 and pCh25 (Figure 14). The constructs have the same vector backbone and encode the same B-domain deleted FVIII protein (Refacto type BDD-FVIII), but differ in their FVIII coding sequences.

[0194] AAV8-based vectors were generated by a three-plasmid transfection method as described in Grieger JC, et al. (Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector, Mol Ther., Oct 6. (2015) doi:10.1038 / mt.2015.187. [Epub ahead of print]), the entire contents of which are incorporated herein by reference for all purposes. HEK293 suspension cells were used for plasmid transfection using the corresponding FVIII vector plasmid, the helper plasmid pXX6-80 (carrying the adenovirus helper genes), and the packaging plasmid pGSK2 / 8 (carrying the rep2 and cap8 genes). To isolate AAV8 constructs, cell pellets of one liter cultures were processed using an iodixanol gradient as described in Grieger et al. (2015, supra). The procedure resulted in vector constructs designated vCS04, vCS08, vCS10, vCS11, and vCH25. Vectors were quantified by qPCR using a universal qPCR procedure targeting the AAV2 inverted repeats (Aurnhammer, Human Gene Therapy Methods: Part B 23:18-28 (2012)). A control vector plasmid carrying the AAV2 inverted repeats served to generate a standard curve. The resulting vCS04 construct is shown in Figures 7A-C as SEQ ID NO:8.

[0195] Vector genome integrity was analyzed by AAV agarose gel electrophoresis. Electrophoresis was performed as described in Fagone et al., Human Gene Therapy Methods 23:1-7 (2012). Briefly, AAV vector constructs were incubated at 75°C for 10 min in the presence of 0.5% SDS and then cooled to room temperature. Approximately 1.5E10 vector genomes (vg) were loaded into each lane of a 1% 1xTAE agarose gel and electrophoresed at 7V / cm gel length for 60 min. The gel was then stained with 2x GelRed (Biotium catalog #41003) solution and imaged by ChemiDocTMMP (Biorad). The results shown in Figure 15 demonstrate that the vCS04 and vCS40 viral vectors have genomes of the same size, as indicated by distinct bands in the 5 kb range (Figure 15, lanes 2-4). Despite the vector size of approximately 5.2 kb, the genome was a uniform band, supporting correct packaging of a genome of somewhat excess size (relative to the 4.7 kb AAV wild-type genome). All other vCS vector constructs show the same genome size (data not shown).

[0196] To confirm the expected pattern of capsid proteins, SDS PAGE and subsequent silver staining was performed on vectors vCS04 and vCS40 (Figure 16). As shown, downstream purification procedures yielded highly purified material exhibiting the expected VP1, VP2 and VP3 protein patterns (Figure 16, lanes 2-4). The same pattern was observed for all other viral constructs (not shown). SDS-PAGE procedures for AAV constructs were performed according to standard procedures. Each lane contained 1E10vg of each viral construct, which was separated on a 4-12% Bis-Tris (NuPAGE® Novex, Life Technologies) gel according to the manufacturer's instructions. Silver staining was performed with the SilverQuest™ kit (Novex, Life Technologies) according to the manufacturer's instructions.

[0197] Surprisingly, the AAV vector vCS04 had higher virion packaging as measured by higher yields of AAV virus production compared to the vCS40 wild-type coding construct and other codon-optimized constructs. As shown in Table 3, the vCS04 vector replicated substantially better than vCS40, with a 5- to 7-fold improvement in yield, expressed as AAV titer.

[0198] Table 3. Yields per liter of cell culture obtained using AAV vector constructs vCS04 and vCD40 purified from cell pellets. TIFF2024167251000011.tif43170

[0199] Example 2 - In vivo expression of codon-modified factor VIII variant expression sequences To test the biological potency of the codon-modified factor VIII variant sequences, mice lacking factor VIII were administered the ReFacto FVIII constructs described in Example 1. Briefly, the assay was performed in C57Bl / 6 FVIII knockout (ko) mice by tail vein injection of 4E12 vector genome (vg) per kilogram of mouse body weight (6-8 mice per group). Blood was collected by retro-orbital puncture 14 days after injection and plasma was prepared and frozen using standard procedures. The expression level at day 14 was chosen because at this time the effects of inhibitor antibodies, which were seen in some animals of this mouse model at later times, are minimal. FVIII activity was determined in mouse plasma by performing the Technochrome FVIII assay with only minor modifications as suggested by the manufacturer (Technoclone, Vienna, Austria). For the assay, plasma samples were roughly diluted and mixed with an assay reagent containing thrombin, activated factor IX (FIXa), phospholipids, factor X and calcium. After FVIII activation by thrombin, a complex with FIXa, phospholipids and calcium is formed. This complex activates FX to activated FX (FXa), which in turn cleaves paranitroanilide (pNA) from the chromogenic substrate. The kinetics of pNA formation is measured at 405 nm. The rate is directly proportional to the FVIII concentration of the sample. The FVIII concentration is read from a standard curve and the results are given in IU FVIII / ml.

[0200] The results, shown in Table 4 below, demonstrate that the codon-modified sequences (CS10, CS11 and CH25) designed using commercially available algorithms only resulted in a moderate increase (3-4 fold) in BDD-Factor VIII expression compared to the wild-type BDD-Factor VIII construct (CS40). Similarly, the codon-modified BDD-Factor VIII construct (CS08) made as described in Radcliffe et al. only resulted in a 3-4 fold increase in BDD-FVIII expression. This result is consistent with the results reported in Radcliff et al. Surprisingly, the CS04 construct resulted in much higher BDD-FVIII expression (e.g., 74 fold increase) in an in vivo biological potency assay.

[0201] Table 4. Expression of FVIII in plasma of FVIII knockout mice induced by various AAV vector constructs TIFF2024167251000012.tif73166

[0202] Example 3 - Non-clinical efficacy and toxicology evaluation of human FVIII gene therapy vectors in mice Hemophilia A is an inherited bleeding disorder caused by a lack or deficiency of factor VIII (FVIII) and is treated with plasma-derived or recombinant factor concentrates. These concentrates need to be transfused regularly to maintain sufficient FVIII levels to manage and prevent bleeding events. Given the challenges of protein replacement therapy, gene therapy may offer an alternative therapeutic approach for patients with hemophilia A. By introducing a functional F8 gene copy into targeted liver cells to induce endogenous FVIII expression, frequent transfusions of clotting factors may no longer be necessary.

[0203] Adeno-associated virus (AAV)-based gene therapy has the potential to provide clinical benefit to patients with hemophilia A. A recombinant (r)AAV8-based gene therapy vector containing the CS04 Factor VIII codon-optimized construct was designed to deliver a human codon-optimized B-domain deleted FVIII (BDDFVIII) transgene under the control of the liver-specific transthyretin promoter. This construct was used to investigate the dose-response relationship of FVIII activity in F8 knockout (ko) mice and to evaluate toxicity after a single intravenous administration.

[0204] Briefly, to test the efficacy of the treatment, 12 male FVIII knockout mice per group were administered 3.0 × 10 11 , 1.2×10 12 or 3.0×10 12 A single intravenous dose of 100 vector capsid particles (cp) / kg or 10 mL / kg of buffer was administered. Retro-orbital blood samples were collected every other week for 8 weeks and analyzed for FVIII using a chromogenic assay. Plasma samples obtained from the last in-life bleed were also used for analysis of FVIII binding and neutralizing antibodies. At the end of the observation period, hemostasis controls were assessed using a tail-tip bleeding assay.

[0205] At the end of the study, binding and neutralizing antibodies were positive (3.0 × 10 12 All samples from all but four animals (treated with 1.2×10 cp / kg of vector) were negative for anti-BDD-FVIII binding antibodies. These animals were excluded from the statistical analysis of FVIII activity levels and blood loss in the tail-tip bleeding assay. 12 or 3.0×10 12 Administration of 10 cp / kg of vector increased mean plasma FVIII activity calculated over the study period in a dose-dependent manner to 0.6 and 1.9 IU / mL, respectively, whereas 3.0 × 10 11 Mice treated with cp / kg vector had FVIII activity below the lower limit of quantification (LLOQ) (Figure 17).

[0206] Efficacy was assessed in a tail tip bleeding assay on day 63. Blood loss over 60 minutes is shown in Figure 18 in mg / g body weight. 11 Animals treated with cp / kg gene therapy vector showed similar blood loss (6.1 mg / g and 7.5 mg / g, respectively), consistent with the absence of detectable FVIII activity. Higher doses of gene therapy vector significantly reduced blood loss in a dose-dependent manner (1.2×10 12 : 0.6mg / g, 3.0×10 12 : 0.4 mg / g, Jonkheel-Tapstra test: one-sided P value < 0.001).

[0207] To test the toxicology of the constructs, male C57BL / 6J mice (n=20 / group) were injected with 1×10 13 , 3×10 13 or 5×10 13 A single bolus dose of cp / kg of vector or formulation buffer was injected intravenously (Table 5). Toxicity assessment was based on clinical signs, body weight, food intake, ophthalmology, and clinical and anatomical pathology. Complete necropsies were performed on five animals from each cohort, and macroscopic findings, organ weights, and microscopic results were recorded. Tissues were harvested from an additional five animals from each cohort for biodistribution assessment by quantitative polymerase chain reaction. Blood was collected pre-dose and at necropsy. FVIII activity, BDD-FVIII antigen, bound anti-BDD-FVIII antibodies, neutralizing anti-BDD-FVIII antibodies, and bound anti-AAV8 antibodies were analyzed.

[0208] Table 5. Toxicity study design TIFF2024167251000013.tif59128

[0209] 5×10 13A single intravenous bolus administration of the gene therapy vector at up to cp / kg was found to be well tolerated. No deaths occurred during the study, and no clinical signs or post-dosing findings were considered related to administration of the vector. No adverse ophthalmologic findings were observed. No effects on body weight or food intake were noted. No changes were noted in clinical chemistry, hematology, or urinalysis parameters. And no toxicologically relevant macroscopic or microscopic findings were related to administration of the gene therapy vector.

[0210] FVIII activity and BDD-FVIII antigen assessment tended to be variable, most likely a result of the generation of neutralizing antibodies against human BDD-FVIII. However, individual animals in all vector groups had activity higher than typical baseline levels at day 3 and week 3 and week 18 (data not shown). In collected tissue samples, vector DNA was detected primarily in the liver. Biodistribution to liver and other tissues was dose-related, generally highest at the earliest time points and decreased over time. The presence of vector DNA in brain and testes decreased significantly over time, falling below the LLOQ of the assay by week 18 in most animals (Figure 19).

[0211] In summary, the results showed that codon-optimized BDD-FVII gene therapy reduced the 12 The study showed that the drug was effective when administered to FVIII knockout mice at doses of 5.0 × 10 cp / kg or higher. The level at which no side effects were observed was 5.0 × 10 13 It was considered to be cp / kg.

[0212] In some embodiments, the dose administered to mice can be converted to a human dosage according to the guidance provided in “Guidance for Industry-Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,” USDepartment of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), July 2005, Pharmacology and Toxicology, the contents of which are incorporated by reference in their entirety for all purposes.

[0213] It is understood that the examples and embodiments described herein are for illustrative purposes only, and that various modifications or changes in light thereof will be suggested to those skilled in the art and are to be included within the spirit and scope of this application and the appended claims. All publications, patents, and patent applications cited herein are incorporated by reference in their entirety for all purposes.

[0214] Sequence information SEQUENCE LISTING <110> BAXALTA INCORPORATED BAXALTA GMBH <120> GENE THERAPY OF HEMOPHILIA A USING VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION <150> US 62 / 698,680 <151> 2018-07-16 <150> US 62 / 867,171 <151> 2019-06-26 <160> 15 <170> PatentIn version 3.5 <210> 1 <211> 4374 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polynucleotide <400> 1 atgcagattg agctgagcac ctgcttcttc ctgtgcctgc tgaggttctg cttctctgcc 60 accaggagat actacctggg ggctgtggag ctttcttggg actacatgca gtctgacctg 120 ggggagctgc ctgtggatgc caggttccca cccagagtgc ccaaatcctt cccattcaac 180 acctctgtgg tctacaagaa gaccctcttt gtggagttca ctgaccacct gttcaacatt 240 gccaaaccca ggccaccctg gatgggactc ctgggaccca ccattcaggc tgaggtgtat 300 gacactgtgg tcatcaccct caagaacatg gcctcccacc ctgtgagcct gcatgctgtg 360 ggggtcagct actggaaggc ctctgagggg gctgagtatg atgaccagac ctcccagagg 420 gagaaggagg atgacaaagt gttccctggg ggcagccaca cctatgtgtg gcaggtcctc 480 aaggaagaatg gccccatggc ctctgaccca ctctgcctga cctactccta cctttctcat 540 gtggacctgg tcaaggacct caactctgga ctgattgggg ccctgctggt gtgcagggag 600 ggctccctgg ccaaaagaga gacccagacc ctgcacaagt tcattctcct gtttgctgtc 660 tttgatgagg gcaagagctg gcactctgaa accaagaact ccctgatgca ggacagggat 720 gctgcctctg ccagggcctg gcccaagatg caacactgtga atggctatgt gaacaggagc 780 ctgcctggac tcattggctg ccacaggaaa tctgtctact ggcatgtgat tggcatgggg 840 acaacccctg aggtgcactc cattttcctg gagggccaca ccttcctggt caggaaccac 900 agacaggcca gcctggagat cagccccatc accttctcca ctgcccagac cctgctgatg 960 gacctcggac agttcctgct gttctgccac atcagctccc accagcatga tggcatggag 1020 gcctatgtca aggtggacag ctgccctgag gagccacagc tcaggatgaa gaaatgag 1080 gaggctgagg actatgatga tgacctgact gactctgaga tggatgtggt ccgctttgat 1140 gatgaacaa gcccatcctt cattcagatc aggtctgtgg ccaagaaaca ccccaagacc 1200 tgggtgcact acattgctgc tgaggaggag gactgggact atgccccact ggtcctggcc 1260 cctgatgaca ggagctacaa gagccagtac ctcaacaatg gcccacagag gattggacgc 1320 aagtacaaga aagtcaggtt catggcctac actgatgaaa ccttcaagac cagggaggcc 1380 attcagcatg agtctggcat cctgggccca ctcctgtatg gggaggtggg ggacaccctg 1440 ctcatcatct tcaagaacca ggcctccagg ccctacaaca tctacccaca tggcatcact 1500 gatgtcaggc ccctgtacag ccgcaggctg ccaaaggggg tgaaacacct caaggacttc 1560 cccattctgc ctggggagat cttcaagtac aagtggactg tcactgtgga ggatggacca 1620 accaaatctg accccaggtg cctcaccaga tactactcca gctttgtgaa catggagagg 1680 gacctggcct ctggcctgat tggcccactg ctcatctgct acaaggagtc tgtggaccag 1740 aggggaaacc agatcatgtc tgacaagagg aatgtgattc tgttctctgt ctttgatgag 1800 aacaggagct ggtacctgac tgagaacatt cagcgcttcc tgcccaaccc tgctggggtg 1860 cagctggagg accctgagtt ccaggccagc aacatcatgc actccatcaa tggctatgtg 1920 tttgacagcc tccagctttc tgtctgcctg catgaggtgg cctactggta cattctttct 1980 attggggccc agactgactt cctttctgtc ttcttctctg gctacacctt caaacacaag 2040 atggtgtatg aggacaccct gaccctcttc ccattctctg gggagactgt gttcatgagc 2100 atggagaacc ctggcctgtg gattctggga tgccacaact ctgacttccg caacaggggc 2160 atgactgccc tgctcaaagt ctcctcctgt gacaagaaca ctggggacta ctatgaggac 2220 agctatgagg acatctctgc ctacctgctc agcaagaaca atgccattga gcccaggagc 2280 ttcagccaga atccacctgt cctgaaacgc caccagaggg agatcaccag gaccaccctc 2340 cagtctgacc aggaggagat tgactatgat gacaccattt ctgtggagat gaagaaagag 2400 gactttgaca tctatgacga ggacgagaac cagagcccaa ggagcttcca gaagaagacc 2460 aggcactact tcattgctgc tgtggagcgc ctgtgggact atggcatgag ctccagcccc 2520 catgtcctca ggaacagggc ccagtctggc tctgtgccac agttcaagaa agtggtcttc 2580 caagagttca ctgatggcag cttcacccag cccctgtaca gaggggagct gaatgagcac 2640 ctgggactcc tgggcccata catcagggct gaggtggagg acaacatcat ggtgaccttc 2700 cgcaaccagg cctccaggcc ctacagcttc tacagctccc tcatcagcta tgaggaggac 2760 cagaggcagg gggctgagcc acgcaagaac tttgtgaaac ccaatgaaac caagacctac 2820 ttctggaaag tccagcacca catggccccc accaaggatg agtttgactg caaggcctgg 2880 gcctacttct ctgatgtgga cctggagaag gatgtgcact ctggcctgat tggcccactc 2940 ctggtctgcc acaccaacac cctgaaccct gcccatggaa ggcaagtgac tgtgcaggag 3000 tttgccctct tcttcaccat ctttgatgaa accaagagct ggtacttcac tgagaacatg 3060 gagcgcaact gcagggcccc atgcaacatt cagatggagg accccacctt caaagagaac 3120 taccgcttcc atgccatcaa tggctacatc atggacaccc tgcctgggct tgtcatggcc 3180 caggaccaga ggatcaggtg gtacctgctt tctatgggct ccaatgagaa cattcactcc 3240 atccacttct ctgggcatgt cttcactgtg cgcaagaagg aggagtacaa gatggccctg 3300 tacaacctct accctggggt ctttgagact gtggagatgc tgccctccaa agctggcatc 3360 tggagggtgg agtgcctcat tggggagcac ctgcatgctg gcatgagcac cctgttcctg 3420 gtctacagca acaagtgcca gacccccctg ggaatggcct ctggccacat cagggacttc 3480 cagatcactg cctctggcca gtatggccag tgggccccca agctggccag gctccactac 3540 tctggatcca tcaatgcctg gagcaccaag gagccattca gctggatcaa agtggacctg 3600 ctggccccca tgatcatcca tggcatcaag acccaggggg ccaggcagaa gttctccagc 3660 ctgtacatca gccagttcat catcatgtac agcctggatg gcaagaaatg gcagacctac 3720 agaggcaact ccactggaac actcatggtc ttctttggca atgtggacag ctctggcatc 3780 aagcacaaca tcttcaaccc cccaatcatc gccagataca tcaggctgca ccccacccac 3840 tacagcatcc gcagcaccct caggatggag ctgatgggct gtgacctgaa ctcctgcagc 3900 atgcccctgg gcatggagag caaggccatt tctgatgccc agatcactgc ctccagctac 3960 ttcaccaaca tgtttgccac ctggagccca agcaaggcca ggctgcacct ccagggaagg 4020 agcaatgcct ggaggcccca ggtcaacaac ccaaaggagt ggctgcaggt ggacttccag 4080 aagaccatga aggtcactgg ggtgaccacc cagggggtca agagcctgct caccagcatg 4140 tatgtgaagg agttcctgat cagctccagc caggatggcc accagtggac cctcttctc 4200 cagaatggca aggtcaaggt gttccagggc aaccaggaca gcttcacccc tgtggtgaac 4260 agcctggacc cccccctcct gaccagatac ctgaggattc acccccagag ctgggtccac 4320 cagattgccc tgaggatgga ggtcctggga tgtgaggccc aggacctgta ctga 4374 <210> 2 <211> 1457 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2 With Gln Ile Glu Leu Ser Thr Cys Phe Phe Leu Cys Leu Leu Arg Phe 1 5 10 15 Cys Phe Ser Ala Thr Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser 20 25 30 Trp Asp Tyr Met Gln Ser Asp Leu Gly Glu Leu Pro Val Asp Ala Arg 35 40 45 Phe Pro Pro Arg Val Pro Lys Ser Phe Pro Phe Asn Thr Ser Val Val 50 55 60 Tyr Lys Lys Thr Leu Phe Val Glu Phe Thr Asp His Leu Phe Asn Ile 65 70 75 80 Ala Lys Pro Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr Ile Gln 85 90 95 Ala Glu Val Tyr Asp Thr Val Val Ile Thr Leu Lys Asn Met Ala Ser 100 105 110 His Pro Val Ser Leu His Ala Val Gly Val Ser Tyr Trp Lys Ala Ser 115 120 125 Glu Gly Ala Glu Tyr Asp Asp Gln Thr Ser Gln Arg Glu Lys Glu Asp 130 135 140 Asp Lys Val Phe Pro Gly Gly Ser His Thr Tyr Val Trp Gln Val Leu 145 150 155 160 Lys Glu Asn Gly Pro Met Ala Ser Asp Pro Leu Cys Leu Thr Tyr Ser 165 170 175 Tyr Leu Ser His Val Asp Leu Val Lys Asp Leu Asn Ser Gly Leu Ile 180 185 190 Gly Ala Leu Leu Val Cys Arg Glu Gly Ser Leu Ala Lys Glu Lys Thr 195 200 205 Gln Thr Leu His Lys Phe Ile Leu Leu Phe Ala Val Phe Asp Glu Gly 210 215 220 Lys Ser Trp His Ser Glu Thr Lys Asn Ser Leu Met Gln Asp Arg Asp 225 230 235 240 Ala Ala Ser Ala Arg Ala Trp Pro Lys Met His Thr Val Asn Gly Tyr 245 250 255 Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Arg Lys Ser Val 260 265 270 Tyr Trp His Val Ile Gly Met Gly Thr Thr Pro Glu Val His Ser Ile 275 280 285 Phe Leu Glu Gly His Thr Phe Leu Val Arg Asn His Arg Gln Ala Ser 290 295 300 Leu Glu Ile Ser Pro Ile Thr Phe Leu Thr Ala Gln Thr Leu Leu Met 305 310 315 320 Asp Leu Gly Gln Phe Leu Leu Phe Cys His Ile Ser Ser His Gln His 325 330 335 Asp Gly Met Glu Ala Tyr Val Lys Val Asp Ser Cys Pro Glu Glu Pro 340 345 350 Gln Leu Arg Met Lys Asn Asn Glu Glu Ala Glu Asp Tyr Asp Asp Asp 355 360 365 Leu Thr Asp Ser Glu Met Asp Val Val Arg Phe Asp Asp Asp Asn Ser 370 375 380 Pro Ser Phe Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr 385 390 395 400 Trp Val His Tyr Ile Ala Ala Glu Glu Glu Asp Trp Asp Tyr Ala Pro 405 410 415 Leu Val Leu Ala Pro Asp Asp Arg Ser Tyr Lys Ser Gln Tyr Leu Asn 420 425 430 Asn Gly Pro Gln Arg Ile Gly Arg Lys Tyr Lys Lys Val Arg Phe Met 435 440 445 Ala Tyr Thr Asp Glu Thr Phe Lys Thr Arg Glu Ala Ile Gln His Glu 450 455 460 Ser Gly Ile Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr Leu 465 470 475 480 Leu Ile Ile Phe Lys Asn Gln Ala Ser Arg Pro Tyr Asn Ile Tyr Pro 485 490 495 His Gly Ile Thr Asp Val Arg Pro Leu Tyr Ser Arg Arg Leu Pro Lys 500 505 510 Gly Val Lys His Leu Lys Asp Phe Pro Ile Leu Pro Gly Glu Ile Phe 515 520 525 Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp 530 535 540 Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Phe Val Asn Met Glu Arg 545 550 555 560 Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu 565 570 575 Ser Val Asp Gln Arg Gly Asn Gln Ile Met Ser Asp Lys Arg Asn Val 580 585 590 Ile Leu Phe Ser Val Phe Asp Glu Asn Arg Ser Trp Tyr Leu Thr Glu 595 600 605 Asn Ile Gln Arg Phe Leu Pro Asn Pro Ala Gly Val Gln Leu Glu Asp 610 615 620 Pro Glu Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val 625 630 635 640 Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr Trp 645 650 655 Tyr Ile Leu Ser Ile Gly Ala Gln Thr Asp Phe Leu Ser Val Phe Phe 660 665 670 Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr 675 680 685 Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro 690 695 700 Gly Leu Trp Ile Leu Gly Cys His Asn Ser Asp Phe Arg Asn Arg Gly 705 710 715 720 Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp Lys Asn Thr Gly Asp 725 730 735 Tyr Tyr Glu Asp Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu Ser Lys 740 745 750 Asn Asn Ala Ile Glu Pro Arg Ser Phe Ser Gln Asn Pro Pro Val Leu 755 760 765 Lys Arg His Gln Arg Glu Ile Thr Arg Thr Thr Leu Gln Ser Asp Gln 770 775 780 Glu Glu Ile Asp Tyr Asp Asp Thr Ile Ser Val Glu Met Lys Lys Glu 785 790 795 800 Asp Phe Asp Ile Tyr Asp Glu Asp Glu Asn Gln Ser Pro Arg Ser Phe 805 810 815 Gln Lys Lys Thr Arg His Tyr Phe Ile Ala Ala Val Glu Arg Leu Trp 820 825 830 Asp Tyr Gly Met Ser Ser Ser Pro His Val Leu Arg Asn Arg Ala Gln 835 840 845 Ser Gly Ser Val Pro Gln Phe Lys Lys Val Val Phe Gln Glu Phe Thr 850 855 860 Asp Gly Ser Phe Thr Gln Pro Leu Tyr Arg Gly Glu Leu Asn Glu His 865 870 875 880 Leu Gly Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val Glu Asp Asn Ile 885 890 895 Met Val Thr Phe Arg Asn Gln Ala Ser Arg Pro Tyr Ser Phe Tyr Ser 900 905 910 Ser Leu Ile Ser Tyr Glu Glu Asp Gln Arg Gln Gly Ala Glu Pro Arg 915 920 925 Lys Asn Phe Val Lys Pro Asn Glu Thr Lys Thr Tyr Phe Trp Lys Val 930 935 940 Gln His His Met Ala Pro Thr Lys Asp Glu Phe Asp Cys Lys Ala Trp 945 950 955 960 Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys Asp Val His Ser Gly Leu 965 970 975 Ile Gly Pro Leu Leu Val Cys His Thr Asn Thr Leu Asn Pro Ala His 980 985 990 Gly Arg Gln Val Thr Val Gln Glu Phe Ala Leu Phe Phe Thr Ile Phe 995 1000 1005 Asp Glu Thr Lys Ser Trp Tyr Phe Thr Glu Asn Met Glu Arg Asn 1010 1015 1020 Cys Arg Ala Pro Cys Asn Ile Gln Met Glu Asp Pro Thr Phe Lys 1025 1030 1035 Glu Asn Tyr Arg Phe His Ala Ile Asn Gly Tyr Ile Met Asp Thr 1040 1045 1050 Leu Pro Gly Leu Val Met Ala Gln Asp Gln Arg Ile Arg Trp Tyr 1055 1060 1065 Leu Leu Ser Met Gly Ser Asn Glu Asn Ile His Ser Ile His Phe 1070 1075 1080 Ser Gly His Val Phe Thr Val Arg Lys Lys Glu Glu Tyr Lys Met 1085 1090 1095 Ala Leu Tyr Asn Leu Tyr Pro Gly Val Phe Glu Thr Val Glu Met 1100 1105 1110 Leu Pro Ser Lys Ala Gly Ile Trp Arg Val Glu Cys Leu Ile Gly 1115 1120 1125 Glu His Leu His Ala Gly Met Ser Thr Leu Phe Leu Val Tyr Ser 1130 1135 1140 Asn Lys Cys Gln Thr Pro Leu Gly Met Ala Ser Gly His Ile Arg 1145 1150 1155 Asp Phe Gln Ile Thr Ala Ser Gly Gln Tyr Gly Gln Trp Ala Pro 1160 1165 1170 Lys Leu Ala Arg Leu His Tyr Ser Gly Ser Ile Asn Ala Trp Ser 1175 1180 1185 Thr Lys Glu Pro Phe Ser Trp Ile Lys Val Asp Leu Leu Ala Pro 1190 1195 1200 Met Ile Ile His Gly Ile Lys Thr Gln Gly Ala Arg Gln Lys Phe 1205 1210 1215 Ser Ser Leu Tyr Ile Ser Gln Phe Ile Ile Met Tyr Ser Leu Asp 1220 1225 1230 Gly Lys Lys Trp Gln Thr Tyr Arg Gly Asn Ser Thr Gly Thr Leu 1235 1240 1245 Met Val Phe Phe Gly Asn Val Asp Ser Ser Gly Ile Lys His Asn 1250 1255 1260 Ile Phe Asn Pro Pro Ile Ile Ala Arg Tyr Ile Arg Leu His Pro 1265 1270 1275 Thr His Tyr Ser Ile Arg Ser Thr Leu Arg Met Glu Leu Met Gly 1280 1285 1290 Cys Asp Leu Asn Ser Cys Ser Met Pro Leu Gly Met Glu Ser Lys 1295 1300 1305 Ala Ile Ser Asp Ala Gln Ile Thr Ala Ser Ser Tyr Phe Thr Asn 1310 1315 1320 Met Phe Ala Thr Trp Ser Pro Ser Lys Ala Arg Leu His Leu Gln 1325 1330 1335 Gly Arg Ser Asn Ala Trp Arg Pro Gln Val Asn Asn Pro Lys Glu 1340 1345 1350 Trp Leu Gln Val Asp Phe Gln Lys Thr Met Lys Val Thr Gly Val 1355 1360 1365 Thr Thr Gln Gly Val Lys Ser Leu Leu Thr Ser Met Tyr Val Lys 1370 1375 1380 Glu Phe Leu Ile Ser Ser Ser Gln Asp Gly His Gln Trp Thr Leu 1385 1390 1395 Phe Phe Gln Asn Gly Lys Val Lys Val Phe Gln Gly Asn Gln Asp 1400 1405 1410 Ser Phe Thr Pro Val Val Asn Ser Leu Asp Pro Pro Leu Leu Thr 1415 1420 1425 Arg Tyr Leu Arg Ile His Pro Gln Ser Trp Val His Gln Ile Ala 1430 1435 1440 Leu Arg Met Glu Val Leu Gly Cys Glu Ala Gln Asp Leu Tyr 1445 1450 1455 <210> 3 <211> 2220 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polynucleotide <400> 3 gccaccagga gatactacct gggggctgtg gagctttctt gggactacat gcagtctgac 60 ctgggggagc tgcctgtgga tgccaggttc ccacccagag tgcccaaatc cttcccattc 120 aacacctg tggtctacaa gaagaccctc tttgtggagt tcactgacca cctgttcaac 180 attgccaaac ccaggccacc ctggatggga ctcctgggac ccaccattca ggctgaggtg 240 tatgacactg tggtcatcac cctcaagaac atggcctccc accctgtgag cctgcatgct 300 gtgggggtca gctactggaa ggcctctgag ggggctgagt atgatgacca gacctcccag 360 agggagaagg aggatgacaa agtgttccct gggggcagcc acacctatgt gtggcaggtc 420 ctcaaggaga atggccccat ggcctctgac ccactctgcc tgacctactc ctacctttct 480 catgtggacc tggtcaagga cctcaactct ggactgattg gggccctgct ggtgtgcagg 540 gagggctccc tggccaaaga gaagacccag accctgcaca agttcattct cctgtttgct 600 gtctttgatg agggcaagag ctggcactct gaaaccaaga actccctgat gcaggacagg 660 gatgctgcct ctgccagggc ctggcccaag atgcacactg tgaatggcta tgtgaacagg 720 agcctgcctg gactcattgg ctgccacagg aaatctgtct actggcatgt gattggcatg 780 gggacaaccc ctgaggtgca ctccattttc ctggagggcc acaccttcct ggtcaggaac 840 cacagacagg ccagcctgga gatcagcccc atcaccttcc tcactgccca gaccctgctg 900 atggacctcg gacagttcct gctgttctgc cacatcagct cccaccagca tgatggcatg 960 gaggcctatg tcaaggtgga cagctgccct gaggagccac agctcaggat gaagaacaat 1020 gaggaggctg aggactatga tgatgacctg actgactctg agatggatgt ggtccgcttt 1080 gatgatgaca acagcccatc cttcattcag atcaggtctg tggccaagaa acaccccaag 1140 acctgggtgc actacattgc tgctgaggag gaggactggg actatgcccc actggtcctg 1200 gcccctgatg acaggagcta caagagccag tacctcaaca atggcccaca gaggattgga 1260 cgcaagtaca agaaagtcag gttcatggcc tacactgatg aaaccttcaa gaccagggag 1320 gccattcagc atgagtctgg catcctgggc ccactcctgt atggggaggt gggggacacc 1380 ctgctcatca tcttcaagaa ccaggcctcc aggccctaca acatctaccc acatggcatc 1440 actgatgtca ggcccctgta cagccgcagg ctgccaaagg gggtgaaaca cctcaaggac 1500 ttccccattc tgcctgggga gatcttcaag tacaagtgga ctgtcactgt ggaggatgga 1560 ccaaccaaat ctgaccccag gtgcctcacc agatactact ccagctttgt gaacatggag 1620 agggacctgg cctctggcct gattggccca ctgctcatct gctacaagga gtctgtggac 1680 cagaggggaa accagatcat gtctgacaag aggaatgtga ttctgttctc tgtctttgat 1740 gagaacagga gctggtacct gactgagaac attcagcgct tcctgcccaa ccctgctggg 1800 gtgcagctgg aggaccctga gttccaggcc agcaacatca tgcactccat caatggctat 1860 gtgtttgaca gcctccagct ttctgtctgc ctgcatgagg tggcctactg gtacattctt 1920 tctattgggg cccagactga cttcctttct gtcttcttct ctggctacac cttcaaacac 1980 aagatggtgt atgaggacac cctgaccctc ttcccattct ctggggagac tgtgttcatg 2040 agcatggaga accctggcct gtggattctg ggatgccaca actctgactt ccgcaacagg 2100 ggcatgactg ccctgctcaa agtctcctcc tgtgacaaga acactgggga ctactatgag 2160 gacagctatg aggacatctc tgcctacctg ctcagcaaga acaatgccat tgagcccagg 2220 <210> 4 <211> 2052 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polynucleotide <400> 4 gagatcacca ggaccaccct ccagtctgac caggaggaga ttgactatga tgacaccatt 60 tctgtggaga tgaagaaaga ggactttgac atctatgacg aggacgagaa ccagagccca 120 aggagcttcc agaagaagac caggcactac ttcattgctg ctgtggagcg cctgtgggac 180 tatggcatga gctccagccc ccatgtcctc aggaacaggg cccagtctgg ctctgtgcca 240 cagttcaaga aagtggtctt ccaagagttc actgatggca gcttcaccca gcccctgtac 300 agaggggagc tgaatgagca cctgggactc ctgggcccat acatcagggc tgaggtggag 360 gacaacatca tggtgacctt ccgcaaccag gcctccaggc cctacagctt ctacagctcc 420 ctcatcagct atgaggagga ccagaggcag ggggctgagc cacgcaagaa ctttgtgaaa 480 cccaatgaaa ccaagaccta cttctggaaa gtccagcacc acatggcccc caccaaggat 540 gagtttgact gcaaggcctg ggcctacttc tctgatgtgg acctggagaa ggatgtgcac 600 tctggcctga ttggcccact cctggtctgc cacaccaaca ccctgaaccc tgcccatgga 660 aggcaagtga ctgtgcagga gtttgccctc ttcttcacca tctttgatga aaccaagagc 720 tggtacttca ctgagaacat ggagcgcaac tgcagggccc catgcaacat tcagatggag 780 gaccccacct tcaaagagaa ctaccgcttc catgccatca atggctacat catggacacc 840 ctgcctgggc ttgtcatggc ccaggaccag aggatcaggt ggtacctgct ttctatgggc 900 tccaatgaga acattcactc catccacttc tctgggcatg tcttcactgt gcgcaagaag 960 gaggagtaca agatggccct gtacaacctc taccctgggg tctttgagac tgtggagatg 1020 ctgccctcca aagctggcat ctggagggtg gagtgcctca ttggggagca cctgcatgct 1080 ggcatgagca ccctgttcct ggtctacagc aacaagtgcc agacccccct gggaatggcc 1140 tctggccaca tcagggactt ccagatcact gcctctggcc agtatggcca gtgggccccc 1200 aagctggcca ggctccacta ctctggatcc atcaatgcct ggagcaccaa ggagccattc 1260 agctggatca aagtggacct gctggccccc atgatcatcc atggcatcaa gacccagggg 1320 gccaggcaga agttctccag cctgtacatc agccagttca tcatcatgta cagcctggat 1380 ggcaagaaat ggcagaccta cagaggcaac tccactggaa cactcatggt cttctttggc 1440 aatgtggaca gctctggcat caagcacaac atcttcaacc ccccaatcat cgccagatac 1500 atcaggctgc accccaccca ctacagcatc cgcagcaccc tcaggatgga gctgatgggc 1560 tgtgacctga actcctgcag catgcccctg ggcatggaga gcaaggccat ttctgatgcc 1620 cagatcactg cctccagcta cttcaccaac atgtttgcca cctggagccc aagcaaggcc 1680 aggctgcacc tccagggaag gagcaatgcc tggaggcccc aggtcaacaa cccaaaggag 1740 tggctgcagg tggacttcca gaagaccatg aaggtcactg gggtgaccac ccagggggtc 1800 aagagcctgc tcaccagcat gtatgtgaag gagttcctga tcagctccag ccaggatggc 1860 caccagtgga ccctcttctt ccagaatggc aaggtcaagg tgttccaggg caaccaggac 1920 agcttcaccc ctgtggtgaa cagcctggac ccccccctcc tgaccagata cctgaggatt 1980 cacccccaga gctgggtcca ccagattgcc ctgaggatgg aggtcctggg atgtgaggcc 2040 caggacctgt ac 2052 <210> 5 <211> 42 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide <400> 5 agcttcagcc agaatccacc tgtcctgaaa cgccaccaga gg 42 <210> 6 <211> 7827 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polynucleotide <400> 6 tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60 cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120 ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 180 accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcaggcgcc 240 attcgccatt caggctgcgc aactgttggg aagggcgatc ggtgcgggcc tcttcgctat 300 tacgccagct ggcgaaaggg ggatgtgctg caaggcgatt aagttgggta acgccagggt 360 tttcccagtc acgacgttgt aaaacgacgg ccagtgaatt cctcgagatt taaatgacgt 420 tggccactcc ctctctgcgc gctcgctcgc tcactgaggc cgggcgacca aaggtcgccc 480 gacgcccggg ctttgcccgg gcggcctcag tgagcgagcg agcgcgcaga gagggagtgg 540 ccaactccat cactaggggt tcctgagttt aaacttcgtc gacgattcga gcttgggctg 600 caggtcgagg gcactgggag gatgttgagt aagatggaaa actactgatg acccttgcag 660 agacagagta ttaggacatg ttgaacagg ggccgggcga tcagcaggta gctctagagg 720 atccccgtct gtctgcacat ttcgtagagc gagtgttccg atactctaat ctccctaggc 780 aaggttcata tttgtgtagg ttacttattc tccttttgtt gactaagtca ataatcagaa 840 tcagcaggtt tggagtcagc ttggcaggga tcagcagcct gggttggaag gagggggtat 900 aaaagcccct tcaccaggag aagccgtcac acagactagg cgcgccaccg ccaccatgca 960 gattgagctg agcacctgct tcttcctgtg cctgctgagg ttctgcttct ctgccaccag 1020 gagatactac ctgggggctg tggagctttc ttgggactac atgcagtctg acctggggga 1080 gctgcctgtg gatgccaggt tcccacccag agtgcccaaa tccttcccat tcaacacctc 1140 tgtggtctac aagaagaccc tctttgtgga gttcactgac cacctgttca acattgccaa 1200 acccaggcca ccctggatgg gactcctggg acccaccatt caggctgagg tgtatgacac 1260 tgtggtcatc accctcaaga acatggcctc ccaccctgtg agcctgcatg ctgtgggggt 1320 cagctactgg aaggcctctg agggggctga gtatgatgac cagacctccc agagggagaa 1380 ggaggatgac aaagtgttcc ctgggggcag ccacacctat gtgtggcagg tcctcaagga 1440 gaatggcccc atggcctctg acccactctg cctgacctac tcctaccttt ctcatgtgga 1500 cctggtcaag gacctcaact ctggactgat tggggccctg ctggtgtgca gggagggctc 1560 cctggccaaa gagaagaccc agaccctgca caagttcatt ctcctgtttg ctgtctttga 1620 tgagggcaag agctggcact ctgaaaccaa gaactccctg atgcaggaca gggatgctgc 1680 ctctgccagg gcctggccca agatgcacac tgtgaatggc tatgtgaaca ggagcctgcc 1740 tggactcatt ggctgccaca ggaaatctgt ctactggcat gtgattggca tggggacaac 1800 ccctgaggtg cactccattt tcctggaggg ccacaccttc ctggtcagga accacagaca 1860 ggccagcctg gagatcagcc ccatcacctt cctcactgcc cagaccctgc tgatggacct 1920 cggacagttc ctgctgttct gccacatcag ctcccaccag catgatggca tggaggccta 1980 tgtcaaggtg gacagctgcc ctgaggagcc acagctcagg atgaagaaca atgaggaggc 2040 tgaggactat gatgatgacc tgactgactc tgagatggat gtggtccgct ttgatgatga 2100 caacagccca tccttcattc agatcaggtc tgtggccaag aaacacccca agacctgggt 2160 gcactacatt gctgctgagg aggaggactg ggactatgcc ccactggtcc tggcccctga 2220 tgacaggagc tacaagagcc agtacctcaa caatggccca cagaggattg gacgcaagta 2280 caagaaagtc aggttcatgg cctacactga tgaaaccttc aagaccaggg aggccattca 2340 gcatgagtct ggcatcctgg gcccactcct gtatggggag gtgggggaca ccctgctcat 2400 catcttcaag aaccaggcct ccaggcccta caacatctac ccacatggca tcactgatgt 2460 caggcccctg tacagccgca ggctgccaaa gggggtgaaa cacctcaagg acttccccat 2520 tctgcctggg gagatcttca agtacaagtg gactgtcact gtggaggatg gaccaaccaa 2580 atctgacccc aggtgcctca ccagatacta ctccagcttt gtgaacatgg agagggacct 2640 ggcctctggc ctgattggcc cactgctcat ctgctacaag gagtctgtgg accagagggg 2700 aaaccagatc atgtctgaca agaggaatgt gattctgttc tctgtctttg atgagaacag 2760 gagctggtac ctgactgaga acattcagcg cttcctgccc aaccctgctg gggtgcagct 2820 ggaggaccct gagttccagg ccagcaacat catgcactcc atcaatggct atgtgtttga 2880 cagcctccag ctttctgtct gcctgcatga ggtggcctac tggtacattc tttctattgg 2940 ggcccagact gacttccttt ctgtcttctt ctctggctac accttcaaac acaagatggt 3000 gtatgaggac accctgaccc tcttcccatt ctctggggag actgtgttca tgagcatgga 3060 gaaccctggc ctgtggattc tgggatgcca caactctgac ttccgcaaca ggggcatgac 3120 tgccctgctc aaagtctcct cctgtgacaa gaacactggg gactactatg aggacagcta 3180 tgaggacatc tctgcctacc tgctcagcaa gaacaatgcc attgagccca ggagcttcag 3240 ccagaatcca cctgtcctga aacgccacca gagggagatc accaggacca ccctccagtc 3300 tgaccaggag gagattgact atgatgacac catttctgtg gagatgaaga aagaggactt 3360 tgacatctat gacgaggacg agaaccagag cccaaggagc ttccagaaga agaccaggca 3420 ctacttcatt gctgctgtgg agcgcctgtg ggactatggc atgagctcca gcccccatgt 3480 cctcaggaac agggcccagt ctggctctgt gccacagttc aagaaagtgg tcttccaaga 3540 gttcactgat ggcagcttca cccagcccct gtacagaggg gagctgaatg agcacctggg 3600 actcctgggc ccatacatca gggctgaggt ggaggacaac atcatggtga ccttccgcaa 3660 ccaggcctcc aggccctaca gcttctacag ctccctcatc agctatgagg aggaccagag 3720 gcagggggct gagccacgca agaactttgt gaaacccaat gaaaccaaga cctacttctg 3780 gaaagtccag caccacatgg cccccaccaa ggatgagttt gactgcaagg cctgggccta 3840 cttctctgat gtggacctgg agaaggatgt gcactctggc ctgattggcc cactcctggt 3900 ctgccacacc aacaccctga accctgccca tggaaggcaa gtgactgtgc aggagtttgc 3960 cctcttcttc accatctttg atgaaaccaa gagctggtac ttcactgaga acatggagcg 4020 caactgcagg gccccatgca acattcagat ggaggacccc accttcaaag agaactaccg 4080 cttccatgcc atcaatggct acatcatgga caccctgcct gggcttgtca tggcccagga 4140 ccagaggatc aggtggtacc tgctttctat gggctccaat gagaacattc actccatcca 4200 cttctctggg catgtcttca ctgtgcgcaa gaaggaggag tacaagatgg ccctgtacaa 4260 cctctaccct ggggtctttg agactgtgga gatgctgccc tccaaagctg gcatctggag 4320 ggtggagtgc ctcattgggg agcacctgca tgctggcatg agcaccctgt tcctggtcta 4380 cagcaacaag tgccagaccc ccctgggaat ggcctctggc cacatcaggg acttccagat 4440 cactgcctct ggccagtatg gccagtgggc ccccaagctg gccaggctcc actactctgg 4500 atccatcaat gcctggagca ccaaggagcc attcagctgg atcaaagtgg acctgctggc 4560 ccccatgatc atccatggca tcaagaccca gggggccagg cagaagttct ccagcctgta 4620 catcagccag ttcatcatca tgtacagcct ggatggcaag aaatggcaga cctacagagg 4680 caactccact ggaacactca tggtcttctt tggcaatgtg gacagctctg gcatcaagca 4740 caacatcttc aaccccccaa tcatcgccag atacatcagg ctgcacccca cccactacag 4800 catccgcagc accctcagga tggagctgat gggctgtgac ctgaactcct gcagcatgcc 4860 cctgggcatg gagagcaagg ccatttctga tgcccagatc actgcctcca gctacttcac 4920 caacatgttt gccacctgga gcccaagcaa ggccaggctg cacctccagg gaaggagcaa 4980 tgcctggagg ccccaggtca acaacccaaa ggagtggctg caggtggact tccagaagac 5040 catgaaggtc actggggtga ccacccaggg ggtcaagagc ctgctcacca gcatgtatgt 5100 gaaggagttc ctgatcagct ccagccagga tggccaccag tggaccctct tcttccagaa 5160 tggcaaggtc aaggtgttcc agggcaacca ggacagcttc acccctgtgg tgaacagcct 5220 ggaccccccc ctcctgacca gatacctgag gattcacccc cagagctggg tccaccagat 5280 tgccctgagg atggaggtcc tgggatgtga ggcccaggac ctgtactgat gacgagcggc 5340 cgctcttagt agcagtatcg ataataaaag atctttattt tcattagatc tgtgtgttgg 5400 ttttttgtgt gttaattaag ctcgcgaagg aacccctagt gatggagttg gccactccct 5460 ctctgcgcgc tgctcgctc actgaggccg ggcgaccaaa ggtcgcccga cgcccgggct 5520 ttgcccgggc ggcctcagtg agcgagcgag cgcgcagaga gggagtggcc aagacgattt 5580 aaatgacaag cttggcgtaa tcatggtcat agctgtttcc tgtgtgaaat tgttatccgc 5640 tcacaattcc acacaacata cgagccggaa gcataaagtg taaagcctgg ggtgcctaat 5700 gagtgagcta actcacatta attgcgttgc gctcactgcc cgctttccag tcgggaaacc 5760 tgtcgtgcca gctgcattaa tgaatcggcc aacgcgcggg gagaggcggt ttgcgtattg 5820 ggcgctcttc cgcttcctcg ctcactgact cgctgcgctc ggtcgttcgg ctgcggcgag 5880 cggtatcagc tcactcaaag gcggtaatac ggttatccac agaatcaggg gataacgcag 5940 gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc 6000 tggcgttttt ccataggctc cgcccccctg acgagcatca caaaaatcga cgctcaagtc 6060 agaggtggcg aaacccgaca ggactataaa gataccaggc gtttccccct ggaagctccc 6120 tcgtgcgctc tcctgttccg accctgccgc ttaccggata cctgtccgcc tttctccctt 6180 cgggaagcgt ggcgctttct catagctcac gctgtaggta tctcagttcg gtgtaggtcg 6240 ttcgctccaa gctgggctgt gtgcacgaac cccccgttca gcccgaccgc tgcgccttat 6300 ccggtaacta tcgtcttgag tccaacccgg taagacacga cttatcgcca ctggcagcag 6360 ccactggtaa caggattagc agagcgaggt atgtaggcgg tgctacagag ttcttgaagt 6420 ggtggcctaa ctacggctac actagaagaa cagtatttgg tatctgcgct ctgctgaagc 6480 cagttacctt cggaaaaga gttggtagct cttgatccgg caacaaacc accgctgta 6540 gcggtggtttt ttgtttgc aagcagcaga tcgcgcag aaaaaagga tctcaagaag 6600 atcctttgat ctttctacg gggtctgacg ctcagtgga cgaaactca cgttaaggga 6660 ttttggtcat gagattatca aaaggatct tcacctagat ccttttaaat taaaaatgaa 6720 gttttaaatc aatctaaagt atatatgagt aaacttggtc tgacagttac caatgcttaa 6780 tcagtgaggc acctactca gcgatctgtc tattcgttc atccatagtt gcctgactcc 6840 ccgtcgtgta gatactacg atacgggagg gcttaccatc tggccccagt gctgcaatga 6900 taccgcgaga cccacgctca ccggctccag attackcagc ataaaccag cccaccggaa 6960 gggccgagcg cagaagtggt cctgcaactt tatccgcctc catccagtct atttattgtt 7020 gccgggaagc tagatagt agttcgccag ttaatagttt gcgcaacgtt gttgccattg 7080 ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc ttcattcagc tccggttccc 7140 aacgatcaag gcgagttaca tgatccccca tgttgtgcaa aaaagcggtt agctccttcg 7200 gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt atcactcatg gttatggcag 7260 cactgcataa ttctcttact gtcatgccat ccgtaagatg cttttctgtg actggtgagt 7320 actcaaccaa gtcattctga gaatagtgta tgcggcgacc gagttgctct tgcccggcgt 7380 caatacggga taataccgcg ccacatagca gaactttaaa agtgctcatc attggaaaac 7440 gttcttcggg gcgaaaactc tcaaggatct taccgctgtt gagatccagt tcgatgtaac 7500 ccactcgtgc acccaactga tcttcagcat cttttacttt caccagcgtt tctgggtgag 7560 caaaaacagg aaggcaaaat gccgcaaaaa agggaataag ggcgacacgg aaatgttgaa 7620 tactcatact cttcctttt caatattatt gaagcattta tcagggttat tgtctcatga 7680 gcggatacat atttgaatgt atttagaaaa ataaacaaat aggggttccg cgcacatttc 7740 cccgaaaagt gccacctgac gtctaagaaa ccattattat catgacatta acctataaaa 7800 ataggcgtat cacgaggccc tttcgtc 7827 <210> 7 <211> 4374 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polynucleotide <400> 7 atgcagatcg aactgagcac ttgcttcttc ctgtgtctcc tgcgcttttg cttctccgcc 60 acaaggagat actatctcgg tgccgtggag ctcagctggg actacatgca gagcgacttg 120 ggtgaactgc ctgtggacgc caggtttcca ccccgcgtgc ccaagagttt cccgttcaac 180 accagtgtcg tgtacaagaa aaccctcttc gtggaattca ccgaccacct gttcaacatc 240 gccaaaccgc gccctccctg gatggggctg ctcggcccga cgatccaggc tgaggtctat 300 gacacggtgg tgattaccct caagaacatg gctagccacc cggtgagcct gcacgccgtg 360 ggcgtgtcct attggaaagc gtccgagggt gcggagtacg atgaccagac ttcacagcgg 420 gagaaggaag acgacaaagt gttccccggg ggttcccaca cctatgtctg gcaggtcctg 480 aaggagaatg gtcctatggc ctccgaccca ttgtgcctca cctactctta cctaagccat 540 gtggatctcg tcaaggacct gaactcgggg ctgatcggcg ccctgctcgt gtgccgggag 600 ggctcactgg ccaaggagaa gacccaaact ctgcacaagt tcatcctgct gttcgcggta 660 ttcgacgagg ggaagtcctg gcactccgag accaagaaca gcctgatgca ggaccgcgac 720 gcagcctcgg cccgtgcgtg gccaaagatg cacaccgtga acggctacgt taacaggagc 780 ctacccggcc tgatcggctg ccaccgcaaa tcggtctact ggcatgtgat cggaatgggc 840 acaacgcccg aggtccacag tatcttcctc gagggccaca ctttcctggt ccggaatcac 900 cgccaggcca gcctggagat cagccccata acctttctga cggcgcagac cttactcatg 960 gatctcggcc agttcctcct gttctgccac atttcgtccc accagcacga tgggatggaa 1020 gcatatgtga aagtggactc ctgccccgag gaaccccagc ttaggatgaa gaacaatgag 1080 gaggccgagg actacgacga tgaccttacc gattcagaaa tggacgtagt acgctttgac 1140 gacgacaact ctccatcctt catacagatt cgctccgtcg ccaagaagca ccctaagact 1200 tgggtgcact acatcgcggc cgaggaggag gactgggatt atgctcccct ggtgctggcc 1260 cccgacgacc gcagctacaa gagccagtac ctgaataacg ggccccagcg catcggccgg 1320 aagtacaaga aagtgcggtt catggcttac acggacgaga ccttcaagac ccgggaggct 1380 atccagcatg agagcggcat cttggggccc ctcctgtacg gcgaagttgg agacacactg 1440 ctgatcatct tcaagaacca ggcgagcagg ccctacaaca tctaccccca cggcattacc 1500 gatgtccggc cgttgtacag ccgacggctg cccaagggcg tgaagcacct gaaggacttt 1560 ccgatcctgc cgggcgagat cttcaagtac aagtggactg tgaccgtgga ggatgggccg 1620 accaagagcg atccgcgctg cctgacccgt tactactcca gctttgtcaa tatggagcgc 1680 gacctcgcta gcggcttgat tggccctctg ctgatctgct acaaggagtc cgtggaccag 1740 agggggaatc agatcatgag tgacaagagg aacgtgatcc tgttctccgt gttcgacgaa 1800 aaccgcagct ggtatctcac cgagaatatc cagcgcttcc tgcccaaccc ggccggtgtg 1860 cagctggagg accccgagtt tcaggccagc aacatcatgc attctatcaa cggatatgtg 1920 tttgattccc tgcagctctc agtgtgtctg cacgaggtcg cctactggta tatcctcagc 1980 attggggcac agaccgactt cctgagcgtg ttcttctccg ggtatacctt caagcacaag atggtgtacg aggataccct gaccctgttc ccctttagcg gcgaaccgt gtttatgtct atggagaacc ccgggctctg gatccttggc tgccataact ccgacttccg caaccgcgga atgaccgcgc tcctgaaagt gtcgagttgt gacaagaaca ccggcgacta ttacgaggac 2220 agttacgagg acatctctgc gtacctcctt agcagaata acgccatcga gccaagatcc ttcagccaga accccccagt gctgaagagg catcagcggg agatcacccg cacgaccctg cagtcggatc aggaggat tgattacgac gacacgatca gtgtggagat gaagaggag gacttcgaca tctacgacga agatgaaaac cagtcccctc ggtccttcca aaagaagacc cggcactact tcatcgccgc tgtggaacgc ctgtgggact atggaatgtc ttctagccct 2520 cacgttttga ggaaccgcgc ccagtcgggc agcgtgcccc agttcaagaa agtggtgttc 2580. caggagttca ccgacggctc cttcacccag ccctttacc ggggcgagct caatgaacat ctgggcctgc tgggacccta catcagggct gaggtggagg acaacatcat ggtgacattc cggaatcagg ccagcagacc atacagtttc tacagttcac tcatctccta cgaggaggac 2760 cagcgccagg gggctgaacc ccgtaagaac ttcgtgaagc caaacgaa aaagacctac 2820 ttctggaagg tccagcacca catggcacct accaagggacg agttcgattg caaggcctgg 2880 gcctacttct ccgacgtgga cctggagaaa gatgtgcaca gcggcctgat tggccctctg 2940 ctggtgtgtc acacgaacac actcaaccct gcacacgggc ggcaggtcac tgtgcaggaa 3000 ttcgccctgt tctttaccat ctttgatgag acgaagtcct ggtatttcac cgaaaacatg 3060 gaggagaact gccgcgcacc ctgcaacatc cagatggaag atccgacatt caaggaaac 3120 taccggttcc atgccatcaa tggctacatc atggacaccc tgcctggcct cgtgatggcc 3180 caagaccagc gtatccgctg gtatctgctg tcgatgggct ccaacgagaa catccatagt 3240 atccacttca gcgggcatgt cttcacggtg aggaaaaagg aggagtacaa gatggcactg 3300 tacaacctct atcccggcgt gttcgagacc gtggagatgc tgccctccaa ggccggcatc 3360 tggagagtgg aatgcctgat cggcgagcac ctccacgctg ggatgtccac gctgttcctc 3420 gtttacagca ataagtgcca gacccctctg ggcatggcga gcggccacat ccgcgacttc 3480. 3540. cagattacag ccagcggcca gtacggtcag tgggctccaa agctggcccg tctgcactac tccggatcca tcaacgcctg gtccaccaag gaaccgttct cctggatcaa owner ctagccccca tgatcattca cggcatcaag acacaaggcg cccgacaga gttctcgagc ctctatatct cccagttcat catcatgtat agcctggacg gaaagaagtg gcagacttac 3720. cgcggaact cgacagggac cctgatggta ttcttcggta acgtggacag ctccggaatc 3840. aagcacaaca tcttcaaccc acccattatc gcccgctaca tccgcctgca ccccactcac father ggtccaccct gcgaatggag ctcatgggct gtgacctgaa cagctgtagc atgcccctcg gcatggagtc taaggcgatc tccgacgcac agataacggc atcatcctac 3960. tttaccaaca tgttcgctac ctggtccccc tccaaggccc gactccacct gcaagggaga tccaacgcct ggcggccaca ggtcaacaat cccaaggagt ggctgcaagt ggactttcag aaaactatga aagtcaccgg agtgaccaca cagggagtga agtctctgct gaccagcatg tacgtgaagg agttcctcat ctccagttcg caggatggcc accagtggac gttgttcttc 4200 caaaacggta aagtcaaagt cttccaaggg aaccaggaca gctttacacc cgtcgtgaac 4260 tccctggacc ccccgcttct cactagatac ctccgcatcc accctcagag ctgggtgcac 4320 cagattgccc tgcgcatgga ggttctgggg tgtgaagccc aggacctgta ctaa 4374 <210> 8 <211> 4374 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polynucleotide <400> 8 atgcagattg agctctccac ctgcttcttt ctctgccttc ttcgcttctg cttttctgcc 60 acacgcaggt actatttggg agcagtggaa ctgagctggg attacatgca gagtgacctt 120 ggtgaacttc ctgtggacgc tcgttttcca cctagagttc ccaagtcctt ccccttcaac 180 acctcagtgg tctacaagaa aacgctgttt gtggagttca ctgaccacct cttcaacatt 240 gccaaaccaa gacccccttg gatgggattg ctgggaccca caatacaagc agaagtctac 300 gacacggtgg tgattaccct gaagaacatg gcgtcacacc ctgtttcact tcacgctgtt 360 ggggtcagtt attggaaagc ctcagagggt gcggaatacg atgatcaaac cagccagagg 420 gaggaag atgacaaggt ctttcctggg ggtagccata cctatgtttg gcaggtgctg 480 aaagagaatg ggcctatggc ctctgatccc ttgtgcctca catactctta cctgagtcac 540 gtcgacctgg tgaaagacct gaatagcggt ctgattggtg cactgcttgt ttgtagagag 600 gggagtttgg ccaaggagaa aactcagact ctccacaagt ttatcctcct gtttgctgtg 660 ttcgacgagg gcaagtcttg gcactctgaa aaaagaact ccctgatgca gcacagagat 720 gctgcatctg caagggcttg gccaaaaaatg cacagatga acggctatgt gaatcgatca 780 ctgccaggac tgataggctg tcatcgcaag tcagtgtatt ggcacgttat cgggatggga 840 acaactccag aagtgcacag catcttcctt gagggccaca ctttcctggt tcggaatcat 900 agacaggcca gccttgagat cagcccaatc acctttctga ctgcccaaac cttgctgatg 960 gatctgggac agttcctcct gttttgtcac atctctccc accaacatga cgggatggag 1020 gcttatgtga aggtcgatag ctgtccggag gaaccacaac tgaggatgaa gaacaacgaa 1080 gaggcagagg actatgacga cgatctgact gacagtgaaa tggacgtggt tcggttcgac 1140 gatgacaatt ctccttcatt tatccagatc cgttccgtgg ccaagaagca ccccaagact 1200 tgggttcatt acatcgctgc tgaggaggag gattgggact acgcgccctt ggtgttggcc 1260 ccagacgatc gctcatacaa gagccagtac cttaacaatg gtccacaaag gatcggccgg 1320 aagtacaaga aggttagatt tatggcttat accgacgaga cttttaaaac tagggaagca 1380 attcagcatg aaagtggcat tcttggaccc ctgctgtatg gcgaggttgg cgacaccctg 1440 ctgattatct ttaagaacca ggcaagccgg ccctacaaca tctacccgca cggcataacc 1500 gatgtacgac ccctgtacag tcgcagactt cctaaagggg tgaaacacct gaaggacttc 1560 ccaattctgc ccggggagat cttcaagtat aaatggaccg tgacggttga ggatggtccc 1620 acaaagtccg atccgagatg ccttacccga tattattcca gcttcgtgaa catggaaagg 1680 gacctggcca gcgggctgat tggcccactg ctgatttgtt acaaggagtc tgtcgatcaa 1740 agaggaaacc aaataatgag cgacaacgt aacgtcatcc tgttcagcgt ctttgatgag 1800 atagaagct ggtacctcac agaaaatatt cagcggtttc tgcctaaccc cgcaggcgtc 1860 cagctggaag atcccgagtt cagcctca aacatcatgc atagcatca cggatacgta 1920 ttcgatagcc tgcagctgtc cgtctgtctc catgaagtgg catattgta catcctgagt 1980 atcggggcgc agaccgactt cctgagcgtg ttctttctg gatacacgtt caacacaaa 2040 atggtctatg aagataccct gactctgttt ccattctcag gagacagt ctttatgagt 2100 atggaaaatc ctggactgtg gatcctgggc tgtcacaatt ctgatttcg gaacagaggc 2160 atgacagccc tgcttaagt gagctcatgc ganagaaca ccggtgatta ctacgaagat 2220 agctatgagg acatcagtgc gtatttgctc tccagaaca acgctatcga gccacggtct 2280 ttcagtcaga atcctcccgt tctgaagcgg catcagcgcg aataacacg cacaaccctt 2340 cagtcagacc agaggaaat cgactacgat gatactatct ctgtggatt gagaaggag 2400 gatttcgaca tttacgacga ggacgagaat cagtccccaa ggagctttca gagaaaaca 2460 agacactatt tcattgccgc cgtggagcga ctgtgggact acggcatgtc tagctctccg 2520 catgtactta gaaatagggc acaaagcgga tccgtgcctc agtttaagaa agttgtcttt 2580 caggagttta cagatggctc cttcacccag cccttgtatc gcggggaact caatgaacac 2640 ctgggcctcc tgggtcctta tattagggcc gaagtcgagg acaatatcat ggtgaccttt 2700 aggaaccagg catctagacc ttactctttc tactctccc tgatatccta tgaggagac 2760 cagcggcaag gcgctgagcc tcggaagaac tttgtgaagc caaatgaaac caaaacatac 2820 ttttggaaag ttcagcacca catggctccc acgaggacg aatttgactg taaagcctgg 2880 gcctacttct cagatgtaga tctcgagaaa gacgtgcact cagggctcat tggtcccctc 2940 ctggtctgtc atactaatac cctcaatcca gcacacggac gtcaggtaac cgtccaggaa 3000 tttgccctgt tctttaccat tttcgatgag actaaatcct ggtactttac cgaaaacatg 3060 gagaggaatt gcagagcccc atgcaacatc cagatggagg accctacctt caaagagaac 3120 tatcgcttcc atgccattaa cggttacatt atggatactc tcccaggact tgtgatggca 3180 caggatcagc ggataagatg gtatctgttg agcatgggct ccaacgagaa tattcacagc 3240 atccatttct ccggtcacgt gtttacagtg agaaagaaag aagagtacaa gatggctctg 3300 tataatctct atccaggcgt attcgaaacg gtggagatgt tgcctagcaa ggccggcatt 3360 tggcgagtag aatgccttat cggggaacat ctgcatgccg gaatgagcac gctcttcctg 3420 gtgtatagta acaagtgcca gactccgctg ggcatggcat ctggccatat acgggacttt 3480 cagattacgg ctagcgggca gtatgggcag tgggcaccca aacttgcgcg actgcactat 3540 tcaggctcta tcaatgcatg gtccaccaag gaacccttct cttggattaa ggtggacctt 3600 ttggcgccca tgataatcca tgggatcaaa acccagggcg ctcgtcagaa attctcatca 3660 ctctacatct ctcagttcat aataatgtat tcactggatg ggaagaaatg gcagacttac 3720 agaggaaaca gcaccgggac gctgatggtg ttctttggca acgtggacag cagcggcatc 3780 aaacacaaca tcttcaatcc tcccattatt gcccgtata ttagactgca tcccactcac 3840 tactctatac gcagcacact taggatggag ctcatgggat gcgacctgaa cagttgtagt 3900 atgcccttgg ggatggagtc caaagctata agcgacgcac aaattacagc tagctcttac 3960 tttacgaata tgttcgccac gtggagccca agcaaagccc ggctgcattt gcagggtcgg 4020 agtaatgctt ggcgcccaca ggtgaataac cctaaggaat ggttgcaagt agatttccag 4080 aaaactatga aggtaaccgg cgtcactaca cagggagtca agtccctctt gacctctatg 4140 tacgtcaagg agttcctgat tagcagcagt caggatgggc accaatggac actgttcttc 4200 cagaatggga aagttaaagt atttcagggt aaccaggact cctttacacc tgtggtgaat 4260 agcctcgacc cacccctgct gacacgatac ctccgcatcc accctcagtc ttgggtgcat 4320 caaattgccc tgcgaatgga ggtgttggga tgcgaagctc aggacctcta ctga 4374 <210> 9 <211> 4374 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polynucleotide <400> 9 atgcagatcg aactctctac ttgcttcttc ctgtgccttc tgaggttctg cttctctgcc 60 actcgccgat attacctcgg ggccgtggag ttgagttggg actacatgca atcagatctg 120 ggcgaactcc ctgtggatgc ccgattccca ccgcgcgtgc ccaagtcttt cccatttaat 180 acttctgtgg tgtacaagaa gacattgttt gtggagttta ccgatcacct gttcaacatc 240 gccaaaccgc ggcccccatg gatgggtctg cttgggccca ccattcaagc ggaggtctat 300 gatacagtgg tgataacgct taagaacatg gcgagccacc cagtgtctct gcatgccgtt 360 ggtgtatcat attggaaggc cagcgaagga gcggagtacg atgaccagac ctctcagaga 420 gaggaag acgataaggt ttttcctggc ggaagtcata catatgtatg gcaggtcctg 480 aaagagaatg ggccgatggc ttctgacccc ctttgtctta cctatagtta tctgagccac 540 gtggacctgg tcaaggacct caacagtggt ctgattgggg ctctgcttgt ttgtagagag 600 ggtagcttgg ctaaggaa aacccaaaca ctccataagt tcattttgct gttcgcggtg 660 ttcgacgagg gaagagttg gcacagcgaa acaaagaatt cactgatgca agacagggac 720 gccgcttccg caagggcttg gcctaagatg catacggtga atgggtatgt gaaccggagc 780 ctcccggggc tgatcgggtg ccatcgcaag tctgtttact ggcacgtcat tggaatgggg 840 acaacgccag aggtacatag tatatttctt gaaggccaca cgttcctcgt acggaaccac 900 cgacaggctt ccctggagat aagccccatt acctttctga ccgctcagac tctgctgatg 960 gaccttggcc agtttctcct gttctgccat attagcagcc accagcacga cggtatggaa 1020 gcatacgtga aagtcgatag ctgtcctgag gagcctcagc tcagaatgaa gaacaacgag 1080 gaggccgaag actatgacga tgaccttaca gattccgaga tggacgtggt gcgctttgac 1140 gacgataaca gtcctagttt cattcaaatc agatccgtag ccaaaaaagca tccaaagaca 1200 tgggtgcatt acattgcagc cgaagaggag gattgggatt atgcgcccct tgttctggct 1260 ccagatgaca ggagctataa gtcccagtac ttgaacaacg ggccacagcg aatcggtaga 1320 aaataataaga aggtaagatt catggcctac actgacgaaa catttaaaac cagggaagct 1380 atccaacacg aatctggaat tctcggccct ctgctctacg gtgaggtggg ggacaccttg 1440 ctgatcattt tcaaaaaatca ggcatccagg ccttacaaca tataccccca tggcatcacc 1500 gatgtccgcc cgctgtattc cagaagactc cccaagggag tgaaacatct gaaagatttt 1560 cccatcctgc cgggcgagat ctttaaatac aaatggactg tgactgtaga ggacgggcct 1620 acaaaatcag acccacggtg cctgacaagg tattacagta gcttcgtcaa catggaacgc 1680 gacctcgcca gcggactcat tggcccactg ttgatctgtt acaaagagtc agtggatcag 1740 aggggaaatc agatcatgag cgataagaga aacgttatcc tgtttagtgt cttcgacgag 1800 aaccggtctt ggtaccttac tgagaacatc cagaggttcc tgccgaatcc ggctggcgtt 1860 cagctcgagg acccagagtt ccaggccagt aatataatgc actcaatcaa cggttatgtg 1920 ttcgatagcc tgcagctgag cgtctgcctc cacgaggtag cctattggta catattgtcc 1980 atcggggctc agaccgattt tctgtccgtg ttctttagcg ggtatacctt taaacataaa 2040 atggtctatg aagacaccct gaccctgttc ccattctccg gtgagactgt gttcatgtcc 2100 atggagaacc cagggctgtg gatcctgggg tgtcacaata gtgactttag gaatcgggga 2160 atgacggcac tgctgaaggt gagttcttgc gataaaaata caggagatta ctatgaggat 2220 agttacgagg atatcagtgc ctatctgctt tcaaaaaaca acccaattga gccccggtct 2280 ttctcacaaa acccccggt gctgaagcgc caccagcgcg aaattacccg vakaaccttg 2340 cagtccgacc aggaaat cgattgac gatactaca gtgtagaaat gaaaaaggag 2400 gattttgata tttacgacga agacgagaac cagtctccgc gaagttttca gagaaaacg 2460 cgacactact ttatagctgc cgtggaacga ctctgggat atggcatgtc ctccagccct 2520 catgtcctta ggaatcgagc gcagagtggc tctgtgccctc agttcaaaa gttgtgttc 2580 caggaattca ccgacggctc attacccag ccgctgtaca gaggcgaact caacgaacac 2640 cttgggctgc ttgggccata tattcgagca gaggtggaag ataatcat ggtaaccttt 2700 agaaaccagg cgtcagacc ctattccttc tacagttctc tgatcagcta cgaggaggac 2760 caggaagg gagctgaacc caggagaac ttgtgaaac ctaatgagac siagacctac 2820 ttctggaagg tccagcacca tatggcccca actaagatg aattcgattg caagcctgg 2880 gcttatttca gcgacgtgga tctcgaaag gatgtgcaca gcgggttgat cggaccgctt 2940 ttggtgtgcc acacaatac cctcaatcct gcccacgggc ggcaggtcac agttcaagg 3000 tttgcactct tctttacaat atttgacga acaagtcat gttattttac agagaatg 3060 gagagaaatt gtcgcgcacc ttgcacatt cagatggagg acccacatt class 3120 tacagatttc atgctatcaa tgggtacatt atggatactc tgctgtct ggtcatggcc 3180 caggatcagc gcataggtg gtacttgctg agcatgggat ctaatgagaa tatacacagc 3240 attcacttca gtggccacgt tttactgtt agaaagaagg aggagtacaa atggcgctc 3300 tacaaccttt acccggggtgt gtttgagaca gtggagatgc tgccaagcaa ggcaggcatc 3360 tggaggttg agtgtcttat tggggagcat ctgcatgctg gatgtccac cctctttctt 3420 gtgtacagca ataagtgccaccaccgctt ggcatggcca gcggccacat tagggacttt 3480 cagataactg ccagtggaca gtacggccag tgggctccca agcttgcaag actccactac 3540 tccggaagca taaacgcatg gagcaccaag gaacccttct cttggattaa ggtggacctg 3600 ctggcgccaa tgatcattca cggcataaaa acccaagggg cacgacagaa atttcatct 3660 ttgtatatta gtcagtttat catcatgtac agcttggatg gaaagaagtg gcagacgtac 3720 aggggcaatt ctacaggaac acttatggtg ttttttggga atgtcgattc cagcgggatc 3780 aaacataaca tcttcaatcc tcctattatc gcccgatata tccgcctgca ccctacgcat 3840 tactccatca ggtccacatt gagaatggaa ctgatggggt gcgacctgaa tagttgtagt 3900 atgccactgg gcatggagtc taaagccatc agcgatgcac agatcactgc cagctcttac 3960 ttcaccaaca tgtttgcaac ttggtccccc tctaaagctc gcctgcatct gcagggacgc 4020 tcaaatgcat ggcgaccaca ggtgaacaat ccaaaagagt ggctccaggt cgactttcag 4080 aagacaatga aggtaacagg agtgacaacc cagggtgtaa aaagcctcct tacgagtatg 4140 tacgttaagg agtttctgat ttctagctcc caggacggac accagtggac tctgttcttc 4200 cagaacggca aagtgaaggt atttcaggga aaccaggatt cttttacccc ggtagtgaat 4260 agcctggatc caccgttgct gacccgctat ctgagaattc atccacaatc ctgggtgcat 4320 cagattgccc tccggatgga agtgctcggc tgtgaagctc aggatctgta ttag 4374 <210> 10 <211> 4374 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polynucleotide <400> 10 atgcaaatag agctctccac ctgcttcttt ctgtgccttt tgcgattctg ctttagtgcc 60 accagaagat actacctggg tgcagtggaa ctgtcatggg actatatgca aagtgatctc 120 ggtgagctgc ctgtggacgc aagatttcct cctagagtgc caaaatcttt tccattcaac 180 acctcagtcg tgtacaaaaa gactctgttt gtagaattca cggatcacct tttcaacatc 240 gctaagccaa ggccaccctg gatgggtctg ctaggtccta ccatccaggc tgaggtttat 300 gatacagtgg tcattacact taagaacatg gcttcccatc ctgtcagtct tcatgctgtt 360 ggtgtatcct actggaaagc ttctgaggga gctgaatatg atgatcagac cagtcaaagg 420 gagaaagaag atgataaagt cttccctggt ggaagccata catatgtctg gcaggtcctg 480 aaagagaatg gtccaatggc ctctgaccca ctgtgcctta cctactcata tctttctcat 540 gtggacctgg taaaagactt gaattcaggc ctcattggag ccctactagt atgtagagaa 600 gggagtctgg ccaaggaaaa gacacagacc ttgcacaaat ttatactact ttttgctgta 660 tttgatgaag ggaaaagttg gcactcagaa acaaagaact ccttgatgca ggatagggat 720 gctgcatctg ctcgggcctg gcctaaaatg cacacagtca atggttatgt aaacaggtct 780 ctgccaggtc tgattggatg ccacaggaaa tcagtctatt ggcatgtgat tggaatgggc 840 accactcctg aagtgcactc aatattcctc gaaggtcaca catttcttgt gaggaaccat 900 cgccaggcgt ccttggaaat ctcgccaata actttcctta ctgctcaaac actcttgatg 960 gaccttggac agtttctact gttttgtcat atctcttccc accaacatga tggcatggaa 1020 gcttatgtca aagtagacag ctgtccagag gaaccccaac tacgaatgaa aaataatgaa 1080 gaagcggaag actatgatga tgatcttact gattctgaaa tggatgtggt caggtttgat 1140 gatgacaact ctccttcctt tatccaaatt cgctcagttg ccaagaagca tcctaaaact 1200 tgggtacatt acattgctgc tgaagaggag gactgggact atgctccctt agtcctcgcc 1260 cccgatgaca gaagttataa aagtcaat ttgaacaatg gccctcagcg gattggtagg 1320 aagtacaaa aagtccgatt tatggcatac acgatgaaa cctttaagac tcgtgaagct 1380 attcagcatg atcaggaat cttgggacct ttacttag gggaagttgg agacacactg 1440 ttgattatat ttagaatca agcaagcaga ccatataaca tctaccctca cggaatcact 1500 gatgtccgtc ctttgtattc aaggatta ccaaaggtg taaaacttt gaaggatttt 1560 ccaattctgc caggagaat attcaatat aaatggacag tgactgtaga agatgggcca 1620 actaaatcag atcctcggtg cctgacccgc tattactcta gtttcgttaa tatggagaga 1680 gatctagctt caggactcat tggccctc ctcatctgct aaagaatc tgtagatca 1740 agaggaaacc agataatgtc agacaagagg aatgtcatcc tgttttctgt atttgatgag 1800 aaccgaagct ggtacctcac agagaatata caacgctttc tcccaatcc agctggagtg 1860 cagcttgagg atccagagtt ccaagcctcc aacatcatgc acagcatca tggctatgtt 1920 tttgatagtt tgcagttgtc agtttgttg catgaggtgg catactggta cattctaagc 1980 attggagcac agactgactt cctttctgtc ttctctctg gatatacctt caacacaa 2040 atggtctatg aagacacact caccctattc ccattctcag gagaaactgt cttcatgtcg 2100 atggaaaacc caggtctatg gattctgggg tgccacact cagacttcg gaacagaggc 2160 atgaccgcct tactgaggt tctagttgt vakagaaca ctggtgatta ttacgaggac 2220 agttatgaag atatttcagc atacttgctg agtaaaaaca atgccattga accaagaagc 2280 ttctcccaga atccaccagt ctgaaacgc catcaacggg aaataactcg tactactct 2340 splitcatchc agagaat tgactgat cataccatat splitgatec agagaat 2400 gattttgaca tttatgatga ggatgaaaat cagagccccc gcagctttca aaagaaaaaca 2460 cgacactatt ttattgctgc agtggagagg ctctgggatt atgggatgag tagctcccca 2520 catgttctaa gaacaggggc tcagagtggc agtgtccctc agttcagaa agttgttttc 2580 caggaattta ctgatggctc ctttactcag cccttatacc gtggagaact aaatgaacat 2640 ttgggactcc tggggccata tataagagca gaagttgaag atatatcat ggtaactttc 2700 agaaatcagg cctctcgtcc ctattccttc tattctagcc ttatttctta tgaggaagat 2760 cagaggcaag gagcagaacc tagaaaaaac tttgtcaagc ctaatgaaac caaaacttac 2820 ttttggaaag tgcaacatca tatggcaccc actaaagatg agtttgactg caaagcctgg 2880 gcttatttct ctgatgttga cctggaaaaa gatgtgcact caggcctgat tggacccctt 2940 ctggtctgcc acactaacac actgaaccct gctcatggga gacaagtgac agtacaggaa 3000 tttgctctgt ttttcaccat ctttgatgag accaaaagct ggtacttcac tgaaaatatg 3060 gaaagaaact gcagggctcc ctgcaatatc cagatggaag atcccacttt taaagagaat 3120 tatcgcttcc atgcaatcaa tggctacata atggatacac tacctggctt agtaatggct 3180 caggatcaaa ggattcgatg gtatctgctc agcatgggca gcaatgaaaa catccattct 3240 attcatttca gtggacatgt gttcactgta cgaaaaaaag aggagtataa aatggcactg 3300 tacaatctct atccaggtgt ttttgagaca gtggaaatgt taccatccaa agctggaatt 3360 tggcgggtgg aatgccttat tggcgagcat ctacatgctg ggatgagcac actttttctg 3420 gtgtacagca ataagtgtca gactcccctg ggaatggctt ctggacacat tagagatttt 3480 cagattacag cttcaggaca atatggacag tgggccccaa agctggccag acttcattat 3540 tccggatcaa tcaatgcctg gagcaccaag gagccctttt cttggatcaa ggtggatctg 3600 ttggcaccaa tgattattca cggcatcaag acccagggtg cccgtcagaa gttctccagc 3660 ctctacatct ctcagtttat catcatgtat agtctgatg ggagaagtg gcagacttat 3720 cgaggaaatt ccactggaac cttaatggtc ttctttggca atgtggattc atctgggata 3780 aaacacaata ttttaaccc tccaattatt gctcgataca tccgtttgca cccaactcat 3840 tatagcattc gcagcactct tcgcatggag ttgatgggct gtgatttaaa tagttgcagc 3900 atgccattgg gatggagag taaagcaata tcagatgcac agattactgc ttcatcctac 3960 tttaccaata tgttgccac ctggtctcct tcaaagctc gactcacct ccaagggagg 4020 agtaatgcct ggagacctca ggtgaataat ccaaagagt ggctgcaagt ggacttccag 4080 aagacaatga aagtcacagg agtaactact cagggagtaa aatctctgct taccaccatg 4140 tatgtgaagg agttcctcat ctccagcagt caagatggcc atcagtggac tctcttttt 4200 cagaatggca aagtaaaggt ttttcaggga aatcaagact ccttcacacc tgtggtgaac 4260 tctctagacc caccgttact gactcgctac cttcgaattc acccccagag ttgggtgcac 4320 cagattgccc tgaggatgga ggttctgggc tgcgaggcac aggacctcta ctga 4374 <210> 11 <211> 4374 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polynucleotide <400> 11 atgcagatcg agctgtccac atgcttttt ctgtgcctgc tgcggttctg cttcagcgcc 60 acccggcggt actacctggg cgccgtggag ctgtcctggg actacatgca gagcgacctg 120 ggcgagctgc ccgtggacgc ccggttcccc cccagagtgc ccaagagctt ccccttcaac 180 accagcgtgg tgtacaagaa aaccctgttc gtggagttca ccgaccacct gttcaacatc 240 gccaagccca ggcccccctg gatgggcctg ctgggcccca ccatccaggc cgaggtgtac 300 gacaccgtgg tgatcaccct gaagaacatg gccagccacc ccgtgagcct gcacgccgtg 360 ggcgtgagct actggaaggc ctccgagggc gccgagtacg acgaccagac cagccagcgg 420 gagaagagg acgaaaagt ctttcctggc ggcagccaca cctacgtgtg gcaggtcctg 480 aaagaaaacg gccccatggc ctccgacccc ctgtgcctga cctacagcta cctgagccac 540 gtggacctgg tgaaggacct gaacagcggg ctgattgggg ccctgctggt ctgccgggag 600 ggcagcctgg ccaaagagaa aacccagacc ctgcacaagt tcatcctgct gttcgccgtg 660 ttcgacgagg gcaagagctg gcacagcgag accaagaaca gcctgatgca ggaccgggac 720 gccgcctctg ccagagcctg gcccaagatg cacaccgtga acggctacgt gaagaagagc 780 ctgcccggcc tgattggctg ccaccggaag agcgtgtact ggcacgtgat cggcatgggc 840 accacaccg aggtgcacag catctttctg gaagggcaca cctttctggt gcggaaccac 900 cggcaggcca gcctggaaat cagccctatc accttcctga ccgcccagac actgctgatg 960 gacctgggcc agttcctgct gttttgccac atcagctctc accagcacga cggcatggaa 1020 gcctacgtga aggtggactc ctgccccgag gaaccccagc tgcggatgaa gaacaacgag 1080 gaagccgagg actacgacga cgacctgacc gacagcgaga tggacgtggt gcggttcgac 1140 gacgacaaca gccccagctt catccagatc agaagcgtgg ccaagaagca ccccaagacc 1200 tgggtgcact acatcgccgc cgaggaagag gactgggact acgcccccct ggtgctggcc 1260 cccgacgaca gaagctacaa gagccagtac ctgaacaatg gcccccagcg gatcggccgg 1320 aagtacaaga aagtgcggtt catggcctac accgacgaga ccttcaagac ccgggaggcc 1380 atccagcacg agagcggcat cctgggcccc ctgctgtacg gcgaagtggg cgacacactg 1440 ctgatcatct tcaagaacca ggccagccgg ccctacaaca tctaccccca cggcatcacc 1500 gacgtgcggc ccctgtacag caggcggctg cccaagggcg tgaagcacct gaaggacttc 1560 cccatcctgc ccggcgagat cttcaagtac aagtggaccg tgaccgtgga ggacggcccc 1620 accaagagcg accccagatg cctgacccgg tactacagca gcttcgtgaa catggaacgg 1680 gacctggcct ccgggctgat cggacctctg ctgatctgct acaaagaaag cgtggaccag 1740 cggggcaacc agatcatgag cgacaagcgg aacgtgatcc tgttcagcgt gttcgatgag 1800 aaccggtcct ggtatctgac cgagaacatc cagcggtttc tgcccaaccc tgccggggtg 1860 cagctgggaag atcccgagtt ccaggccagc aacatcatgc actccatcaa tggctacgtg 1920 ttcgacagcc tgcagctgtc cgtgtgtctg cacgaggtgg cctactggta catcctgagc 1980 atcggcgccc agaccgactt cctgagcgtg ttcttcagcg gctacacctt caagcaag 2040 atggtgtacg aggacaccct gaccctgttc cctttcagcg gcgagaccgt gttcatgagc 2100 atggaaaacc ccggcctgtg gatcctgggc tgccacaaca gcgacttccg gaaccggggc 2160 atgaccgccc tgctgaaggt gtccagctgc gaagaaca ccggcgacta ctacgaggac 2220 agctacgagg atatcagcgc ctacctgctg tccaagaaca acgccatcga gcccagaagc 2280 ttcagccaga acccccctgt gctgaagcgg caccagagag agatcacccg gaccaccctg 2340 cagtccgacc aggaagagat cgattacgac gacaccatca gcgtggagat gaaaaaagaa 2400 gatttcgaca tctacgacga ggacgagaac cagagccccc ggtccttcca gaaaaacc 2460 cggcactact ttatcgccgc cgtggagcgg ctgtgggact acggcatgag cagcagcccc 2520 cacgtgctgc ggaaccgggc ccagagcggc agcgtgcccc agttcaagaa agtggtgttc 2580 caggaattca ccgacggcag cttcacccag cccctgtacc ggggcgagct gaacgagcac 2640 ctggggctgc tggggcccta catcagggcc gaagtggagg acaacatcat ggtgaccttc 2700 cggaatcagg ccagcagacc ctactccttc tacagcagcc tgatcagcta cgaagaggac 2760 cagcggcagg gcgctgaacc ccggaagaac ttcgtgaagc ccaatgagac caagacctac 2820 ttctggaaag tgcagcacca catggccccc accaaggacg agttcgactg caaggcctgg 2880 gcctacttca gcgacgtgga tctggaaaag gacgtgcact ctggactgat tggccctctg 2940 ctggtgtgcc acaccaacac cctgaacccc gcccacggcc ggcaggtgac cgtgcaggaa 3000 ttcgccctgt tcttcaccat cttcgacgag accaagtcct ggtacttcac cgagaatatg 3060 gaacggaact gcagagcccc ctgcaacatc cagatggaag atcctacctt caaagagaac 3120 taccggttcc acgccatcaa cggctacatc atggacaccc tgcctggcct ggtgatggcc 3180 caggaccaga ggatccggtg gtatctgctg tccatgggca gcaacgagaa tatccacagc 3240 atccacttca gcggccacgt gttcaccgtg aggaagaaag aagagtacaa gatggccctg 3300 tacaacctgt accccggcgt gttcgagacc gtggagatgc tgcccagcaa ggccggcatc 3360 tggcgggtgg agtgtctgat cggcgagcac ctgcatgccg ggatgagcac cctgtttctg 3420 gtgtacagca acaagtgcca gacccccctg ggcatggcca gcggccacat ccgggacttc 3480 cagatcaccg cctccggcca gtacggccag tgggccccca agctggcccg gctgcactac 3540 agcggcagca tcaacgcctg gtccaccaaa gagcccttca gctggatcaa ggtggacctg 3600 ctggccccta tgatcatcca cggcattaag acccagggcg ccaggcagaa gttcagcagc 3660 ctgtacatca gccagttcat catcatgtac agcctggacg gcaagaagtg gcagacctac 3720 cggggcaaca gcaccggcac cctgatggtg ttcttcggca acgtggacag cagcggcatc 3780 aagcacaaca tcttcaaccc ccccatcatc gcccggtaca tccggctgca ccccacccac 3840 tacagcatca gatccaccct gcggatggaa ctgatgggct gcgacctgaa ctcctgcagc 3900 atgcctctgg gcatggaaag caaggccatc agcgacgccc agatcacagc cagcagctac 3960 ttcaccaaca tgttcgccac ctggtccccc tccaaggcca ggctgcacct gcagggccgg 4020 tccaacgcct ggcggcctca ggtgaacaac cccaaagaat ggctgcaggt ggactttcag 4080 aaaaccatga aggtgaccgg cgtgaccacc cagggcgtga aaagcctgct gaccagcatg 4140 tacgtgaaag agttctgat cagcagcagc caggacggcc accagtggac cctgttcttt 4200 cagaacggca aggtgaaagt gttccagggc aaccaggact ccttcacccc cgtggtgaac 4260 tccctggacc cccccctgct gacccgctac ctgcggatcc acccccagtc ttgggtgcac 4320 cagatcgccc tgaggatgga agtgctggga tgtgaggccc aggatctgta ctga 4374 <210> 12 <211> 2351 <212> PRT <213> Homo sapiens <400> 12 With Gln Ile Glu Leu Ser Thr Cys Phe Phe Leu Cys Leu Leu Arg Phe 1 5 10 15 Cys Phe Ser Ala Thr Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser 20 25 30 Trp Asp Tyr Met Gln Ser Asp Leu Gly Glu Leu Pro Val Asp Ala Arg 35 40 45 Phe Pro Pro Arg Val Pro Lys Ser Phe Pro Phe Asn Thr Ser Val Val 50 55 60 Tyr Lys Lys Thr Leu Phe Val Glu Phe Thr Asp His Leu Phe Asn Ile 65 70 75 80 Ala Lys Pro Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr Ile Gln 85 90 95 Ala Glu Val Tyr Asp Thr Val Val Ile Thr Leu Lys Asn Met Ala Ser 100 105 110 His Pro Val Ser Leu His Ala Val Gly Val Ser Tyr Trp Lys Ala Ser 115 120 125 Glu Gly Ala Glu Tyr Asp Asp Gln Thr Ser Gln Arg Glu Lys Glu Asp 130 135 140 Asp Lys Val Phe Pro Gly Gly Ser His Thr Tyr Val Trp Gln Val Leu 145 150 155 160 Lys Glu Asn Gly Pro Met Ala Ser Asp Pro Leu Cys Leu Thr Tyr Ser 165 170 175 Tyr Leu Ser His Val Asp Leu Val Lys Asp Leu Asn Ser Gly Leu Ile 180 185 190 Gly Ala Leu Leu Val Cys Arg Glu Gly Ser Leu Ala Lys Glu Lys Thr 195 200 205 Gln Thr Leu His Lys Phe Ile Leu Leu Phe Ala Val Phe Asp Glu Gly 210 215 220 Lys Ser Trp His Ser Glu Thr Lys Asn Ser Leu Met Gln Asp Arg Asp 225 230 235 240 Ala Ala Ser Ala Arg Ala Trp Pro Lys Met His Thr Val Asn Gly Tyr 245 250 255 Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Arg Lys Ser Val 260 265 270 Tyr Trp His Val Ile Gly Met Gly Thr Thr Pro Glu Val His Ser Ile 275 280 285 Phe Leu Glu Gly His Thr Phe Leu Val Arg Asn His Arg Gln Ala Ser 290 295 300 Leu Glu Ile Ser Pro Ile Thr Phe Leu Thr Ala Gln Thr Leu Leu Met 305 310 315 320 Asp Leu Gly Gln Phe Leu Leu Phe Cys His Ile Ser Ser His Gln His 325 330 335 Asp Gly Met Glu Ala Tyr Val Lys Val Asp Ser Cys Pro Glu Glu Pro 340 345 350 Gln Leu Arg Met Lys Asn Asn Glu Glu Ala Glu Asp Tyr Asp Asp Asp 355 360 365 Leu Thr Asp Ser Glu Met Asp Val Val Arg Phe Asp Asp Asp Asn Ser 370 375 380 Pro Ser Phe Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr 385 390 395 400 Trp Val His Tyr Ile Ala Ala Glu Glu Glu Asp Trp Asp Tyr Ala Pro 405 410 415 Leu Val Leu Ala Pro Asp Asp Arg Ser Tyr Lys Ser Gln Tyr Leu Asn 420 425 430 Asn Gly Pro Gln Arg Ile Gly Arg Lys Tyr Lys Lys Val Arg Phe Met 435 440 445 Ala Tyr Thr Asp Glu Thr Phe Lys Thr Arg Glu Ala Ile Gln His Glu 450 455 460 Ser Gly Ile Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr Leu 465 470 475 480 Leu Ile Ile Phe Lys Asn Gln Ala Ser Arg Pro Tyr Asn Ile Tyr Pro 485 490 495 His Gly Ile Thr Asp Val Arg Pro Leu Tyr Ser Arg Arg Leu Pro Lys 500 505 510 Gly Val Lys His Leu Lys Asp Phe Pro Ile Leu Pro Gly Glu Ile Phe 515 520 525 Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp 530 535 540 Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Phe Val Asn Met Glu Arg 545 550 555 560 Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu 565 570 575 Ser Val Asp Gln Arg Gly Asn Gln Ile Met Ser Asp Lys Arg Asn Val 580 585 590 Ile Leu Phe Ser Val Phe Asp Glu Asn Arg Ser Trp Tyr Leu Thr Glu 595 600 605 Asn Ile Gln Arg Phe Leu Pro Asn Pro Ala Gly Val Gln Leu Glu Asp 610 615 620 Pro Glu Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val 625 630 635 640 Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr Trp 645 650 655 Tyr Ile Leu Ser Ile Gly Ala Gln Thr Asp Phe Leu Ser Val Phe Phe 660 665 670 Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr 675 680 685 Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro 690 695 700 Gly Leu Trp Ile Leu Gly Cys His Asn Ser Asp Phe Arg Asn Arg Gly 705 710 715 720 Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp Lys Asn Thr Gly Asp 725 730 735 Tyr Tyr Glu Asp Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu Ser Lys 740 745 750 Asn Asn Ala Ile Glu Pro Arg Ser Phe Ser Gln Asn Ser Arg His Pro 755 760 765 Ser Thr Arg Gln Lys Gln Phe Asn Ala Thr Thr Ile Pro Glu Asn Asp 770 775 780 Ile Glu Lys Thr Asp Pro Trp Phe Ala His Arg Thr Pro Met Pro Lys 785 790 795 800 Ile Gln Asn Val Ser Ser Ser Asp Leu Leu Met Leu Leu Arg Gln Ser 805 810 815 Pro Thr Pro His Gly Leu Ser Leu Ser Asp Leu Gln Glu Ala Lys Tyr 820 825 830 Glu Thr Phe Ser Asp Asp Pro Ser Pro Gly Ala Ile Asp Ser Asn Asn 835 840 845 Ser Leu Ser Glu Met Thr His Phe Arg Pro Gln Leu His His Ser Gly 850 855 860 Asp Met Val Phe Thr Pro Glu Ser Gly Leu Gln Leu Arg Leu Asn Glu 865 870 875 880 Lys Leu Gly Thr Thr Ala Ala Thr Glu Leu Lys Lys Leu Asp Phe Lys 885 890 895 Val Ser Ser Thr Ser Asn Asn Leu Ile Ser Thr Ile Pro Ser Asp Asn 900 905 910 Leu Ala Ala Gly Thr Asp Asn Thr Ser Ser Leu Gly Pro Pro Ser Met 915 920 925 Pro Val His Tyr Asp Ser Gln Leu Asp Thr Thr Leu Phe Gly Lys Lys 930 935 940 To Be To Be Pro Leu Thr Glu To Be Gly Gly Pro Leu To Be Leu To Be Glu Glu 945 950 955 960 Asn Asn Asp Ser Lys Leu Leu Glu Ser Gly Leu Met Asn Ser Gln Glu 965 970 975 Ser Ser Trp Gly Lys Asn Val Ser Ser Thr Glu Ser Gly Arg Leu Phe 980 985 990 Lys Gly Lys Arg Ala His Gly Pro Ala Leu Leu Thr Lys Asp Asn Ala 995 1000 1005 Leu Phe Lys Val Ser Ile Ser Leu Leu Lys Thr Asn Lys Thr Ser 1010 1015 1020 Asn Asn Ser Ala Thr Asn Arg Lys Thr His Ile Asp Gly Pro Ser 1025 1030 1035 Leu Leu Ile Glu Asn Ser Pro Ser Val Trp Gln Asn Ile Leu Glu 1040 1045 1050 Ser Asp Thr Glu Phe Lys Lys Val Thr Pro Leu Ile His Asp Arg 1055 1060 1065 Met Leu Met Asp Lys Asn Ala Thr Ala Leu Arg Leu Asn His Met 1070 1075 1080 Ser Asn Lys Thr Thr Ser Ser Lys Asn Met Glu Met Val Gln Gln 1085 1090 1095 Lys Lys Glu Gly Pro Ile Pro Pro Asp Ala Gln Asn Pro Asp Met 1100 1105 1110 Ser Phe Phe Lys Met Leu Phe Leu Pro Glu Ser Ala Arg Trp Ile 1115 1120 1125 Gln Arg Thr His Gly Lys Asn Ser Leu Asn Ser Gly Gln Gly Pro 1130 1135 1140 Ser Pro Lys Gln Leu Val Ser Leu Gly Pro Glu Lys Ser Val Glu 1145 1150 1155 Gly Gln Asn Phe Leu Ser Glu Lys Asn Lys Val Val Val Gly Lys 1160 1165 1170 Gly Glu Phe Thr Lys Asp Val Gly Leu Lys Glu Met Val Phe Pro 1175 1180 1185 Ser Ser Arg Asn Leu Phe Leu Thr Asn Leu Asp Asn Leu His Glu 1190 1195 1200 Asn Asn Thr His Asn Gln Glu Lys Lys Ile Gln Glu Glu Ile Glu 1205 1210 1215 Lys Lys Glu Thr Leu Ile Gln Glu Asn Val Val Leu Pro Gln Ile 1220 1225 1230 His Thr Val Thr Gly Thr Lys Asn Phe Met Lys Asn Leu Phe Leu 1235 1240 1245 Leu Ser Thr Arg Gln Asn Val Glu Gly Ser Tyr Asp Gly Ala Tyr 1250 1255 1260 Ala Pro Val Leu Gln Asp Phe Arg Ser Leu Asn Asp Ser Thr Asn 1265 1270 1275 Arg Thr Lys Lys His Thr Ala His Phe Ser Lys Lys Gly Glu Glu 1280 1285 1290 Glu Asn Leu Glu Gly Leu Gly Asn Gln Thr Lys Gln Ile Val Glu 1295 1300 1305 Lys Tyr Ala Cys Thr Thr Arg Ile Ser Pro Asn Thr Ser Gln Gln 1310 1315 1320 Asn Phe Val Thr Gln Arg Ser Lys Arg Ala Leu Lys Gln Phe Arg 1325 1330 1335 Leu Pro Leu Glu Glu Thr Glu Leu Glu Lys Arg Ile Ile Val Asp 1340 1345 1350 Asp Thr Ser Thr Gln Trp Ser Lys Asn Met Lys His Leu Thr Pro 1355 1360 1365 Ser Thr Leu Thr Gln Ile Asp Tyr Asn Glu Lys Glu Lys Gly Ala 1370 1375 1380 Ile Thr Gln Ser Pro Leu Ser Asp Cys Leu Thr Arg Ser His Ser 1385 1390 1395 Ile Pro Gln Ala Asn Arg Ser Pro Leu Pro Ile Ala Lys Val Ser 1400 1405 1410 Ser Phe Pro Ser Ile Arg Pro Ile Tyr Leu Thr Arg Val Leu Phe 1415 1420 1425 Gln Asp Asn Ser Ser His Leu Pro Ala Ala Ser Tyr Arg Lys Lys 1430 1435 1440 Asp Ser Gly Val Gln Glu Ser Ser His Phe Leu Gln Gly Ala Lys 1445 1450 1455 Lys Asn Asn Leu Ser Leu Ala Ile Leu Thr Leu Glu Met Thr Gly 1460 1465 1470 Asp Gln Arg Glu Val Gly Ser Leu Gly Thr Ser Ala Thr Asn Ser 1475 1480 1485 Val Thr Tyr Lys Lys Val Glu Asn Thr Val Leu Pro Lys Pro Asp 1490 1495 1500 Leu Pro Lys Thr Ser Gly Lys Val Glu Leu Leu Pro Lys Val His 1505 1510 1515 Ile Tyr Gln Lys Asp Leu Phe Pro Thr Glu Thr Ser Asn Gly Ser 1520 1525 1530 Pro Gly His Leu Asp Leu Val Glu Gly Ser Leu Leu Gln Gly Thr 1535 1540 1545 Glu Gly Ala Ile Lys Trp Asn Glu Ala Asn Arg Pro Gly Lys Val 1550 1555 1560 Pro Phe Leu Arg Val Ala Thr Glu Ser Ser Ala Lys Thr Pro Ser 1565 1570 1575 Lys Leu Leu Asp Pro Leu Ala Trp Asp Asn His Tyr Gly Thr Gln 1580 1585 1590 Ile Pro Lys Glu Glu Trp Lys Ser Gln Glu Lys Ser Pro Glu Lys 1595 1600 1605 Thr Ala Phe Lys Lys Lys Asp Thr Ile Leu Ser Leu Asn Ala Cys 1610 1615 1620 Glu Ser Asn His Ala Ile Ala Ala Ile Asn Glu Gly Gln Asn Lys 1625 1630 1635 Pro Glu Ile Glu Val Thr Trp Ala Lys Gln Gly Arg Thr Glu Arg 1640 1645 1650 Leu Cys Ser Gln Asn Pro Pro Val Leu Lys Arg His Gln Arg Glu 1655 1660 1665 Ile Thr Arg Thr Thr Leu Gln Ser Asp Gln Glu Glu Ile Asp Tyr 1670 1675 1680 Asp Asp Thr Ile Ser Val Glu Met Lys Lys Glu Asp Phe Asp Ile 1685 1690 1695 Tyr Asp Glu Asp Glu Asn Gln Ser Pro Arg Ser Phe Gln Lys Lys 1700 1705 1710 Thr Arg His Tyr Phe Ile Ala Ala Val Glu Arg Leu Trp Asp Tyr 1715 1720 1725 Gly Met Ser Ser Ser Pro His Val Leu Arg Asn Arg Ala Gln Ser 1730 1735 1740 Gly Ser Val Pro Gln Phe Lys Lys Val Val Phe Gln Glu Phe Thr 1745 1750 1755 Asp Gly Ser Phe Thr Gln Pro Leu Tyr Arg Gly Glu Leu Asn Glu 1760 1765 1770 His Leu Gly Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val Glu Asp 1775 1780 1785 Asn Ile Met Val Thr Phe Arg Asn Gln Ala Ser Arg Pro Tyr Ser 1790 1795 1800 Phe Tyr Ser Ser Leu Ile Ser Tyr Glu Glu Asp Gln Arg Gln Gly 1805 1810 1815 Ala Glu Pro Arg Lys Asn Phe Val Lys Pro Asn Glu Thr Lys Thr 1820 1825 1830 Tyr Phe Trp Lys Val Gln His His Met Ala Pro Thr Lys Asp Glu 1835 1840 1845 Phe Asp Cys Lys Ala Trp Ala Tyr Phe Ser Asp Val Asp Leu Glu 1850 1855 1860 Lys Asp Val His Ser Gly Leu Ile Gly Pro Leu Leu Val Cys His 1865 1870 1875 Thr Asn Thr Leu Asn Pro Ala His Gly Arg Gln Val Thr Val Gln 1880 1885 1890 Glu Phe Ala Leu Phe Phe Thr Ile Phe Asp Glu Thr Lys Ser Trp 1895 1900 1905 Tyr Phe Thr Glu Asn Met Glu Arg Asn Cys Arg Ala Pro Cys Asn 1910 1915 1920 Ile Gln Met Glu Asp Pro Thr Phe Lys Glu Asn Tyr Arg Phe His 1925 1930 1935 Ala Ile Asn Gly Tyr Ile Met Asp Thr Leu Pro Gly Leu Val Met 1940 1945 1950 Ala Gln Asp Gln Arg Ile Arg Trp Tyr Leu Leu Ser Met Gly Ser 1955 1960 1965 Asn Glu Asn Ile His Ser Ile His Phe Ser Gly His Val Phe Thr 1970 1975 1980 Val Arg Lys Lys Glu Glu Tyr Lys Met Ala Leu Tyr Asn Leu Tyr 1985 1990 1995 Pro Gly Val Phe Glu Thr Val Glu Met Leu Pro Ser Lys Ala Gly 2000 2005 2010 Ile Trp Arg Val Glu Cys Leu Ile Gly Glu His Leu His Ala Gly 2015 2020 2025 Met Ser Thr Leu Phe Leu Val Tyr Ser Asn Lys Cys Gln Thr Pro 2030 2035 2040 Leu Gly Met Ala Ser Gly His Ile Arg Asp Phe Gln Ile Thr Ala 2045 2050 2055 Ser Gly Gln Tyr Gly Gln Trp Ala Pro Lys Leu Ala Arg Leu His 2060 2065 2070 Tyr Ser Gly Ser Ile Asn Ala Trp Ser Thr Lys Glu Pro Phe Ser 2075 2080 2085 Trp Ile Lys Val Asp Leu Leu Ala Pro Met Ile Ile His Gly Ile 2090 2095 2100 Lys Thr Gln Gly Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser 2105 2110 2115 Gln Phe Ile Ile Met Tyr Ser Leu Asp Gly Lys Lys Trp Gln Thr 2120 2125 2130 Tyr Arg Gly Asn Ser Thr Gly Thr Leu Met Val Phe Phe Gly Asn 2135 2140 2145 Val Asp Ser Ser Gly Ile Lys His Asn Ile Phe Asn Pro Pro Ile 2150 2155 2160 Ile Ala Arg Tyr Ile Arg Leu His Pro Thr His Tyr Ser Ile Arg 2165 2170 2175 Ser Thr Leu Arg Met Glu Leu Met Gly Cys Asp Leu Asn Ser Cys 2180 2185 2190 Ser Met Pro Leu Gly Met Glu Ser Lys Ala Ile Ser Asp Ala Gln 2195 2200 2205 Ile Thr Ala Ser Ser Tyr Phe Thr Asn Met Phe Ala Thr Trp Ser 2210 2215 2220 Pro Ser Lys Ala Arg Leu His Leu Gln Gly Arg Ser Asn Ala Trp 2225 2230 2235 Arg Pro Gln Val Asn Asn Pro Lys Glu Trp Leu Gln Val Asp Phe 2240 2245 2250 Gln Lys Thr Met Lys Val Thr Gly Val Thr Thr Gln Gly Val Lys 2255 2260 2265 Ser Leu Leu Thr Ser Met Tyr Val Lys Glu Phe Leu Ile Ser Ser 2270 2275 2280 Ser Gln Asp Gly His Gln Trp Thr Leu Phe Phe Gln Asn Gly Lys 2285 2290 2295 Val Lys Val Phe Gln Gly Asn Gln Asp Ser Phe Thr Pro Val Val 2300 2305 2310 Asn Ser Leu Asp Pro Pro Leu Leu Thr Arg Tyr Leu Arg Ile His 2315 2320 2325 Pro Gln Ser Trp Val His Gln Ile Ala Leu Arg Met Glu Val Leu 2330 2335 2340 Gly Cys Glu Ala Gln Asp Leu Tyr 2345 2350 <210> 13 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 13 Ser Phe Ser Gln Asn Pro Pro Val Leu Lys Arg His Gln Arg 1 5 10 <210> 14 <211> 24 <212> PRT <213> On sp. <400> 14 Dear Phe Ala Gln Asn Dear Arg Pro Pro Dear Ala Dear Ala Pro Lys Pro 1 5 10 15 Pro Val Leu Arg Arg His Gln Arg 20 <210> 15 <211> 16 <212> PRT <213> On sp. <400> 15 Ser Phe Ser Gln Asn Ser Arg His Gln Ala Tyr Arg Tyr Arg Arg Gly 1 5 10 15

Claims

1. A human subject diagnosed with hemophilia A is administered 2×10 12 1. A method of treating hemophilia A comprising intravenously infusing a dose of adeno-associated virus (AAV) particles, wherein the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA).

2. A human subject diagnosed with hemophilia A is administered 6×10 12 1. A method of treating hemophilia A comprising intravenously infusing a dose of adeno-associated virus (AAV) particles, wherein the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA).

3. 3. The method of claim 1 or claim 2, further comprising administering to the human subject diagnosed with hemophilia A a course of prednisolone or prednisone.

4. 4. The method of claim 3, wherein the course of prednisolone or prednisone is administered following infusion of the AAV particles.

5. administering said course of prednisolone or prednisone; administering to the human subject 60 mg of prednisolone or prednisone per day for the first week immediately following infusion of the AAV particles; administering to the human subject 40 mg of prednisolone or prednisone per day for a second week immediately following infusion of the AAV particles; and administering to the human subject 30 mg of prednisolone or prednisone per day for the third week immediately following infusion of the AAV particles. The method of claim 3 or claim 4, comprising:

6. 6. The method of claim 5, further comprising administering tapering doses of prednisolone or prednisone after the third week immediately following infusion of the AAV particles.

7. administering said tapered dose of prednisolone or prednisone, administering to said human subject 20 mg of prednisolone or prednisone per day for five consecutive days immediately following completion of an initial course of prednisolone or prednisone; administering to said human subject 15 mg of prednisolone or prednisone per day for three consecutive days immediately following said five day period during which said human subject was administered 20 mg of prednisolone or prednisone; administering to said human subject 10 mg of prednisolone or prednisone per day for three consecutive days immediately following the three day period during which said human subject was administered 15 mg of prednisolone or prednisone; and administering to said human subject 5 mg of prednisolone or prednisone per day for three consecutive days immediately following said three days during which said human subject received 10 mg of prednisolone or prednisone. The method of claim 6, comprising:

8. administering said tapered dose of prednisolone or prednisone, administering to said human subject 30 mg of prednisolone or prednisone per day for seven consecutive days immediately following completion of said initial course of prednisolone or prednisone; administering to said human subject 20 mg of prednisolone or prednisone per day for seven consecutive days immediately following said seven day period during which said human subject was administered 30 mg of prednisolone or prednisone; administering to said human subject 15 mg of prednisolone or prednisone per day for 5 consecutive days immediately following said 7 day period during which said human subject was administered 20 mg of prednisolone or prednisone; administering to said human subject 10 mg of prednisolone or prednisone per day for 5 consecutive days immediately following the 5 day period during which said human subject was administered 15 mg of prednisolone or prednisone; and administering to said human subject 5 mg of prednisolone or prednisone per day for 5 consecutive days immediately following said 5 days during which said human subject was administered 10 mg of prednisolone or prednisone. The method of claim 6, comprising:

9. determining a first level of factor VIII activity in a blood sample collected from a human subject diagnosed with hemophilia A after administering to the human subject an adeno-associated virus (AAV) particle comprising a polynucleotide encoding a factor VIII protein and while the human subject is receiving an initial course of glucocorticoid steroid treatment; determining a second level of Factor VIII activity in a blood sample collected from the human subject after the first course of glucocorticoid steroid treatment is completed; comparing said second level of factor VIII activity with said first level of factor VIII activity; and administering tapering doses of said glucocorticoid steroid, if said second level of factor VIII activity is equal to or greater than said first level of factor VIII activity, administering a first tapering dose of said glucocorticoid steroid over a period of not more than three weeks; if the second level of factor VIII activity is less than the first level of factor VIII activity, a second tapered dose of the glucocorticoid steroid is administered over a period of greater than three weeks. The administering The method includes:

10. determining a first level of liver enzyme activity in a blood sample collected from a human subject diagnosed with hemophilia A prior to administering to the human subject an adeno-associated virus (AAV) particle comprising a polynucleotide encoding a Factor VIII protein; determining a second level of liver enzyme activity in a blood sample collected from the human subject after administering to the human an AAV particle comprising a polynucleotide encoding a Factor VIII protein and after completing an initial course of glucocorticoid steroid treatment; comparing said second level of liver enzyme activity to said first level of liver enzyme activity; and administering tapering doses of said glucocorticoid steroid, if said second level of liver enzyme activity is equal to or less than said first level of liver enzyme activity, a first tapered dose of said glucocorticoid steroid is administered over a period of no more than three weeks; if the second level of liver enzyme activity is greater than the first level of factor VIII activity, a second tapered dose of the glucocorticoid steroid is administered over a period of greater than three weeks. The administering The method includes:

11. administering said first tapered dose of said glucocorticoid steroid; administering to said human subject 20 mg of prednisolone or prednisone per day for 5 consecutive days immediately following completion of said initial course of glucocorticoid steroid treatment; administering to said human subject 15 mg of prednisolone or prednisone per day for three consecutive days immediately following said five day period during which said human subject was administered 20 mg of prednisolone or prednisone; administering to said human subject 10 mg of prednisolone or prednisone per day for three consecutive days immediately following the three day period during which said human subject was administered 15 mg of prednisolone or prednisone; and administering to said human subject 5 mg of prednisolone or prednisone per day for three consecutive days immediately following said three days during which said human subject received 10 mg of prednisolone or prednisone. The method of claim 9 or claim 10, comprising:

12. administering said second tapered dose of said glucocorticoid steroid; administering to said human subject 30 mg of prednisolone or prednisone per day for seven consecutive days immediately following completion of said initial course of glucocorticoid steroid treatment; administering to said human subject 20 mg of prednisolone or prednisone per day for seven consecutive days immediately following said seven day period during which said human subject was administered 30 mg of prednisolone or prednisone; administering to said human subject 15 mg of prednisolone or prednisone per day for 5 consecutive days immediately following said 7 day period during which said human subject was administered 20 mg of prednisolone or prednisone; administering to said human subject 10 mg of prednisolone or prednisone per day for 5 consecutive days immediately following the 5 day period during which said human subject was administered 15 mg of prednisolone or prednisone; and administering to said human subject 5 mg of prednisolone or prednisone per day for 5 consecutive days immediately following said 5 days during which said human subject was administered 10 mg of prednisolone or prednisone. The method according to any one of claims 9 to 11, comprising:

13. 1. A method for monitoring the effectiveness of factor VIII gene therapy for hemophilia A using adeno-associated virus (AAV) particles comprising a polynucleotide encoding a factor VIII polypeptide, comprising: determining whether factor VIII inhibitor antibodies are present in a blood sample collected from the human subject after administration of the AAV particles to the human subject; and Upon detecting the presence of a factor VIII inhibitor in the blood of said human subject, administering to said human subject an alternative drug for the treatment of hemophilia A. The method comprising:

14. 14. The method of claim 13, wherein the replacement agent comprises a chemically modified human Factor VIII protein.

15. 14. The method of claim 13, wherein the replacement agent comprises porcine factor VIII protein.

16. 14. The method of claim 13, wherein the alternative agent is a factor VIII bypass therapy agent, including factors II, IX and X.

17. a) to a patient with hemophilia A, 2 x 10 per kilogram of the patient's body weight 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of SEQ ID NO:1 or a fragment thereof in the bloodstream of said patient at a later time point, said later time point being 7 days or later. The method includes:

18. a) to a patient with hemophilia A, 6 x 10 per kilogram of the patient's body weight 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of SEQ ID NO:1 or a fragment thereof in the bloodstream of said patient at a later time point, said later time point being 7 days or later. The method includes:

19. a) administering to a patient with hemophilia A a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide encoding a factor VIII protein; and b) measuring the level of the polynucleotide encoding the factor VIII protein or a fragment thereof in the bloodstream of the patient at a later time point, wherein the later time point is 7 days or later. The method includes:

20. The method of any one of claims 17 to 19, wherein said later time point is 7 days.

21. The method of any one of claims 17 to 19, wherein said later time point is 14 days.

22. The method of any one of claims 17 to 19, wherein said later time point is 21 days.

23. a) to a patient with hemophilia A, 2 x 10 per kilogram of the patient's body weight 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of said capsid protein in the bloodstream of said patient at a later time point, said later time point being 7 days or later. The method includes:

24. a) to a patient with hemophilia A, 6 x 10 per kilogram of the patient's body weight 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of said capsid protein in the bloodstream of said patient at a later time point, said later time point being 7 days or later. The method includes:

25. a) administering to a patient with hemophilia A a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide encoding a Factor VIII protein; and b) measuring the level of said capsid protein in the bloodstream of said patient at a later time point, said later time point being 7 days or later. The method includes:

26. The method of any one of claims 23 to 25, wherein the later time point is 7 days.

27. The method of any one of claims 23 to 25, wherein said later time point is 14 days.

28. 26. The method of any one of claims 23 to 25, wherein said later time point is 21 days.

29. a) to a patient with hemophilia A, 2 x 10 per kilogram of the patient's body weight 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of anti-Factor VIII antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes:

30. a) to a patient with hemophilia A, 6 x 10 per kilogram of the patient's body weight 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of anti-Factor VIII antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes:

31. a) administering to a patient with hemophilia A a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a polynucleotide encoding a factor VIII protein; and b) measuring the level of anti-Factor VIII antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes:

32. The method of any one of claims 29 to 31, wherein said later time point is 7 days.

33. 32. The method of any one of claims 29 to 31, wherein said later time point is 14 days.

34. 32. The method of any one of claims 29 to 31, wherein said later time point is 21 days.

35. a) to a patient with hemophilia A, 2 x 10 per kilogram of the patient's body weight 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of anti-capsid protein antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes:

36. a) to a patient with hemophilia A, 6 x 10 per kilogram of the patient's body weight 12 administering a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:1 (CS04-FL-NA); and b) measuring the level of anti-capsid protein antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes:

37. a) administering to a patient with hemophilia A a dose of adeno-associated virus (AAV) particles, wherein at a first time point, the AAV particles comprise a capsid protein and a polynucleotide encoding a Factor VIII protein; and b) measuring the level of anti-capsid protein antibodies in the patient's bloodstream at a later time point, said later time point being 7 days or later. The method includes:

38. c) measuring a baseline level of anti-capsid protein antibodies in the bloodstream of the patient prior to administering to the patient the dose of the adeno-associated virus (AAV) particles; and d) optionally comparing said measured level of anti-capsid protein antibodies in said patient's bloodstream at said later time point with said baseline level of anti-capsid protein antibodies in said patient's bloodstream. The method of any one of claims 35 to 37, further comprising:

39. The method of any one of claims 35 to 38, wherein the later time point is 7 days.

40. 39. The method of any one of claims 35 to 38, wherein said later time point is 14 days.

41. 39. The method of any one of claims 35 to 38, wherein said later time point is 21 days.

Citation Information

Patent Citations

  • modified factor viii

    JP2005538694A

  • Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same

    WO2017053677A1

  • Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

    WO2017083762A1